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Abstract 
Axons use a conserved program to actively drive their own destruction after injury. Axon 
degeneration is present in many neurological disorders and an axon death program could be a 
major pharmaceutical target to preserve neuronal function. This intrinsic signaling cascade 
activates pro-degenerative dSarm/Sarm1, rapidly depletes axonal stores of NAD+, and 
terminates in cytoskeletal breakdown. Conversely, loss of dSarm/Sarm1, maintenance of NAD+ 
levels or its biosynthetic enzyme Nmnat, result in long-term morphological perseveration of 
severed axons. Exactly how dSarm/Sarm1 and loss of NAD+ execute axon death remains poorly 
defined.  
We sought to uncover novel regulators of axon death and maintenance by performing a 
deficiency screen and a forward genetic mutagenesis screen in axotomized Drosophila wing 
sensory neurons. We identified a BTB domain protein enriched in neurons, we named Axundead 
(Axed), which is specifically required for axon death. Severed axons harboring loss of function 
mutations in axed, similar to dSarm mutants, remain preserved for 50 days post axotomy. 
Spontaneous neurodegeneration induced by activated dSarm or dNmnat depletion are both 
suppressed in axed mutants, but not in dSarm mutant alleles.  Additionally, severed axed mutant 
axons also expressing activated dSarm or lacking Nmnat are preserved. These results indicate 
that dSarm acts upstream of dNmnat loss, and both events precede essential Axed function and 
axon destruction. Thus, the axon death pathway converges on Axed function.  
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Preface 
All of the work presented here was performed by myself in close collaboration with 
Lukas Neukomm PhD in the laboratory of Marc Freeman. Specific attribution for 
experiments, figures, and writing are given in the preface of each chapter. Drosophila 
images in the introduction are modified from Neukomm et al., PNAS 2014. Members of 
the Freeman lab, the Neurobiology Department, the UMass community, and others 
shared fly stocks, and gave critical feedback and advice on the work presented in this 
thesis. 
 
I isolated the genetic mutations and identified the causative genes, through lethality 
mapping and genetic rescue experiments, responsible for two unique phenotypes: 1) a 
partial blockade of axon degeneration (gene-of-interest-#1345x); 2) a progressive dying-
back of axons with extreme membrane dysregulation (gene-of-interest-#2596x & gene-of-
interest-#21013x), however, due to my own time constraints and focus on probing axed 
mechanism, other graduate students are working to complete and publish these projects. 
As such, data I obtained beyond basic phenotypes will not be presented in this thesis. 
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CHAPTER I: Introduction 
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Introduction 1-1: Neuronal Architecture & the Nervous System 
 Neurons evolved a unique cellular morphology to receive, interpret, and respond 
to cellular stimuli, via a dendritic arbor, a cell soma/body, and a long axon, respectively.  
In order to connect disparate locations in an organism, bursts of electrochemical 
impulses, generated and propagated by membrane depolarization, transmit information 
down the length of an axon to synaptic terminals.  Synaptic linkages between neurons 
form nervous systems ranging in complexity from the very simple neural nets in radially 
symmetric organisms to mammalian central nervous systems with trillions of 
connections. 
 Axons form the bulk of the neuronal volume and vary widely in length, width, 
and branching complexity. For example, the axon-like process of primary sensory 
afferents in the blue whale can be as long as ~25-30 meters in length (Smith, 2009), while 
a similar neuron in humans extends a ~1m long process along the spinal cord from the 
dermal layer of the largest toe to the brain.  Axons also differ widely in caliber depending 
on the information they are required to transmit in the form of electrical spikes, the 
number of which influence an axon’s energy consumption (Perge et al., 2012). 
Maintaining a functional axon is energetically demanding and requires coordination of a 
vast economy of organelles such as mitochondria to provide cellular energy in the form 
of adenosine triphosphate (ATP), an axoplasmic reticulum to store calcium ions (Ca2+) 
among other functions, an intracellular filament system to define membrane cytoskeletal 
structure and serve as transport rails for vesicles with attached or enclosed proteins and 
messenger/transfer ribonucleic acids (RNA) from the cell body to the axon, a cellular 
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garbage clearing ubiquitin-proteasome system (UPS) and a lysosomal network. Axons do 
not exist in a vacuum however, and are supported by several types of glial cells that 
enwrap single axons or bundles of axon in nerves. Glial cells support axons by accepting 
waste, transferring energy-rich glycolytic substrates such as pyruvate or lactate in 
exosomes or microvesicles, and speeding information transmission by providing a layer 
of electrical insulation in the form of myelin (Davis et al., 2014; Frühbeis et al., 2013; 
Fünfschilling et al., 2012). Even with the aid of supporting glial cells, disease and trauma 
can lead to catastrophic breakdown of the axon, such as in trauma brain injury or 
neurodegenerative ailments such as multiple sclerosis or Parkinson’s disease (Adalbert 
and Coleman, 2013; Burke and O’Malley, 2013; Dikranian et al., 2008).  
 
Introduction 1-2: Wallerian Degeneration 
Complete transection of axons is a devastating injury that leads to axon 
destruction.  Degeneration of axons after transection was first described in 1850 by 
Augustus Waller. He observed three distinct phases of destruction after severing 
hypoglossal nerve fibers in frog tongues (Waller, 1850). In the first phase, now termed 
the ‘latency period’, no morphological changes are observable in the nerve for up to four 
days post axotomy. In the second phase, lasting from approximately five to ten days, 
severed nerves undergo an explosive granular fragmentation which Waller described as 
“disorganized, fusiform masses at intervals” and regression of surrounding glia 
membranes (Waller, 1850). Finally, fragments are cleared by twelve to fifteen days, 
likely by neighboring macrophages. Today, these three phases of degeneration have been 
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observed in many neuronal subtypes across a range of organisms from Drosophila to 
humans, both in vivo and in vitro, albeit on faster time scales than frogs, usually less than 
24 hours (MacDonald et al., 2006; Schlaepfer and Bunge, 1973).  
In addition to his observations, Waller presciently hypothesized that simple 
transection caused “certain organic and physical changes in the tubular fibre” that may 
also be intimately related to diseases of the nervous system (Waller, 1850). We now have 
evidence that axon degeneration often precedes, and possibly induces, the death of 
neuronal cell bodies across a range of neurodegenerative diseases and traumas (Alobuia 
et al., 2013; Conforti et al., 2014). Thus, we might attenuate overall neuron loss and halt 
disease progression by promoting axon survival or inhibiting axon death.  However, in 
order to therapeutically target axons we must understand those organic and physical 
changes in the axon that contribute to their demise. To do this the field has developed a 
variety of model systems, described below, to genetically and biochemically probe how 
axons degenerate after a simple transection in a process now called Wallerian 
degeneration.  
Wallerian degeneration was first thought to result from a gradual consumption 
and subsequent loss of “essential metabolic factors” no longer supplied by the cell body 
and early models of axon degeneration followed the breakdown of excised rat nerve 
segments ex vivo (Joseph, 1973; Vial, 1958). These descriptive experiments observed the 
disruption of axoplasmic reticulum, swelling of mitochondria, and the disintegration of 
microtubules and neurofilaments using electron microscopy (Vial, 1958). Additionally, it 
was discovered that rising axoplasmic [Ca2+] was necessary and sufficient for axon 
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degeneration: transected axons remained intact when nerves were incubated in Ca2+-free 
media or with L-type calcium channel blockers and accelerated with the addition of Ca2+ 
ionophore, A23187 (George et al., 1995; Schlaepfer, 1974, 1977; Schlaepfer and Hasler, 
1979). This was the first clue that an intrinsic activation of pro-degenerative molecules, 
namely calcium-sensitive proteases, were required for axon death (Schlaepfer and Hasler, 
1979). Additionally, severed axon segments degenerate at a glacial pace in some 
invertebrate cell types such as crayfish medial giant axons, where anucleate axons remain 
intact for 5-9 months (Ballinger and Bittner, 1980), and even in vertebrates: goldfish 
spinal cord Mauthner axons, ~160 days (Murray and Edwards, 1982), frog optic axons, 
~30-60 days (Lázár, 1980; Matsumoto and Scalia, 1981), and garfish olfactory axons, 
~19 days (Cancalon, 1982). One such microscopic wasp even survives in its adult form 
with a nervous system comprised of primarily anucleated neuronal processes (Polilov, 
2012).  Other evidence from emerging apoptosis and cell death fields suggested that some 
degeneration was strictly controlled by intrinsic cellular processes. Thus, axons might 
contain their own signaling cascade to destroy themselves, which is altered or not present 
in some organisms or cell types.  
Shifting the field from a passive to active degeneration model required more 
striking evidence provided by C57/BL/6/Ola mutant mouse strain. In this mouse, severed 
sciatic nerve axons remained morphologically intact for weeks and able to conduct action 
potentials up to 16 days post injury, in striking contrast to wild type axons that 
degenerated and failed to conduct action potentials by 2-3 days (Lunn et al., 1989). This 
mouse strain was renamed Wallerian Degeneration Slow or WldS and harbored 
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spontaneous tandem triplication which fused nmnat1 and ube4b. This fusion resulted in 
the overexpression of a novel fusion protein consisting of nmnat1 plus18 amino acids of 
its 5’UTR and 70 amino acids of the N-terminus of ube4b (nmnat = 
nicotinamide/nicotinic acid mononucleotide; ube4b = Ubiquitin conjugation factor E4B; 
UTR = untranslated region) (Mack et al., 2001). Axonal protection afforded by WldS was 
not limited to mice, it also strongly preserved severed axons when expressed in models of 
axotomy in Drosophila and zebrafish (MacDonald et al., 2006; O’Donnell et al., 2013). 
Cross species axonal protection suggested that WldS may be impinging on a conserved 
axon death program activated post injury, however the mechanism of inhibition remained 
an open question. In order to determine which WldS domains were required for axon 
preservation, in vivo and in vitro model systems recapitulating axon degeneration were 
developed in Drosophila and mouse. Each system also provided a platform to uncover 
novel endogenous molecules required for injury-induced axon death using either a 
candidate approach or unbiased forward screening. Before proceeding to proposed 
mechanisms of axon death, it is necessary to describe the main model systems used to 
disentangle the pathway, with a focus on the Drosophila wing model of axon death, as it 
was used to acquire the majority of data presented in this thesis. 
 
Introduction 1-3: Model Systems to Study Axon Degeneration  
The transection of mouse sciatic nerve and observation of degeneration either in 
vivo or ex vivo was an early model of injury-induced axon death used to discover and 
describe Wlds. Sciatic nerve transection provides platform with properties replicated by 
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later model systems in the following ways: 1) axons undergo stereotyped Wallerian 
degeneration, 2) the injury is non-lethal, so axon integrity can be assessed over time and 
3) the site of assessment is distant from the site of injury and avoids artifacts induced by 
mechanical stress involved with the surgery or perturbation of surrounding glial/epithelial 
cells. The in vivo environment might also provide signals required for axon degeneration 
from the surrounding tissues or extracellular milieu which would be especially relevant 
for future therapeutics. Optic nerve crush can also model injury-induced axon death 
(Knöferle et al., 2010). Additionally, several other mouse in vivo models display 
prominent axon dysfunction, but involve more complex etiologies than Wallerian 
degeneration: traumatic brain injury paradigms, vincristine or taxol induced peripheral 
neuropathy, progressive motor neuropathy mouse model, and some other 
neurodegenerative disease models (Bommel et al., 2002; Geisler et al., 2016; Henninger 
et al., 2016; Wang et al., 2002; Yang et al., 2015). 
Several different neuronal types can be successfully cultured in vivo that extend 
processes long enough to be transected and analyzed after injury. Both PNS and CNS 
neurons undergo Wallerian degeneration after injury in culture and are typically derived 
from sensory/motor neurons within the DRG or cortical neurons from the superior 
cervical ganglia, respectively (PNS = peripheral nervous system; CNS = central nervous 
system, DRG = dorsal root ganglia) (Buckmaster et al., 1995; Osterloh et al., 2012). PNS 
neuron processes can even be induced to grow directionally towards supplied nerve 
growth factor (NGF) (Campenot, 1977). Removal of this NGF leads to a caspase 
dependent axon retraction and neuronal cell death independent from injury-induced 
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degeneration (Cusack et al., 2013; Finn et al., 2000; Simon et al., 2012). Campenot 
chambers utilize directional axonal growth into isolated compartments, enabling axon or 
cell body specific experimental interventions, as well as the collection of pure, axon only 
material for biochemical analysis (Campenot, 1977). Proteins packaged inside viral-like 
particles introduced directly into severed axons in such systems has become the gold 
standard to definitely demonstrate protein function within the axon after injury and define 
a time post injury in which a protein is required (Sasaki and Milbrandt, 2010). In vitro 
models also allow for high throughput screening of inhibitors or enhancers of axon death 
by either genetic approaches, like RNAi knockdown, or using large drug/small molecule 
libraries. A few criticisms of in vitro culture systems is that they lack extracellular signals 
present in vivo and neonatal derived cultures may remain in a permanent developmental 
state with altered gene expression profiles (Zhu and Oxford, 2011).  
Drosophila in vivo models of axon death allow for rapid genetic screening and 
pathway dissection, using extensive genetic tools developed by a rich history of fly 
geneticists. The co-opting binary systems from yeast, particularly the transcriptional 
activator, GAL4, and upstream activator sequence, UAS, enables expression of unique 
proteins under UAS control, restricted to the subset of cells expressing GAL4 (Brand and 
Perrimon, 1993). For example, Wallerian degeneration was first demonstrated in 
Drosophila by using an olfactory receptor neuron (ORN) specific GAL4 to drive 
expression of UAS controlled membrane tagged green fluorescent protein (GFP) and 
severing axons by removing cell bodies housed in the antenna (MacDonald et al., 2006). 
Axons underwent prototypical axon degeneration characterized by a short lag phase and 
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followed by complete granular fragmentation by 24 hours post axotomy (hpa) and full 
clearance of axonal debris by 3 days post axotomy (dpa) (MacDonald et al., 2006). As 
previously noted, overexpressing WldS, also using UAS, remarkably preserved axons for 
the lifetime of the fly (MacDonald et al., 2006). The ORN model of axon degeneration 
allows for long term observation of sensory axons within the adult fly brain and 
visualization of proteins by antibody staining or genetically encoded fluorescent tags, but 
requires time consuming adult brain dissection and mounting. Drosophila larvae also 
provide a platform for assessing axon death by crush injury or laser ablation of ventral 
abdominal nerves containing axons from both sensory and motor neurons (Xiong et al., 
2010). Larval injury models allow for live imaging of axon bundles and observation of 
stereotyped neuromuscular junction structure proximal to injury site, but analysis is 
limited to 2-3 dpa since larvae begin to pupate. (Avery et al., 2012; Xiong and Collins, 
2012; Xiong et al., 2012). This system was used to identify highwire (hiw), an E3 ligase 
required for axon death. 
Recently, mechanosensory neurons in Drosophila wing have emerged as an 
efficient model of axon death, easily visualized through the thin cuticle of the wing 
without dissection (Figure 1.1) (Fang et al., 2012; Neukomm et al., 2014). In this model, 
cell bodies receive input from dendritic contacts with sensory bristle shafts and transmit 
sensory information down axons, within the L1 vein, into the thoracic ganglia. By cutting 
the wing, a subset of axons with cell bodies distal to the injury site undergo Wallerian 
degeneration within 12-24 hours. Injured axons proximal to the cut site can be visualized 
live or fixed at any time within the lifetime of the fly, as long as wings are kept free of 
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damage, by expressing GFP with variety of neuronal GAL4 drivers. Importantly, the 
injury caused by a crush or transection of axon bundle is non-lethal and takes place far 
from the point of axon assessment, avoiding complications induced by damaged glia near 
the transection site (Neukomm et al., 2014). Since a random subset of labeled neurons are 
axotomized when removing the distal half of the wing, neurons proximal to the cut site 
are used as uninjured controls and are noted in figures as cell bodies. Thus, within an 
injured wing, severed axons undergo granular fragmentation within 12-24 hours, while 
uninjured axons remain intact within the same axon bundle (Figure 1.1). 
Each of the Drosophila model systems is amenable to screening using both 
mutagenesis and a variety of genetic tools such as RNAi knockdown, transposon 
disruption, and UAS overexpression (St Johnston, 2002). However, the tools noted above 
sometimes induce homozygous lethal alternations to the genome, thus limiting screening 
to non-lethal homozygous or heterozygous animals. To overcome this limitation, mosaic 
analysis with a repressible cell marker (MARCM) can be used to generate clones, 
homozygous for somatic lethal mutations and labeled with a fluorescent marker such as 
GFP (Figure 1.1) (Lee and Luo, 2001). This system requires the use of flippase (FLP) 
recombinase, under the control of specific promoters, to drive recombination between 
short flippase recognition target (FRT) sites located near the centromere of each 
Drosophila chromosomal arm, excluding the 4th and Y.   
In the case of the wing, differential expression strengths randomly inserted asense 
driven FLPs can induce a graded number of neuronal clones. Using FLPs that induce few 
clones produces an added benefit of enabling single axon resolution within the L1 wing 
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vein. This resolution allows the integrity of each individual severed axon to be assessed, 
rather than attempting to assess the status ~40+ neurons labeled using OK371-GAL4 or 
dpr-GAL4 (Figure 1.1) (Neukomm et al., 2014). This system was used to generate mutant 
clones in both ORN and wing models of axotomy, and it was required to identify 
homozygous lethal Drosophila Sterile alpha/ARMadillo/toll-interleukin receptor 
homology protein (dsarm) loss of function alleles that suppress axon death (Osterloh et 
al., 2012). Unique mutations were then identified using a combination of traditional 
genetic mapping and whole genome sequencing with next generation sequencing (NGS) 
technology (Gonzalez et al., 2012).  
 
Introduction 1-4: Nmnat is an Axon Survival Factor 
A series elegant experiments were undertaken in several labs to tease apart the 
axon protective determinants of the WldS molecule. Briefly, domains of Wlds were 
overexpressed in a number of combinations and each was assessed for efficiency of axon 
protection post injury. Also included in these studies were each of the three mammalian 
Nmnat genes, which have distinct neuronal localization patterns: Nmnat1 in the nucleus, 
Nmnat2 in the cytoplasm/axoplasm and attached to Golgi derived vesicles, and Nmnat3 
to mitochondria. To summarize evidence from experiments in a variety of model systems, 
the efficiency axon preservation from Wlds was dependent on enzymatically active, 
stabilized Nmnat1 localized within the axoplasm (Araki et al., 2004; Avery et al., 2009; 
Babetto et al., 2010; Milde et al., 2013; Sasaki and Milbrandt, 2010). The Wlds N16 
linker interaction with valosin-containing protein (VCP) results in the usually nuclear 
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Nmnat1, to be re-localized to the axoplasm and axonal mitochondria. Consistent with this 
finding, each Nmnat protein can suppress axon death if stably re-localized to the 
axoplasm (Avery et al., 2009; Conforti et al., 2009; Laser et al., 2006; Wilbrey et al., 
2008). Axon death can even be suppressed when Nmnat protein is delivered directly to 
severed axons within viral-like particles (Sasaki and Milbrandt, 2010). This experiment 
convincingly ruled out any contribution to axon death by Nmnat-induced alterations of 
gene expression within the nucleus.  
If artificial Nmnat overexpression suppressed axon death so strongly, the field 
hypothesized that levels of an endogenous Nmnat may be tightly correlated to axon death 
and genes required for Nmnat turnover might be required for degeneration. In mammals, 
Nmnat2 was the most attractive candidate for the role of axon survival factor due to its 
endogenous localization to axoplasm. Subsequent analysis confirmed this hypothesis as 
Nmnat2 depletion caused axon death that could not be rescued by overexpression of 
Nmnat1 or Nmnat3 (Gilley and Coleman, 2010). Additionally, Nmnat2 or the sole 
Drosophila Nmnat is required for axon development and survival both in vivo and in 
vitro (Fang et al., 2012; Hicks et al., 2012; Zhai et al., 2006). Since Nmnat2 has a short 
half-life within the axonal compartment and requires constant replenishment by fast 
axonal transport on Golgi derived vesicles from the cell soma, it would follow that 
disruptions to trafficking induced by axon transection or damage to cytoskeletal rails 
would lead to a rapid fall in Nmnat2 levels and degeneration (Milde et al., 2013). As 
predicted, both mammalian Nmnat2 and Drosophila Nmnat levels drop after axonal 
injury and, conversely, disrupting turnover by inhibiting palmitoylation induced 
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membrane localization enhances Nmnat2 protective ability (Milde et al., 2013; Walker et 
al., 2017; Xiong et al., 2012; Yang et al., 2015).  Palmitoylation at cysteine residues 
164/165 governs membrane localization, enhances ubiquitination and thus increases 
targeting to the proteasome (Milde and Coleman, 2014; Milde et al., 2013). Conversely 
overexpressing Nmnat2 without these sites decreases turnover and enhances axon 
protection after injury (Milde et al., 2013). Consistent with these results, axon death is 
also suppressed modestly with broad proteasome inhibitors in vitro, such as MG132, and 
strongly suppressed when yeast de-ubiquitinating (DUB) ubiquitin-specific protease 2 
(UBP2) is overexpressed in vivo (Baker et al., 1992; Xiong et al., 2012; Zhai et al., 2003). 
What proteins were responsible for rapid Nmnat2 turnover? 
The E3 ligase, Highwire (hiw)/Phr1, in an atypical SCF complex with 
SkpA/Skp1a and dFsn/Fbxo45, governs the ubiquitination and turnover of Nmnat, 
possibly coordinating this action at membranes (Phr1 = Protein-Associated-with-
Myc[PAM]/Highwire/Regulator-of-Presynaptic-Morphology[RPM1]; Skp = S-phase 
kinase associated protein; dFsn/Fbxo = F-box protein; SCF = Skp/Cullin/F-box) (Babetto 
et al., 2013; Brace et al., 2014; Xiong et al., 2012; Yamagishi and Tessier-Lavigne, 
2016). Although the atypical SCF complex has only been described in mammalian cell 
culture systems, loss of function alleles of hiw strongly inhibit axon degeneration in 
Drosophila and extend protection for the lifetime of the fly (Neukomm et al., 2014; 
Xiong et al., 2012). Also, mutations in the really-interesting-new-gene (RING) domain 
lead to dominant protection of axons, indicating the ubiquitin ligase activity by the RING 
domain is functionally required for Nmnat turnover (Neukomm et al., 2014; Xiong et al., 
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2012). Knocking down Phr1/Skp1a/Fbxo45 also potently suppresses axon death in 
mammalian models, however it is unclear whether individual components offer different 
levels for protection because experiments recorded axon integrity only up to 24 hours 
(Yamagishi and Tessier-Lavigne, 2016). Removing the components in this complex 
cannot suppress death induced by Nmnat knockdown in mammals or Drosophila, 
suggesting a role for Hiw upstream of Nmnat loss in an axon death pathway (Xiong et al., 
2012; Yamagishi and Tessier-Lavigne, 2016). Taken together, the existing data argue that 
Hiw/Phr1 regulates fast turnover of Nmnat/Nmnat2. 
 Interestingly, proteasome inhibition does not increase basal Nmnat levels to the 
same degree as hiw nulls or UBP2 overexpression, suggesting a regulation is more 
complex than proteasomal turnover (Xiong et al., 2012). Also, MG132 at high 
concentrations inhibits non-proteasomal proteases like calpains, while more specific 
proteasome inhibitors, such as lactacystin or epoxomicin, have variable axon protective 
affects in cultured PNS vs CNS neurons, suggesting that proteasome blockade is not 
universally protective after axon injury and thus, not essential to the axon death pathway 
(Meng et al., 1999; Yang et al., 2013).  
Hiw is a large multi-domain protein with an N-terminal RCC1-like GEF domain, two  
PAM-homology-related (PHR) domains, and a RAE-1 binding domain (RBD) capable of 
multiple cellular processes in addition to its role as a ubiquitin ligase (RCC1 = Regulator-
of-Chromosome-Condensation-1; GEF = guanine exchange factor; RAE-1 = 
Ribonucleic-Acid-Export-1)(Grill et al., 2016). These domains control synaptic 
morphology, axon guidance, growth cone termination, and possibly other functions that 
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seem to be separable from Nmnat regulation with one exclusion, the regulation of 
MAPKKK, Wnd/Dlk levels by ubiquitination and activity through PHR-PPM-2 
phosphatase interactions (MAPKKK = mitogen-activated protein kinase kinase kinase; 
Wnd/Dlk = wallenda/dual-leucine-kinase; PPM-2 = Protein-Phosphatase-
Methyltransferase-1) (Baker et al., 2014; Collins et al., 2006; Klinedinst et al., 2013; Shin 
and DiAntonio, 2011; Wang et al., 2013; Wu et al., 2007; Yan et al., 2009). Loss of 
function alleles of wnd/Dlk modestly suppress axon degeneration and downstream MAP 
kinase signaling cascade components, MLK2/MEKK4, MKK4/MKK7, and JNK1-3 
knock-down and loss of function alleles display variable protection of severed axons 
(MLK = Mixed Lineage Kinase  ;MEKK = mitogen-activated protein Kinase/ERK kinase 
kinase; MKK = mitogen activated protein kinase ; JNK = c-Jun NH2-terminal kinase ) 
(Yang et al., 2015). The protective abilities from restricting MAPK function likely 
derives from increased basal levels of Nmnat2, however several MAPK are 
phosphorylated within minutes to hours post injury and may play a more complex role in 
downstream degeneration (Walker et al., 2017; Yang et al., 2015). Further complicating 
this additional layer of Nmnat2 regulation, JNK also negatively regulates the axon 
protective microtubule stabilizing SCG10, phosphorylates, although no SCG10 homologs 
have been described in Drosophila (SCG = superior-cervical-ganglion-10) (Morii et al., 
2006; Shin et al., 2012a; Walker et al., 2017). 
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Introduction 1-5: Axon Survival and Maintenance of NAD+ 
While increasing Nmnat levels has been clearly demonstrated to be axon protective, 
how exactly does Nmnat provide axon protection? Nmnats can play multiple roles, both 
acting as molecular chaperones and as the key biosynthetic enzyme required to produce 
NAD+ directly from its precursor NMN, or indirectly from NaMN to NaAD then NAD 
synthetase conversion to NAD+ (NAD+ = nicotinamide adenine dinucleotide; NMN = 
nicotinamide mononucleotide; NaMN = nicotinate  mononucleotide; NaAD =  nicotinate  
adenine dinucleotide) (Schweiger et al., 2001; Zang et al., 2013; Zhai et al., 2006). 
Several experiments with Wlds and Nmnats determined that enzymatic NAD+ activity is 
absolutely required for suppression of axon death (Araki et al., 2004; Avery et al., 2009; 
Milde et al., 2013; Sasaki et al., 2006; Wang et al., 2005). Furthermore, NAD+ is rapidly 
depleted by approximately four hours post injury and depleting NAD+ using a 
dimerizable tankyrase-poly-ADP-ribose domain leads to axon death (Araki et al., 2004; 
Gerdts et al., 2015). In contrast, addition of exogenous NAD+, increasing NMN through 
co-application of NR and conversion enzyme NRK1/2, or upregulating Nam conversion 
to NMN by increasing NAMPT activity can modestly delay axon death after injury (NR 
= nicotinamide riboside; NRK = nicotinamide riboside kinase; Nam =  ; NAMPT = 
nicotinamide phosphoribosyltransferase)(Araki et al., 2004; Ratajczak et al., 2016; Wang 
et al., 2005).  
It is not surprising axons require NAD+, as it is used in variety of cellular process as 
a co-factor, precursor to other molecules, or in redox reactions, the most important of 
which is accepting or donating H+ protons in energy production. NAD+ is required for 
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both glycolysis in the cytoplasm and several energy production steps in mitochondria 
including pyruvate oxidation to acetyl coenzyme A and ATP generation by oxidative 
phosphorylation (Rongvaux et al., 2003).  Since ATP seems to fall coincident NAD+ 
levels, the field gravitated toward a model of axon death where injury halted new Nmnat2 
supply, leading to NAD+ depletion and ATP production failure. Without NAD+/ATP, 
Ca2+ ATPase pumps cease and mitochondria depolarize leading to mitochondrial 
permeability transition pore (mPTP) opening (Barrientos et al., 2011; Stein and Imai, 
2012). Both causing a rise of intracellular [Ca2+] to high enough levels to activate 
cytoskeletal destroying calpain proteases (Ma et al., 2013; Yang et al., 2013).  
Seemingly in conflict to this hypothesis however, was data showing that overall 
NAD+ levels had little predictive correlation with axon death (Sasaki et al., 2016). For 
example, NMN deamidase alone or expressed with NMN synthetase + NR protected 
aculeated axon fragments, but had lower and higher basal NAD+ levels relative to wild 
type, respectively (Sasaki et al., 2016). Axons with these manipulations also had similar 
changes in basal levels of NMN, arguing against an alternative theory that NMN levels 
are a degenerative trigger (Loreto et al., 2015; Sasaki et al., 2016; Di Stefano et al., 
2015). While overall levels of NAD+ and metabolites failed to explain axon protection, 
the ability of a specific intervention to suppress a 2-3 fold increase in NAD+ 
consumption rate post injury strongly predicted the degree of axon preservation (Sasaki et 
al., 2016). Thus rapid NAD+ consumption likely drives degeneration by inducing local 
energy deficits leading to the obvious question of what consumed NAD+ post injury. A 
candidate approach ruled out requirements of PARP domain proteins or sirtuins for axon 
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death, but it took unbiased forward genetic screens in the Freeman lab and Millbrandt 
labs to uncover a possible candidate for NAD+ depletion in the pro-degenerative 
dsarm/Sarm1 (Avery et al., 2009; Gerdts et al., 2013, 2015; Osterloh et al., 2012; Wang 
et al., 2005).  
 
Introduction 1-6: Pro-degenerative dSarm/Sarm1 
dsarm is required for axon death and was discovered in a mutagenesis screen 
using the Drosophila ORN model of axotomy (Osterloh et al., 2012). Multiple loss of 
function alleles strongly suppress axon death for the lifetime of the fly, similar to the 
phenotypes observed with Wlds and loss of function hiw alleles (Neukomm et al., 2014; 
Osterloh et al., 2012). The mammalian knockouts the homolog of dsarm, Sarm1, also 
displayed strong suppression of axon death both in vitro and in vivo in all neuronal 
subtypes assayed (Gerdts et al., 2013; Osterloh et al., 2012). Dsarm/Sarm1 is expressed in 
neurons and required cell autonomously within axons after injury for axon death to 
proceed, however plays no role in degeneration induced by NGF withdrawal (Gerdts et 
al., 2013; Osterloh et al., 2012).  
Dsarm/Sarm1 protein consists of several conserved domains, even present in C. 
elegans homolog, TIR-1: 1) an N-terminal 27aa mitochondrial localization domain 
(N27), 2) an N-terminal/HEAT/armadillo (ARM) domain, 3) dual, centrally located 
sterile alpha motif (SAM) domains, and 4) a C-terminal toll/interleukin-1 receptor 
homology domain (TIR) (Chuang and Bargmann, 2005; Gerdts et al., 2013; Osterloh et 
al., 2012; Summers et al., 2016).  Functional analysis of the domains revealed that Sarm 
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required both SAM and TIR domains to induce axon death and removal of the N-terminal 
domain/ARM domain led to a constitutively active form of Sarm that induced 
spontaneous cell death in multiple cell types and organisms (Freeman Lab - Unpublished 
Data, Gerdts et al., 2013; Panneerselvam et al., 2013; Summers et al., 2016). The N27 
mitochondrial localization domain is dispensable for axon death (Gerdts et al., 2013). 
Homotypic interaction between SAM domains results in multimerization between Sarm1 
molecules and TIR dimerization is sufficient to induce a degenerative response, although 
an exact mechanism remains controversial (Gerdts et al., 2013, 2015; Summers et al., 
2016).  
In immunity, TIR domains typically signal downstream by homo/hetero-
dimerizing with toll-like receptor (TLR) proteins at the plasma membrane and serve as 
scaffolding for a variety of kinase signaling cascades including MAPKs (Banerjee and 
Gerondakis, 2007; O’Neill and Bowie, 2007). Sarm1 TIR domain is capable of these 
interactions and works as a repressor in innate immunity, yet this function is separable 
from axon death function as other TIR domains proteins, TLRs, or TLR-adaptor proteins 
show no defects in axon death when removed or inhibited (Carlsson et al., 2016; Lin et 
al., 2014a; Liu et al., 2014). Sarm1 and TIR-1 TIR domains have also been demonstrated 
to control neuronal identity and morphology through MAPK signaling, particularly 
MKK4 and JNK, ultimately regulating cytoskeletal dynamics through transcriptional 
responses (Chang et al., 2011; Chen et al., 2011; Chuang and Bargmann, 2005). 
Knocking down MAPKs however, cannot prevent degeneration induced by artificial 
dimerization of Sarm1 TIR domains, suggesting that MAPKs do not play roles 
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downstream of Sarm1 in degeneration (Walker et al., 2017). Since all of the gain-of-
function or constitutively active forms of dSarm/Sarm1, including dimerized TIR 
domains, induce rapid consumption of NAD+, it has been proposed that TIR dimers 
directly and actively destroy NAD+ using Sarm-specific amino acids, which are not 
present in related TIR domains, between the TIR BB and DD loop structures (Gerdts et 
al., 2015; Summers et al., 2016). Though strongly correlated, direct TIR consumption of 
NAD+ has not been demonstrated and it remains possible that TIR domains work with 
other protein partners to destroy NAD+. Degenerative processes directly downstream of 
Sarm1 remain poorly defined. 
Sarm1 is likely activated by the removal of physical N-terminal/ARM domain 
inhibition of the TIR domain, however the mechanism governing de-repression remains 
unknown.  In C. elegans, TIR-1 is dis-inhibited by upstream Ca2+ activation of 
calcium/calmodulin-dependent protein kinase II (CamKII), likely through kinase activity, 
although this has not been demonstrated (Chuang and Bargmann, 2005). Calcium is an 
attractive upstream activator of Sarm1, as two distinct calcium waves occur after injury 
and calcium is necessary and sufficient for axon death, although recent evidence argues 
against this hypothesis (Loreto et al., 2015; Vargas et al., 2015). Several kinases, maybe 
those MAPKs phosphorylated early post injury, might also mimic CaMKII activity and 
phosphorylate either the ARM or TIR domain to disrupt inhibitory interaction, although 
no evidence currently supports this hypothesis (Yang et al., 2015).  
Conversely, several lines of evidence suggest a role for Nmnat2 upstream of 
Sarm1, where injury-induced loss of Nmnat2 leads directly to Sarm1 disinhibition. First, 
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Nmnat2 -/- are embryonic lethal and can be fully rescued by also knocking out Sarm1 
(Gilley et al., 2015; Hicks et al., 2012). Also, Sarm -/- protects axons after injury, despite 
a precipitous fall in Nmnat2 levels, arguing Sarm1 activity is required downstream of 
Nmnat2 loss (Gilley et al., 2015; Yang et al., 2013). Finally, cytoplasmic Nmnat1 or 
NMN deamidase prevent NAD+ consumption, presumably by blocking Sarm1 activity, 
while NAMPT and NRK+NR do not prevent consumption, but supplement enough 
NAD+ to counteract downstream Sarm1-mediated NAD+ destruction (Sasaki et al., 
2016).  Since direct interaction between Nmnat2 and Sarm1 has not been demonstrated, it 
remains possible that a variety of post-translational modifications such as protease 
cleavage, ubiquitin addition, or ADP ribosylation or  removal of a specific chaperone, 
possibly Nmnat, are responsible for removal of ARM repression. Whatever the stimulus, 
the ARM domain seems to act as general, yet caspase-independent, degenerative sensor 
since Sarm1 is required for cell death downstream of mitochondrial dysfunction, viral 
infection, oxygen/glucose deprivation, reactive oxygen species, and excitotoxic stress 
(Hou et al., 2013; Massoll et al., 2013; Mukherjee et al., 2013; Panneerselvam et al., 
2013; Summers et al., 2014). 
  
Introduction 1-7: Therapeutic Prevention of Axon Death 
 While complete transection is one of the more severe insults axons can 
experience, a vast array of traumatic insults and chronic maladies can lead to axon 
dysfunction followed by neuronal death (Coleman and Perry, 2002; Dikranian et al., 
2008). Even without neuronal death, focal axonal swellings can cause cognitive and 
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functional deficits by disrupting protein transport (Millecamps and Julien, 2013). 
Therapeutics targeting components within axon death pathway could prevent 
degeneration long enough for cytoskeletal repair, thus inhibiting axonal ‘dying-back’ and 
subsequent neuronal loss. Due to the complex etiologies of neurodegenerative disease, 
targeting axon death is not a panacea, however therapeutics could be especially beneficial 
in diseases with prominent axon dysfunction and testing models of disease in Wlds or 
Sarm1 -/- background provides good indication of potential therapeutic success. 
Traumatic brain injury and spinal cord injury without transection are examples of 
insults that result in diffuse and focal axonal dysfunction, respectively, where 
downstream degenerative processes are alleviated by either removing Sarm1 or 
overexpressing Wlds (Gillingwater et al., 2006; Henninger et al., 2016; Yin et al., 2016; 
Zhang et al., 1996). Long axons are particularly affected due to the shear forces 
encountered in these injuries and axonal damage leads to a destructive feedback loop 
where axonal debris drive secondary inflammatory responses from macrophages, 
microglia, and astrocytes in mouse injury models (Gyoneva and Ransohoff, 2015; Lin 
and Wen, 2013).  
Axonal dysfunction is also prominent in both acquired and hereditary 
neuropathies. Acquired peripheral neuropathies occur in ~50% of patients with diabetes 
and in 38% of cancer patients treated with existing chemotherapeutics (Kerckhove et al., 
2017; Stino and Smith, 2017). Both Sarm -/- and Wlds mice have shown resistance to 
axon dysfunction and dying back neuropathies after exposure to chemotherapeutic agents 
such as vincristine and taxol as well as hereditary disorders such as Charcot-Marie-Tooth 
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disease (Berbusse et al., 2016; Geisler et al., 2016; Meyer zu Horste et al., 2011; Wang et 
al., 2002).  
The above are only a few examples of disease states that could benefit from drugs 
targeting axon death and still others may benefit from inhibiting axon degeneration in 
combination with existing therapies.  Intriguingly, therapeutics designed to prevent 
NAD+ consumption or enhance NAD+ levels may also provide alleviation of age related 
decline of NAD+ in neurons and muscle tissue (Chung et al., 2016; Srivastava, 2016). 
 
Introduction 1-8: Thesis Overview 
This thesis describes a screen of 40,319 unique chromosomal arms in the 
Drosophila wing model of axotomy to identify a novel BTB domain containing gene 
required for axon degeneration, axundead (axed).  Chapters 2, 3, and 4 present the 
rational, the results, and brief discussion of experiments undertaken. In Chapter 2, I 
describe the genetic schemes used to screen, isolate, and identify two mutations in axed 
as well as other mutants essential for both axon death and maintenance. Chapter 3 
demonstrates Axed requirement downstream of dSarm pro-degenerative signaling and 
death induced by reduction or ablation of Nmnat.  Chapter 4 attempts to determine which 
conserved domains of Axed are required for axon death function, as well as which 
cellular processes Axed might utilize to destroy axons.  Finally, Chapter 5 is a discussion 
of how our experimental data fits with existing hypotheses in the axon death field and 
specific future experiments that could address outstanding questions. Finally, I briefly 
address how to therapeutically target axon death proteins in neurodegenerative diseases.  
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To adequately proceed requires a brief review of BTB containing proteins and their roles 
in diverse cellular processes. 
 
 
 
Introduction 1-9: BTB Domain Containing Proteins 
The bric-a-brac tramtrack broad (BTB) domain has a wide variety of roles in a 
complex tree of evolutionarily diverged proteins that function as transcriptional 
repressors (Melnick et al., 2000), cytoskeletal regulators (Bomont et al., 2000), ion 
channels (Kreusch et al., 1998), and adaptors for ubiquitin E3 ligase complexes (Canning 
et al., 2013).  To accomplish these functions, the versatile BTB fold can homo-
tetramerize (Kreusch et al., 1998), homodimerize (Melnick et al., 2000; Soltysik-
Espanola et al., 1999), or heterodimerize with other BTB domain containing proteins 
(Errington et al., 2012) as well as interact with non-BTB structures such as ATP 
(T’Jampens et al., 2002).  BTB family of proteins have well described roles aiding cullin-
RING-ligase (CRL) complexes to covalently attach ubiquitin to specific substrates for 
designation to the proteasome or mono-ubiquitin modification that can alter the substrate 
function or subcellular localization (Canning et al., 2013; Pintard et al., 2004).  Two BTB 
domains unify the complex into an efficient ubiquitinating dimer by enhancing 
concentration and substrate availability (Errington et al., 2012; Zhuang et al., 2009). To 
tune CRL complex activity, recent evidence suggests alternate BTB-domain containing 
proteins can be incorporated in the complex by heterodimerization (Errington et al., 
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2012). This type of modularity could act as a ‘molecular rheostat’ and possibly shift the 
complex between long chain polyubiquitination and monoubiquitylation (Errington et al., 
2012). Interestingly, the BTB domain only Skp family, plays noted roles in axon 
degeneration and pruning, with Skp1a/SkpA aiding a Phr1-Fbxo45 complex in the 
regulation of basal levels of Nmnat2/dNmnat (Brace et al., 2014; Yamagishi and Tessier-
Lavigne, 2016).  
Drosophila CG8398 is located on chromosome 3L and has a conserved BTB and 
BACK domain, though notably, no Kelch domains or DNA binding domains. CG8398 is 
expressed in neurons according to FlyAtlas Anatomical Expression dataset and enriched 
in the testis (Chintapalli et al., 2007). In C. elegans, CG8398 homolog BTBD2 
contributes to non-apoptotic linker cell death in complex with CUL-3, RBX-1, and 
SIAH-1 plus UBE2D2 downstream of a pathway similar to a proposed model of axon 
degeneration: active dsarm/TIR-1 signaling via a MAPK cascade then through a non-
canonical function of HSF-1(RBX-1 = RING-box protein; SIAH-1 = seven in absentia 
homolog 1; UBE2D2 = Ubiquitin Conjugating Enzyme E2 D2; HSF-1 = heat shock 
transcription factor 1) (Kinet et al., 2016). What that CRL complex tags with ubiquitin 
for proteasomal degradation remains unknown. 
CG8398 closest related protein in mammals is BTBD2 with 39% amino acid 
identity homology (short isoform of CG8398), followed by closely related proteins 
BTBD3, BTBD6, and BTBD1. These four proteins have a BTB domain and a BACK 
domain in which the C-terminal kelch repeats have been replaced by a PHR domain, 
curiously similar to domains in Drosophila Hiw. Homology between CG8398 and 
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BTBD2 is strongly determined by the BACK domain. BTBD2 and BTBD1 share 80% 
amino acid identity and interact with topoisomerase I (TOP1) in the nucleus and also with 
tripartite motif family 5 alpha splice variant (TRIM5δ) in punctate cytoplasmic bodies in 
HeLa cells (Xu et al., 2002, 2003). Complexed together, BTBD1/BTBD2/TRIM5/TOP1 
may serve as a first line of defense against retroviral infections such as HIV-1 (Khurana 
et al., 2010).  Interestingly, loss of function mutations in a related TRIM E3 ligase, 
TRIM2, cause early onset axonal neuropathy by failing to recycle NF-L via the UPS 
(Ylikallio et al., 2013).  
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Figures 
Figure 1.1: An F1 mutagenesis screen for regulators of axon death in the Drosophila 
wing 
 
Figure 1.1: 
P0 males were fed mutagen (ethyl methanesulfonate, EMS), and crossed to virgin 
females. Both males and females carried genetic elements to induce MARCM clones.  
The resulting F1 males were heterozygous (mut/+) and mosaic for EMS-induced 
mutations. Sensory neuron MARCM clones were GFP+-labeled and homozygous 
(mut/mut) mutant. One wing was injured and used to screen for axon death defective 
phenotypes at 7 days post axotomy (dpa). Wild type axons degenerate and are cleared by 
7dpa, while severed axons persist in axon death mutants. Genotypes are listed in 
Materials & Methods in Chapter II.
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CHAPTER II: Deficiency and Mutagenesis Screening for Regulators of Axon Death 
 
This work was conducted in the laboratory of Marc Freeman. Lukas Neukomm built 
many of the Drosophila lines required for the screen as described in the 2014 PNAS 
article  (Neukomm et al., 2014). I performed the Drosophila screen described, along with 
Lukas Neukomm, Jonathan Farley, and Elizabeth Allen. I performed all of the described 
Drosophila work in close collaboration with Lukas Neukomm who performed the 
following: 1) isolated and characterized axed2094 2) cloned axedlong and axedshort 3) tested 
3L deficiency and mimic lines. Tim Rooney tested a subset of deficiency lines listed in 
the ORNs, which I repeated in the wing. Drosophila mutations were sequenced in the 
laboratory of Stephan Zuchner. As described in the thesis preface, gene-of-interest-#1345x, 
gene-of-interest-#2596x, gene-of-interest-#21013x are introduced, however a full 
characterization of function is currently being performed by Jon Farley and others. 
 
The following publication is in preparation as follows: 
Axon death pathways converge on Axed to promote functional and structural axon 
disassembly. Lukas J. Neukomm* & Thomas C. Burdett*, Jaeda Coutinho-Budd, 
Andrew M. Seeds, Stefanie Hampel, Jack Wong, Yonca Karadeniz, Jeannette M. 
Osterloh, Amy E. Sheehan, and Marc R. Freeman 
(* denotes co-first authorship) 
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Abstract 
 
This chapter describes the work undertaken to identify novel candidate genes 
required for axon degeneration and maintenance.  Two different unbiased forward genetic 
screens were utilized. In the first, numerous genes within molecularly defined deletions 
that removed large sections of the Drosophila genome were screened, while in the second 
screen, a mutagen was used induce random mutations across the genome. In both 
strategies, mutant phenotypes derived from cell autonomous malfunctions, as only 
neuronal clones homozygous for deletions or mutations were observed. Causative 
mutations for each candidate were determined by a combination of next generation 
sequencing, Sanger sequencing, and classic genetic techniques such as complementation 
testing, deficiency mapping and rescue by adding back functional genes. Initial 
phenotypic analysis is presented, describing the lack of axon degeneration in axed0011 & 
axed2094. Additionally, I describe two other distinct genes with notable axon death and 
maintenance phenotypes.  
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Chapter II: Results & Discussion 
 
Results 2-1: Deficiency screening for axon death genes in Drosophila wing neurons 
clones. 
To identify novel genes required for axon death we first screened a set of 
molecularly defined deletions with FRT sites in axotomized Drosophila wing sensory 
clones after injury. We generated deletion homozygous GFP+ clones as described 
previously and (detailed genotypes in Material & Methods) allowed flies to age for 5 
days before injury to ensure clearance pre-clone induction protein. Since, the majority of 
axonal debris from severed axons are cleared by ~5 dpa in wild type, we decided to 
screen for severed mutant axons that remained preserved at 5-7dpa.  
Deficiencies tested comprised of 38.7% of the 1st chromosome, 24.2% of the 2nd 
chromosome (30.1% of the left arm and 18.7% of the right arm), and 14.5% of the whole 
Drosophila genome. I uncovered a single deficiency with an axon death defective 
phenotype, Df(1)ED7289 that uncovers hiw (Figure 2.1, Table 2.1) Several deficiencies 
resulted visible clones only in wing sensory neurons, but not ORNs (Df(2L)Exel6001 & 
Df(2L)Exel6036) and some deficiencies where no clones were generated 
(Df(2L)Exel6012, Df(2L)Exel7043, & Df(2L)Exel7059). 
 
Results 2-2: Mutagenesis screening for axon death and maintenance genes in Drosophila 
wing neurons clones. 
To identify novel genes required for axon death and maintenance, we performed an 
unbiased forward genetic mutagenesis screen in glutamatergic sensory neuron MARCM 
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clones in the adult Drosophila wing (Figure 1.1) (Neukomm et al., 2014). We introduced 
random mutations by ethyl methanesulfonate (EMS) screened extensively on the 1st, 2nd, 
and 3rd chromosomes. Since this was a clonal screen, we were unable to analyze 
Chromosome 4 and the male Y chromosome because they lack FRT sites. We were also 
unable to screen any mutations as homozygous if the affected genes were located between 
the FRT site and telomere. To effectively saturate the genome, we screened 40,319 mutant 
flies on the 1st, 2nd, and 3rd chromosome. 
On the 1st chromosome we performed an F2 screen, while on autosomes we were 
able to perform a more rapid F1 screen. In the F2 screen, P0 males were mutagenized with 
EMS and bred to virgin females with balancers twice to generate a mutant F2 stock. Mutant 
F2 flies were crossed to flies harboring the required genetic elements to generate 
homozygous mutant GFP+ neuronal clones in the wing (detailed genotypes in Materials & 
Methods). In the F1 screen, P0 males were mutagenized with EMS and bred to virgin 
females to produce F1 offspring males heterozygous for randomly introduced mutations 
and homozygous for the same mutations in GFP+-labeled sensory neuron clones (Figure 
1.1) (detailed genotypes in Materials & Methods). As described previously, we then 
transected axons by mechanically severing the wing and assessed axon death in the L1 vein 
at 7 days post axotomy (Figure 1.1) (Neukomm et al., 2014). 
We screened 2,045 mutants on the 1st chromosome, 15959 on the 2nd left arm, 7286 
on 2nd right arm, 7646 on the 3rd left arm, and 7383 on the 3rd right arm and identified one 
mutant on the X chromosome where a subset of severed axons were preserved at 7 dpa, 
345x (Figure 2.2), two mutants on the X chromosome in which uninjured axons 
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progressively degenerate, 596x  & 1013x (Figure 2.3), and two mutants on chromosome 
arm 3L with severed axons that remained morphologically preserved at 7 dpa, 3L.0011 & 
3L.2094 (Figure 2.4).  
I also isolated several axon death defective mutant alleles of highwire: hiw157x 
encoding an early nonsense mutation (K1312*), hiw587x encoding nonsense mutation in the 
middle of the gene (W3641*), and hiw275x encoding a dominant nonsense mutation in the 
RING domain.   Characterization of these can be found in the following publication: 
Neukomm, L.J., Burdett, T.C., Gonzalez, M.A., Züchner, S., and Freeman, M.R. (2014). 
Rapid in vivo forward genetic approach for identifying axon death genes in Drosophila. 
Proc Natl Acad Sci USA 111, 9965–9970. 
 
 
Results 2-3: Isolation & identification of alleles defective for axon death & axon 
maintenance on the 1st chromosome 
 We recovered a single mutant stock, 345x, harboring both intact and degenerating 
severed axons at 7 dpa (Figure 2.2-A).  To quantify axon death in this assay and others, 
we scored uninjured control axons extending from cell bodies proximal to the wing cut 
site (cb, indicated in the upper right corner of each example), extra axons that were 
severed but axon death defective (severed intact), as well as uncleared axonal fragments 
(debris). An initial characterization of the axon death phenotype revealed a delay in 
degeneration with ~20% & ~12% of severed axons remaining intact at 7 & 14 dpa, 
respectively, compared to no intact remaining anucleated axons after 1 day in wild type 
(Figure 2.2-B). The stock was embryonic lethal and lethality was linked to the axon death 
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defective mutation even after five rounds of outcrossing to a wild type genome. 
Duplications uncovering hiw failed to rescue lethality and no mutations within hiw locus 
were observed (data not presented in this thesis). Subsequent duplication mapping, PCR 
confirmation of mutations, and rescue experiments revealed a single causative mutation 
within the splice site of the 1st and 2nd exons of gene-of-interest #1, (GOI#1), a 
transcription factor (data not presented in this thesis).  
I also isolated two distinct mutants on the 1st chromosome with wild type axon 
death, but severely altered axon morphology in uninjured neurons characterized by large 
protrusions of the plasma membrane in both axons and dendrites (Figure 2.3-A). Each 
mutant was homozygous lethal and lethality was linked to the membrane blebbing 
phenotype after several rounds of outcrossing to a wild type genome. Sequencing 
revealed one stock, 596x, with a single missense mutation and mutant stock 1013x with 
two missense mutations within the accessory or catalytic domains of gene-of-interest #2 
(GOI#2). Additional loss of function alleles and RNAi knockdown of GOI#2 
recapitulated membrane dysfunction (data not in this thesis). Initial characterization of 
GOI #2596x revealed progressive membrane swelling over time culminating in axonal 
breaks and dying back from distal axonal portions to proximal, while mitochondria 
within axon fragments and blebs are condensed rather than elongated, matching 
observations in transected axons (Figure 2.3-B). 
 
Results 2-4: Isolation & identification of novel axon death defective mutations in axed. 
We isolated two individual mutants with defective axons death on the 3rd left 
chromosomal arm that were both homozygous lethal at the larval L1 stage. After several 
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rounds of outcrossing to a wild type chromosome, lethality was consistently linked to 
axon degeneration suppression. Mutations 3L.0011 & 3L.2094 failed to produce trans-
heterozygous offspring (Table 2.2), forming a single complementation group suggesting a 
single affected gene, which we named axundead or axed. 
Severed axons in axed0011 and axed2094 mutants exhibited robust morphological 
preservation equivalent to that observed in dsarm mutants at 7 dpa (Figure 2.4-A/B) 
(Neukomm et al., 2014). Axon preservation was quantified as above. To precisely assess 
axon preservation, we compared the number of neuronal cell bodies removed to the 
number of intact severed axons remaining and found that 99.3% and 100% of severed 
axed0011 and axed2094 mutant axons, respectively, remained morphologically intact at 7 
dpa (Figure 2.4-C). 
Next, we asked if Axed is required for axon death broadly in the nervous system.  
We assessed axon death cholinergic olfactory receptor neurons (ORNs) using a 
previously established antennal ablation assay (MacDonald et al., 2006). In wild type, 
unilateral antennal ablation destroys ORN cell bodies and induces fragmentation of 
ipsilateral axons that is cleared from the CNS in ~ 7 days, while contralateral axons serve 
as uninjured controls. In contrast to wild type, mutant axons lacking axed remain 
preserved at both 7 and 50 dpa (Figure 2.4-D), far beyond the mean lifespan of the fly. 
Thus, axed is essential for axon death, and axed mutations preserve axonal morphological 
integrity to a similar extent as mutations in dsarm or hiw (Osterloh et al., 2012; Xiong et 
al., 2012). 
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To identify the causative gene, we mapped the lethality of axed0011 and axed2094 
using molecularly defined deficiencies (Dfs) (Figure 2.5-A) and assayed those Dfs that 
failed to complement lethality for defects in axon death in homozygous Df MARCM 
clones (Figure 2.5-B). Both axed alleles failed to complement a large Df ZN47, and 
within that region, one smaller Df, BSC411 (uncovering ~100 genes), while all other 
partially overlapping deficiencies were able complement the lethality of both axed alleles. 
Within the non-overlapping region of ED211 and BSC411 were 7 candidate genes that 
could be responsible for axed phenotype. We used all available mutations in these genes 
to complement the lethality of both axed alleles and found only a single Minos 
transposon insertion within CG8398 (Mi{MIC}13270 or CG8398MI13270) (Figure 2.5-C) 
(Table 2.2). Consistent with our mapping strategy, MARCM clones of BSC411 or 
Mi{MIC}13270 (hereof axedMI13270) were also defective in axon death (Figure 2.5-B/D).  
While NGS failed to detect mutations in CG8398, focused Sanger sequencing 
revealed a 16bp deletion in exon 3 in axed0011 resulting in loss of function. However, we 
were not able to identify a molecular lesion within the open reading frame of CG8398 in 
axed2094, suggesting it might be a regulatory mutation (Table 2.3). To support our 
findings that CG8398 is required for axon death, we also created de novo axed alleles 
using two distinct methods, CRISPR/Cas9 and imprecise transposon excision (Metaxakis 
et al., 2005; Sebo et al., 2014) (Materials & Methods). CRISPR/Cas9 mutants harboring 
deletions in exon 2 (axedCrisprA, axedCrisprB & axedCrisprC; containing 194bp, and two 
distinct 14bp deletions, respectively), and Minos imprecise excision-based alleles 
(axedExMI07, axedExMI65 & axedExMI96), all failed to complement the lethality of our original 
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axed mutagenesis alleles, and they were also defective in axon death (Table 2.3). We 
therefore conclude that CG8398 encodes the axed gene. 
The CG8398 locus (hereafter axed) encodes two predicted isoforms (axedlong and 
axedshort, respectively) (Figure 2.5-C). We generated transgenic flies harboring isoform 
specific cDNA rescue constructs containing endogenous 5’ and 3’ UTRs under the 
control of the Gal4/UAS binary expression system (UAS-axedlong and UAS-axedshort, 
respectively). Expression of either axedlong or axedshort was sufficient to rescue the axon 
death phenotype in all axed alleles tested (Figure 2.5-D).  
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Chapter II: Materials and Methods 
 
Mutagenesis Screen: 
Males were starved for 12 hours before consuming mutagen, 25 mM ethyl methane 
sulphonate (EMS) in 1% sucrose, for 12 hours. Before breeding, males recovered in fresh 
vials for 12 hours. 
 
Wing injury & antennal ablation assays: 
Both assays are described previously (Neukomm et al., 2014). Wing: Wings were cut 
with MicroPoint Scissors (EMS, VANNAS Scissors; angled on side, delicate, 5-mm 
cutting edge, # 72933–04) and mounted in Halocarbon Oil 27 on a microscopy slide and 
covered with a coverslip, and immediately used for microscopy. Antennae: Antennae 
were ablated using high precision and ultra-fine tweezers (EMS, 78520-5). Adult brain 
dissections were performed as described(Wu and Luo, 2006). 
 
Immunohistochemistry & Confocal microscopy: 
Slides with Drosophila wings, mounted in Halocarbon Oil 27 (Neukomm et al., 2014), 
and brains, stained with anti-GFP mounted in Vectashield anti-fade reagent, were imaged 
on a Zeiss spinning disc confocal microscope (Intelligent Imaging Innovations, Denver, 
CO).  
 
Drosophila sequencing 
Next-generation sequencing technology (Gonzalez et al., 2012) was used to produce 74bp 
reads and align reads of each mutant to the Drosophila melanogaster reference genome. 
Backcrossing to a wild type genome was used to remove random background mutations 
and ‘clean up’ stocks before sending for sequencing or re-sequencing. PCR and Sanger 
sequencing of used to confirm NGS results and uncover novel genetic changes 
overlooked by NGS in specific difficult to read areas.  
 
Cloning: 
The cDNA of axedlong & axedshort was cloned from clone AY075255 (Berkeley Drosophila 
Genome Project, http://www.fruitfly.org/). Gibson Assembly was used to clone long and 
short cDNAs into pUAST (Brand and Perrimon, 1993). pUAST was linearized (EcoRI & 
XbaI), and PCR products containing endogenous 5’ and 3’ UTRs as well as coding 
sequences were inserted using the following primers:  
pLN287: p(5x)UAST-axedlong,w+ 
5’primer:CTCTGAATAGGGAATTGGGAATTCgttttgccatcaactggcaggtattttc 
3’primer:CCACAGAAGTAAGGTTCCTTCACAAAGATCCTCTAGAcataagcgctaatattcgtttaatg
c 
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pLN288: p(5x)UAST-axedshort,w+ 
5’primer:GAGAACTCTGAATAGGGAATTGGGAATTCccaaattccctctggtgggcgccc 
3’primer:CCACAGAAGTAAGGTTCCTTCACAAAGATCCTCTAGAcataagcgctaatattcgtttaatg
c  
Plasmids were sequenced & injected (Bestgene).  
 
Drosophila Stocks and Genotypes in Display Items: 
Flies were raised and maintained on standard Drosophila media at 25°C unless otherwise 
noted.  Most stocks listed below were obtained from the Bloomington Drosophila Stock 
Center (NIH P40OD018537) 
 
Deficiency lines: 
Chromosomal deficiencies (Cook et al., 2010, 2012; Parks et al., 2004; Thibault et al., 
2004). Deficiency stocks recombined with FRTs generously provided by Chris Doe, PhD. 
 
X chromosome:  
w, y, sn1 & 5xUAS-mCD8::GFP, and most stocks listed below were obtained from the 
Bloomington Drosophila Stock Center (NIH P40OD018537); elav-Gal4 (Lin and 
Goodman, 1994), ey-FLP2 (Newsome et al., 2000), hs-FLP12 (Chou and Perrimon, 1996), 
hiw∆N (Wu et al., 2005), FRT19A(ry+,hs-neo) (Xu and Rubin, 1993), axed cDNA rescue 
(including endogenous 5’ & 3’ UTR, Pelement): 5xUAS-axedlong #6 (Lukas Neukomm) 
 
Chromosome 2:  
5xUAS-mCD8::GFP, OR22a-Gal4 (Dobritsa et al., 2003), OK371-Gal4 (Mahr and Aberle, 
2006), FRT40A(ry+,hs-neo) (Xu and Rubin, 1993), FRTG13(hs-w+) (FRT42B) (Chou and 
Perrimon, 1996), ase-FLP2a & ase-FLP2e (Neukomm et al., 2014), axed cDNA rescue 
(including endogenous 5’ & 3’ UTR, Pelement): 5xUAS-axedlong #4, 5xUAS-axedshort #2 (Lukas 
Neukomm) 
 
Chromosome 3: 
5xUAS-mCD8::GFP, ey-FLP6 (Newsome et al., 2000), FRT2A(hs-w+) (FRT79D) (Chou and 
Perrimon, 1996), FR82B(ry+,hs-neo) (Xu and Rubin, 1993), axed alleles (See Table 2.3), 
dMCU22, dMCU46, Jv1 (Shapira et al., 2011), ndl7 (Anderson and Nüsslein-Volhard, 1984), 
ndlrm5 (LeMosy and Hashimoto, 2000), Zpg LA00675,cg8368LA00675(Bellen et al., 2004) 
Zpgz2532 & z2533 (Tazuke et al., 2002). 
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Chapter II: Figures & Tables 
 
Figure 2.1: Chromosomal coverage of deficiency lines tested for deficits in axon death.  
 
Figure 2.1: 
A collection a chromosomal deficiencies screened for axon death defective phenotypes at 
5-7 dpa. Deletions with wild type axon degeneration are noted in blue, while a single 
deletion defective for axon death, Df(1)ED7289 which removes hiw, is noted in orange. 
Shading indicates deletion overlap. 
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Figure 2.2: Incomplete axon death after injury in gene-of-interest-#1345x 
 
 
Figure 2.2: 
A. A subset of severed axons in gene-of-interest-#1345x fail to degenerate. Uninjured 
axons are noted as cell bodies (cb) proximal to injury site in the upper right hand corner. 
Scale bar, 10um. 
B. Quantification of severed wild type and axed mutant axon phenotype between 1 to14 
dpa. (Average percent per wing of severed intact axons, green; fragmented, dark gray; 
cleared by glia – no axon present; light gray).  (n = 10+ wings).  
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Figure 2.3: Progressive axon die-back in gene-of-interest-#2  
 
 
Figure 2.3:  
A. Uninjured axons in two mutant alleles of gene-of-interest-#2 exhibit membrane 
deformations and axon death at 7 days post eclosion (dpe). Representative images of 
dendrites & cell bodies (cb) in the distal wing and their axons (number of axons of 
expected axons is noted as number of cell bodies (#cb) in the distal wing). Axons project 
left to right from distal wing to synapse in thoracic ganglion.  
B. Membrane deformations and axon degeneration increase over time in gene-of-interest-
#2596x mutant axons. Axons are labeled in tdTomato (red), while mitochondria are labeled 
with GFP (green). Representative axons in the L1 vein near base of wing, top three 
images, and in distal wing, bottom.  
A & B. Scale bar, 5µm. 
42 
 
 
Figure 2.4: Axundead (axed) is required for injury-induced axon degeneration 
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Figure 2.4: 
A. Mutant alleles axed0011 & axed2094 block axon death in sensory neurons in the wing. 
Examples uninjured and injured (7 days post axotomy (7 dpa)) axons, respectively. In 
injured wings, cell bodies (cb) proximal to cut site and their axons remain intact and 
uninjured, the number is indicated in the lower right corner of each example (scale bar, 5 
μm). 
B. Axon death quantification in the wing. Uninjured control axons (not severed from cell 
bodies in uninjured or injured wings), severed intact axons, and axonal debris (white, 
green and light gray, respectively). Data are shown as average scores (n = 10+ wings). 
C. Quantification of severed wild type and axed mutant axon phenotype at 7 dpa 
(Average percent per wing of severed intact axons, green; fragmented, dark gray; cleared 
by glia – no axon present; light gray).  (n = 24+ wings). 
D. Severed axed mutant axons remain intact for the lifespan of Drosophila. Unilateral 
antennal ablation severs axons from cell bodies in wild type, axed2094 & axed0011 
olfactory receptor neuron (ORN) clones. Axon preservation was scored at indicated time 
points. A magnified representative image of severed axed2094 mutant axons at 50 dpa is 
shown in the upper right corner (scale bar, 10 μm). 
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Figure 2.5: Axed0011 and axed2094 are alleles of the Drosophila gene CG8398. 
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Figure 2.5: 
A. The lethality of axed maps to CG8398. Schematic illustration of the left arm of 
chromosome 3 uncovered by deficiency ZN47 (yellow orange bar) with sequence 
coordinates noted. The lethality of axed2094 & axed0011 was mapped to ZN47 and within the 
smaller deficiency BSC411 (light orange bar), whereas other deficiencies were viable over 
both axed mutant alleles. While mutant alleles of neighboring genes (names in light gray) 
complemented the lethality of the mutant axed alleles, the Minos transposon MI13270 
(Mi{MIC}13270) within the annotated gene CG8398 failed to complement (see Table 2-2). 
B. Loss of CG8398 phenocopies axed. Severed axons of clones harboring either BSC411 
or Mi{MIC}13270 (axedMI13270) remain preserved at 7 dpa (scale bar, 5 μm). 
b)  
C. CG8398 (axed) encodes two predicted transcripts, short and long (UTR and coding 
region; gray and green, respectively). MI13270 insertion in the intron between the last two 
coding exons is noted (v, purple). A 16bp deletion in the 3rd exon of the long isoform and 
2nd exon of the short isoform responsible for disruption in axed0011 is noted (purple wedge). 
D. Clonal expression of either long or short isoform of axed (axedlong or axedshort, 
respectively) rescues the axon death defective phenotype of axed0011, axed2094, axedMI13270, 
and the deficiency BSC411 (scale bar, 5 µm). Shown are averages (n = 10-40 wings each). 
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Table 2.1: List of deficiency lines tested for deficits in axon death  
Deficiency Stock # Location Wing Injury: ORN Ablation: 
Chromosome X (1)       
Df(1)Exel6221 7699 X:470743..523667 WT ND 
Df(1)ED6396 9052 X:493529..523630 WT ND 
Df(1)G1 34050 X:644873..654238 WT ND 
Df(1)ED6443 9053 X:656023..1026707 WT ND 
Df(1)Exel6223 7700 X:769982..909250 WT ND 
Df(1)ED404 8030 X:934942..1135445 WT ND 
Df(1)Exel6225 7702 X:986063..1134927 WT ND 
Df(1)Exel6226 7703 X:1134227..1322377 WT ND 
Df(1)ED6521 9281 X:1135273..1353976 WT ND 
Df(1)Exel6227 7704 X:1322377..1478819 WT ND 
Df(1)Exel8196 7769 X:1478819..1669248 WT ND 
Df(1)ED6565 9299 X:1894112..2317631 WT ND 
Df(1)ED409 8950 X:2042227..2317631 WT ND 
Df(1)ED6574 9054 X:2184630..2387766 WT ND 
Df(1)ED11354 9345 X:2325942..2517801 WT ND 
Df(1)Exel6230 7705 X:2387572..2545663 WT ND 
Df(1)Exel6231 7706 X:2387754..2469301 WT ND 
Df(1)ED411 8031 X:2469859..2642686 WT ND 
Df(1)ED6579 9518 X:2589210..2642686 WT ND 
Df(1)ED6584 9348 X:2636213..2685435 WT ND 
Df(1)ED6630 8948 X:2685540..3036910 WT ND 
Df(1)Exel6233 7707 X:3372961..3485687 WT ND 
Df(1)ED6712 9169 X:3432535..3789615 WT ND 
Df(1)ED6716 24145 X:3799196..4204584 WT ND 
Df(1)ED6720 9055 X:4204351..4544753 WT ND 
Df(1)ED6727 8956 X:4325174..4911061 WT ND 
Df(1)Exel6290 7753 X:5364532..5428543 WT ND 
Df(1)Exel6235 7709 X:5516611..5593966 WT ND 
Df(1)ED6802 8949 X:5679980..5965880 WT ND 
Df(1)Exel6236 7710 X:5679987..5770561 WT ND 
Df(1)Exel6237 7711 X:5770561..5892790 WT ND 
Df(1)ED418 8032 X:5901689..6279401 WT ND 
Df(1)ED6829 8947 X:5901976..6353095 WT ND 
Df(1)Exel6238 7712 X:6068994..6268593 WT ND 
Df(1)Exel6239 7713 X:6344333..6516952 WT ND 
Df(1)Exel6240 7714 X:6543963..6669857 WT ND 
Df(1)ED6878 9625 X:6759293..6862948 WT ND 
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Df(1)ED6906 8955 X:7195084..7405806 WT ND 
Df(1)Exel6241 7715 X:8709821..8806576 WT ND 
Df(1)Exel9049 7770 X:9247113..9252165 WT ND 
Df(1)ED6989 9056 X:9686653..10070473 WT ND 
Df(1)ED6991 9216 X:9686653..10211524 WT ND 
Df(1)ED7005 9153 X:10071922..10585431 WT ND 
Df(1)ED7010 9057 X:10546870..10629307 WT ND 
Df(1)ED7067 9154 X:11390038..11600997 WT ND 
Df(1)Exel6242 7716 X:11622385..11715783 WT ND 
Df(1)ED7170 8898 X:12752602..13277326 WT ND 
Df(1)ED7165 9058 X:12752602..13138948 WT ND 
Df(1)ED7217 8952 X:13642083..13822321 WT ND 
Df(1)ED7225 24146 X:13784406..14322206 WT ND 
Df(1)ED7229 9352 X:14222234..14653944 WT ND 
Df(1)ED7261 9218 X:14653809..14839412 WT ND 
Df(1)Exel6248 7719 X:14825993..14923667 WT ND 
Df(1)ED7265 9414 X:14826069..15007907 WT ND 
Df(1)ED7289 29732 X:15024777..15125750 AD Suppressed ND 
Df(1)ED7344 9220 X:15626447..15868141 WT ND 
Df(1)ED7355 8899 X:16091487..16278417 WT ND 
Df(1)ED7374 8954 X:16695187..17107632 WT ND 
Df(1)ED13478 29733 X:18085406..18102011 WT ND 
Chromosome 2 (Left)       
Df(2L)Exel6001 7488 2L:67166..129261 WT no clones 
Df(2L)Exel7002    2L:203089..264275 WT no clones 
Df(2L)Exel8003 7774 2L:559139..715085 WT ND 
Df(2L)Exel7005 7775 2L:777148..868373 WT ND 
Df(2L)Exel6003 7490 2L:826173..1074079 WT no clones 
Df(2L)Exel6004 7491 2L:1074079..1158137 WT no clones 
Df(2L)Exel7006 7776 2L:1158197..1311170 WT no clones 
Df(2L)Exel6005 7492 2L:1555098..1737249 WT no clones 
Df(2L)Exel7007 7778 2L:1716977..1909976 ND no clones 
Df(2L)Exel6006 8000 2L:1911627..2175599 WT no clones 
Df(2L)Exel7008 7780 2L:1989057..2152458 WT no clones 
Df(2L)Exel6007 7493 2L:2175607..2362917 WT no clones 
Df(2L)Exel7010 7782 2L:2221020..2362808 ND WT 
Df(2L)Exel6008 7494 2L:2494660..2755377 WT no clones 
Df(2L)Exel6277 7744 2L:2677694..2808100 WT no clones 
Df(2L)Exel7014 7784 2L:2979654..3056809 WT no clones 
Df(2L)Exel7015 7785 2L:3046635..3310250 WT no clones 
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Df(2L)Exel8008 7786 2L:3302636..3354856 ND WT 
Df(2L)Exel7016 7787 2L:3354818..3473493 WT no clones 
Df(2L)Exel6009 7495 2L:3771368..3888977 WT no clones 
Df(2L)Exel8010    2L:3887981..4031325 WT ND 
Df(2L)Exel9062 7792 2L:4846961..4887766 WT ND 
Df(2L)Exel8012 7793 2L:4846961..4977638 WT no clones 
Df(2L)Exel7021 7795 2L:4915628..4979299 WT no clones 
Df(2L)Exel8013 7796 2L:4975605..5000943 WT ND 
Df(2L)Exel7022 7794 2L:5000837..5058522 ND WT 
Df(2L)Exel6011 7497 2L:5147258..5305646 WT WT 
Df(2L)Exel6012 7498 2L:5305646..5555049 no clones no clones 
Df(2L)Exel7023 7797 2L:5524375..5594234 WT no clones 
Df(2L)Exel6256 7724 2L:5555049..5658629 ND WT 
Df(2L)Exel8016 7798 2L:5555049..5659285 ND WT 
Df(2L)Exel6015 7501 2L:6088361..6200227 WT no clones 
Df(2L)Exel6016 7502 2L:6253010..6411492 ND WT 
Df(2L)Exel9038 7800 2L:6292895..6338855 ND WT 
Df(2L)Exel7027 7801 2L:6664818..6786906 WT no clones 
Df(2L)Exel7029 7802 2L:6922143..7022660 ND WT 
Df(2L)Exel8019 7803 2L:7140259..7202317 ND WT 
Df(2L)Exel7031 7804 2L:7364976..7495492 WT ND 
Df(2L)Exel9031 7805 2L:7637689..7660390 ND WT 
Df(2L)Exel7038 7809 2L:8438123..8528528 WT no clones 
Df(2L)Exel7039 7810 2L:8529124..8801960 WT no clones 
Df(2L)Exel7040 7811 2L:8797995..8984993 ND WT 
Df(2L)Exel6021 7505 2L:8989308..9176164 WT no clones 
Df(2L)Exel8022 7813 2L:9388129..9448660 WT ND 
Df(2L)Exel9064 7814 2L:9415663..9431473 ND WT 
Df(2L)Exel6022 7506 2L:9447643..9560489 WT no clones 
Df(2L)Exel7042 7812 2L:9522946..9622987 ND WT 
Df(2L)Exel6024 7507 2L:9613611..9782218 WT ND 
Df(2L)Exel6025 7508 2L:9782218..9897536 no clones ND 
Df(2L)Exel7043 7816 2L:9860016..9940209 no clones no clones 
Df(2L)Exel9032 7818 2L:10134181..10198945 ND WT 
Df(2L)Exel7046 7819 2L:10276871..10333704 ND WT 
Df(2L)Exel7048 7999 2L:10443323..10544859 ND WT 
Df(2L)Exel8026 7820 2L:10516675..10861982 WT ND 
Df(2L)Exel7049 7821 2L:10853446..10975285 WT ND 
Df(2L)Exel6027 7510 2L:11067029..11155825 ND no clones 
Df(2L)Exel6028 7511 2L:11155825..11358603 WT no clones 
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Df(2L)Exel6029 7512 2L:11358603..11445762 ND WT 
Df(2L)Exel6031 7514 2L:11971081..12066847 WT ND 
Df(2L)Exel6033 7516 2L:12423459..12655793 WT ND 
Df(2L)Exel6034 7517 2L:12655793..12854729 WT no clones 
Df(2L)Exel8028 7822 2L:12832803..12896409 WT ND 
Df(2L)Exel7059 7826 2L:13800829..13878188 no clones no clones 
Df(2L)Exel6035 7518 2L:14300969..14470247 WT ND 
Df(2L)Exel6036 7519 2L:14409711..14490657 WT no clones 
Df(2L)Exel6038 7521 2L:15912343..16042754 WT WT 
Chromosome 2 (Right)       
Df(2R)Exel6052 7534 2R:7493197..7623083 WT ND 
Df(2R)Exel6053 7535 2R:7533553..7665795 WT ND 
Df(2R)Exel6054 7536 2R:7665795..7812472 WT ND 
Df(2R)Exel6056 7538 2R:8061165..8232456 WT ND 
Df(2R)Exel7094   2R:8061165..8131743 WT ND 
Df(2R)Exel6057 7539 2R:8174651..8327431 WT ND 
Df(2R)Exel7096   2R:8433672..8572773 WT ND 
Df(2R)Exel7098 7864 2R:8649482..8733630 WT ND 
Df(2R)Exel6059 7541 2R:10874385..11185938 WT ND 
Df(2R)Exel7121 7869 2R:12570687..12679753 WT ND 
Df(2R)Exel7130 7875 2R:14073080..14212783 WT ND 
Df(2R)Exel7131 7876 2R:14230665..14360425 WT ND 
Df(2R)Exel7135 7879 2R:15129956..15262942 WT ND 
Df(2R)Exel7137   2R:15575885..15859248 no clones ND 
Df(2R)Exel7138 7883 2R:15918423..16007733 WT ND 
Df(2R)Exel7142 7886 2R:16289254..16425289 WT ND 
Df(2R)Exel7145 7887 2R:16731494..16846621 WT ND 
Df(2R)Exel7150 7891 2R:17716262..17782032 WT ND 
Df(2R)Exel7157 7894 2R:18621522..18730771 WT ND 
Df(2R)Exel7158 7895 2R:18705526..18829728 WT ND 
Df(2R)Exel6067 7549 2R:18858042..18947279 WT ND 
Df(2R)Exel6068 7550 2R:18947286..19141949 WT ND 
Df(2R)Exel6069 7551 2R:19141949..19325623 WT ND 
Df(2R)Exel7162 7896 2R:20245186..20313635 WT ND 
Df(2R)Exel7163   2R:20423944..20582746 WT ND 
Df(2R)Exel7164 7898 2R:20582171..20666850 WT ND 
Df(2R)Exel6071 7553 2R:20836033..21056798 WT ND 
Df(2R)Exel6072 7554 2R:21056798..21250845 WT ND 
Df(2R)Exel6076 7556 2R:21379527..21607081 WT ND 
Df(2R)Exel6077 7557 2R:21713968..21872028 WT ND 
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Df(2R)Exel7169 7900 2R:21862233..22039630 WT ND 
Df(2R)Exel6078 7558 2R:22039540..22197643 WT ND 
Df(2R)Exel7170 7901 2R:22039641..22135929 WT ND 
Df(2R)Exel7171 7902 2R:22136002..22243250 WT ND 
Df(2R)Exel7173 7903 2R:22380451..22514138 WT ND 
Df(2R)Exel6079 7559 2R:22729367..22798322 WT ND 
Df(2R)Exel7177 7906 2R:23068684..23203998 WT ND 
Df(2R)Exel7178   2R:23291485..23395914 WT ND 
Df(2R)Exel6082 7561 2R:24257897..24369777 WT ND 
 
Table 2.1: 
MARCM clones for each deficiency line were generated and injured at ~5 days post 
eclosion. Severed axonal integrity was assessed in the L1 wing vein at 5-7days post 
axotomy. At least 10 flies were tested for each deficiency. 
WT = wild type axon death; AD suppressed = axon degeneration is suppressed or 
defective; no clones = no clones were visible in the wing or olfactory glomeruli; ND = no 
data. 
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Table 2.2: Axed complementation test for lethality 
 
Trans-het. Detailed description Lethal or Viable 
axed0011/ 
axed2094 
- Lethal 
axed2094/ 
Df(3L)ZN47 
Deficiency uncovering genomic axed Lethal 
axed2094 OR 0011/  
Df(3L)BSC411 
Deficiency uncovering genomic axed Lethal 
axed2094/  
Df(3L)*** 
***Deficiencies noted in Figure 2-5(A) + 
large deficiencies not uncovering genomic 
axed. 
Viable 
axed2094 OR 0011/  
axedMI13270 
Minos transposon Mi{MIC}CG8398MI13270 Lethal 
axed2094 OR 0011/  
dMCU46 OR 22 
CRISPR/Cas9 generated alleles of 
CG18769 
Viable* 
axed2094 OR 0011/  
Jv1 
Hypomorphic allele of javelin Viable* 
axed2094 OR 0011/  
ndl7 OR rm5 
EMS mutagenesis (ndl7) 
LOF allele (ndlrm5)   
Viable* 
axed2094 OR 0011/  
Zpg+cg8368-
LA00675 
CRISPR/Cas9, 194bp deletion, exon 2 Viable* 
axed2094 OR 0011/  
Zpg z2532,z2533 
CRISPR/Cas9, 14bp deletion, exon 2 Viable* 
 
Table 2.2: 
Axed mutant alleles fail to complement lethality of each other and deficiencies 
uncovering CG8398, but are viable as trans-heterozygotes over other deficiencies and 
genes.  If viable, a (*) indicates that trans-heterozygous animals axons degenerated 
normally after injury. 
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Table 2-3: Novel axed alleles generated 
 
Axed allele Detailed description Axon death phenotype 
axed0011 EMS mutagenesis, 16bp deletion exon 3 yes 
axed2094 EMS mutagenesis yes 
BSC411 Deficiency uncovering genomic axed yes 
axedMI13270 Minos transposon Mi{MIC}CG8398MI13270 yes 
axedEx05 Precise Minos excision no 
axedEx07 Imprecise Minos excision yes 
axedEx65 Imprecise Minos excision yes 
axedEx96 Imprecise Minos excision yes 
axedCrisprA CRISPR/Cas9, 194bp deletion, exon 2 yes# 
axedCrisprB CRISPR/Cas9, 14bp deletion, exon 2 yes# 
axedCrisprC CRISPR/Cas9, 14bp deletion, exon 2 yes# 
 
Table 2-3: 
Summary of all axed alleles used and their axon death phenotypes. If known, the 
molecular nature of each lesion is indicated. #, partial axon death phenotype. 
53 
 
 
Table 2.4: Genotypes for figures/experiments: 
 
Abbreviations: Y: Y chromosome, w: w1118 or w-, OK371: OK371-Gal4, mCD8::GFP: 
5xUAS-mCD8::GFP, OR22a: OR22a-Gal4  
Figure 2-1: 
X: Deficiency,FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b/+ 
2L: elav-Gal4,mCD8::GFP/+ ; Deficiency,FRT40A/tubGal80,FT40A ; mCD8::GFP,aseFLP3a/+ 
2R: elav-Gal4,mCD8::GFP/+ ; FRTG13,Deficiency/FRTG13,tubGal80 ; mCD8::GFP,aseFLP3b/+ 
Mutagenesis Screen: 
X: mut*,FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b/+ 
2L: elav-Gal4,mCD8::GFP/+ ; mut*,FRT40A/tubGal80,FT40A ; mCD8::GFP,aseFLP3a/+ 
2R: elav-Gal4,mCD8::GFP/+ ; FRTG13,mut*/FRTG13,tubGal80 ; mCD8::GFP,aseFLP3b/+ 
3L: w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; mut*,FRT2A/tub-Gal80,FRT2A 
3R: w/Y ; OK371,mCD8::GFP,aseFLP2a/+ ; FRT82B,mut*/FRT82B,tub-Gal80 
Figure 2-2: 
A-B. wild type:  FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b/+ 
A-B. gene of interest #1345x:  GOI#1345x,FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; 
mCD8::GFP,aseFLP3b/+ 
Figure 2-3: 
A. wild type:  FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b/+ 
A. gene of interest #2596x:  GOI#2596x,FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b/+ 
A. gene of interest #21013x:  GOI#21013x,FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b/+ 
B. wild type:  FRT19A/tubGal80,hsFLP,FRT19A ; OK371,10XUAS-IVS-myr::tdTomato,5xUAS-mito-HA-GFP.AP/+ ; 10XUAS-IVS-
myr::tdTomato,aseFLP3b/+ 
B. gene of interest #2596x:  GOI#2596x,FRT19A/tubGal80,hsFLP,FRT19A ; OK371,10XUAS-IVS-myr::tdTomato,5xUAS-mito-HA-
GFP.AP/+ ; 10XUAS-IVS-myr::tdTomato,aseFLP3b/+ 
Figure 2-4: 
A-C. wild type:  w/Y ; OK371,mCD8::GFP,aseFLP2e/OK371,mCD8::GFP ; FRT2A/tub-Gal80,FRT2A 
A-C. axed2094:  w/Y ; OK371,mCD8::GFP,aseFLP2e/OK371,mCD8::GFP ; axed2094,FRT2A/tub-Gal80,FRT2A 
A-C. axed0011:  w/Y ; OK371,mCD8::GFP,aseFLP2e/OK371,mCD8::GFP ; axed0011,FRT2A/tub-Gal80,FRT2A 
D. wild type:  w,eyFLP2/Y ; OR22a,mCD8::GFP/+ ; FRT2A/tub-Gal80,FRT2A 
D. axed2094:  w,eyFLP2/Y ; OR22a,mCD8::GFP/+ ; axed2094,FRT2A/tub-Gal80,FRT2A 
D. axed0011:  w,eyFLP2/Y ; OR22a,mCD8::GFP/+ ; axed0011,FRT2A/tub-Gal80,FRT2A 
Figure 2-5: 
A. Complementation groups for lethality: w/Y ; +/+ ; Deficiency OR Mi{MIC}13270OR lethal alleles of neighboring genes  / axed2094 OR 
axed0011,FRT2A 
B. BSC411: w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; BSC411,FRT2A/tub-Gal80,FRT2A 
B. BSC551:  w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; BSC551,FRT2A/tub-Gal80,FRT2A 
B. Exel8101:  w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; Exel8101,FRT2A/tub-Gal80,FRT2A 
B. BSC373:  w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; BSC373:,FRT2A/tub-Gal80,FRT2A 
B. ED211:  w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; ED211,FRT2A/tub-Gal80,FRT2A 
B. Mi{MIC}13270:  w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; Mi{MIC}13270,FRT2A/tub-Gal80,FRT2A 
C. - 
- wild type:  w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; FRT2A/tub-Gal80,FRT2A 
- axed2094:  w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; axed2094,FRT2A/tub-Gal80,FRT2A 
- axed2094 + axedlong:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axedlong #4 ; axed2094,FRT2A/tub-Gal80,FRT2A 
- axed2094 + axedshort:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axedshort #2 ; axed2094,FRT2A/tub-Gal80,FRT2A 
- axed0011 & axedMI13270 & BSC411:  as above 
Table 2-2: 
Complementation groups for lethality: as noted in Figure 2-5.A 
54 
 
 
Axon death in viable transheterozygotes: w/Y ; OK371,mCD8::GFP ; lethal alleles of neighboring genes  / axed2094 OR 
axed0011,FRT2A 
Table 2-3: 
w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; axedalleles,FRT2A/tub-Gal80,FRT2A 
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CHAPTER III: Axon Death Pathways Converge on Axed to Promote 
Axon Disassembly. 
 
This work was conducted in the laboratory of Marc Freeman. I conducted all of the 
described Drosophila work in close collaboration with the following people who 
performed the following: Lukas Neukomm: 1) generated axedEGFP::FLAG; 2) tested axed 
allele suppression of hid; 3) tested bsk mutant alleles. Jaeda Coutinho-Budd dissected and 
imaged axedEGFP::FLAG and UAS-axed::smGdP-cMyc larval and adult brains; Yonca 
Karadeniz tested axed alleles in mushroom body pruning; Amy Sheehan cloned 5xUAS-
axed::smGdP-cMyc; Jeannette Osterloh initially characterized dsarm deletion constructs 
used. They were generated by Amy Sheehan, re-tested by myself, Lukas Neukomm, & 
Jon Farley in the wing. 
 
The following publication is in preparation as follows: 
Axon death pathways converge on Axed to promote functional and structural axon 
disassembly 
Lukas J. Neukomm* & Thomas C. Burdett*, Jaeda Coutinho-Budd, Andrew M. Seeds, 
Stefanie Hampel, Jack Wong, Yonca Karadeniz, Jeannette M. Osterloh, Amy E. Sheehan, 
and Marc R. Freeman 
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Abstract 
 
 In the previous chapter I described the identification of Axed a novel, essential 
component for injury induced axon death. In this chapter I present our attempts to 
definitively position Axed degenerative function within that pathway. To do this we first 
demonstrate that endogenous, fluorescently tagged Axed is expressed in neurons and 
within the axonal compartment. Next, we show that Axed function is specific to axon 
death and is independent from other axon destroying pruning programs as well as broad 
apoptotic cell death. Finally, we define a position for Axed in the axon death pathway. 
We find that Axed is required for whole cell degeneration induced by constitutively 
active dSarm and induced by Nmnat knock-down or knock-out. Additionally, we find 
Hiw to be upstream of Axed. We do not find a role for MAPKs in several degenerative 
contexts and thus are unable to determine any relationship to Axed. Taken together our 
results suggest a role for Axed downstream of both dSarm pro-degenerative signaling and 
death resulting from declining Nmnat after injury.  
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Chapter III: Results & Discussion 
Results 3-1: Axed is expressed in neurons & within the axonal compartment 
While our data in neuronal clones strongly suggested a cell autonomous role for 
Axed, we sought to visualize endogenous Axed in neurons and define its subcellular 
localization. While attempts to generate Axed antibodies failed, we generated 
endogenously EGFP::FLAG tagged Axed (axedEGFP::FLAG) by Recombination Mediated 
Cassette Exchange (RMCE) (Venken et al., 2011) with the axedMI13270 Minos transposon 
inserted in the intron of the last two coding exons (Figure 2.5-C). If axed protein was 
produced with this transposon present, it would be truncated removing the C-terminal 
region (Figure 3.1-A), however it is likely the mRNA transcript in these flies is subject to 
nonsense mediated decay. In contrast to axedMI13270, axedEGFP::FLAG animals are 
homozygous viable and exhibit normal axon death after axotomy, indicating that 
AxedEGFP::FLAG is functional. Western blots revealed two different AxedEGFP::FLAG proteins 
in heads of axedEGFP::FLAG flies (Figure 3.1-B), which correspond to Axedlong and 
Axedshort. These findings confirmed that both protein isoforms are expressed in adult 
brains. 
We took advantage of axedEGFP::FLAG animals to assess if Axed was expressed in 
neurons and where it localized. First, we explored the expression pattern of Axed, and 
found that it was enriched in the neuropil of the larval ventral nerve cord (Figure 3.1-C, 
top) and adult brain (Figure 3.1-F). The neuropil consists mainly of axons and dendrites 
(neurites), synapses and astrocytic processes, while the cortex houses neuronal cell 
bodies and cortex glia (Coutinho-Budd and Freeman, 2013). We stained for a variety of 
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markers in third instar larval AxedEGFP::FLAG brains, and found that Axed is in close 
proximity to synapses (nc82) (Figure 3.1-C), whereas markers for astrocytic processes 
(GAT) did not indicate a prominent expression of Axed (Figure 3.1-C). Axed also 
expressed at lower relative levels in surrounding cortex. To differentiate between 
neuronal cell bodies and cortex glial processes, we stained for Zydeco, which is 
expressed in glial processes (Melom and Littleton, 2013), and found Axed only in 
neuronal cell bodies, at or near the plasma membrane, but excluded from or expressed at 
extremely low levels in neuronal nuclei (Figure 3.1-C).  To more specifically target 
expression in axons, we visualized neuronal membranes of larval abdominal nerves with 
HRP and found that Axed localized to axons throughout the nerves (Figure 3.1-D). We 
also tagged Axedlong with a non-fluorescent 'spaghetti monster GFP' ('smGdP') consisting 
of 10 cMyc tags under the control of a 5xUAS promoter and expressed it in a subset of 
octopaminergic neurons using Tdc2-Gal4. Similar to AxedEGFP::FLAG, AxedsmGdP-cMyc is 
stably expressed in axons and notably excluded from neuronal nuclei. Within neuronal 
cell bodies, is punctate and closely matches membrane associate myrsmGdP-cMyc (Figure 
3.1-E). Taken together, we conclude that Axed is expressed in neurons, absent in 
neuronal nuclei, and enriched in neuronal processes.  
Does Axed localization change after injury? To explore this possibility we 
performed unilateral antennal ablation and visualized AxedGFP::FLAG intensity over time in 
antennal lobes (Figure 3.1-F). Compared to wild type (i.e. non-GFP) brains, Axed basal 
levels remained unchanged for 2 hours post antennal ablation, but significantly increased 
at 4 and 6 hours, and returned to baseline at 24 hours (Figure 3.1-G). These data are 
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consistent with the notion that AxedGFP::FLAG localization or levels transiently change in 
response to axonal injury. 
 
Results 3-2: Axed is not required for axonal developmental pruning or programmed cell 
death 
We next determined whether Axed is required specifically for axon death or if it 
is also involved in other regressive events such as cell death or pruning. First, we used the 
eye-specific glass multimer reporter to ectopically express pro-apoptotic hid (GMR-hid10) 
to induce widespread cell death in the developing visual system (Figure S3A) (Bergmann 
et al., 1998). While mutant clones of the Nedd2-like caspase droncI29 were able to 
suppress hid mediated eye ablation, wild type or axed clones failed to do so (Figure 3.2-
A). Likewise, we found that pruning of axons or dendrites in larval mushroom body 
(MB) γ neurons was not affected by axed mutations(Lee et al., 2000)(Figure 3.2-B). 
These observations confirm that Axed, like dSarm, is selectively required for axon 
degeneration after injury, but not axon degeneration during pruning or in cell death 
(Osterloh et al., 2012).  
 
Results 3-3: Axed is required downstream of dSarm pro-degenerative signaling 
We next sought to determine where axed functions with respect to the other 
known axon death genes. First we determined if there was any genetic interaction 
between axed and dsarm by producing transheterozygous animals. Null mutations in both 
genes are lethal, while transheterozygotes for axed0011/dsarm4621 were viable and their 
axons underwent death with similar kinetics as observed in wild type axons, as fragments 
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of axons were readily observed at 7 dpa (Figure 3.3-A). Next, we attempted to rescue 
axon death axed and dsarm mutants with a bacterial artificial chromosome (BAC) 
containing a genomic copy of wild type dsarm. While the genomic copy of wild type 
dsarm was able to fully rescue the axon death phenotype in dsarm4314 mutants, it failed to 
rescue axed0011 or axed2094 mutants (Figure 3.3-B). Overexpression of full length 
dsarmP862Q (dSarm with a single missense mutation) fully rescues degeneration in 
dsarm896, but has no effect on preserved severed axons in axed0011 (Figure 3.3-C).  
dSarm consists of a conserved N-terminal armadillo (ARM), two sterile alpha 
motifs (2xSAM), and a C-terminal Toll/interleukin-1 receptor homology (TIR) domain. 
Consistent with structure/function studies in worms and mouse cultured neurons(Chuang 
and Bargmann, 2005; Gerdts et al., 2013, 2015; Yang et al., 2015), previous work in the 
Freeman lab found that the SAM and TIR functional domains were essential to rescue the 
axon death phenotype in dsarm896 mutant clones (data not shown in thesis, see preface for 
unpublished work cited). Expression of constructs lacking the SAM or TIR domains did 
not dominantly alter axon death in wild type, or cause spontaneous axon degeneration in 
the absence of injury. However, clones expressing dSarm lacking the ARM domain 
(dsarm∆ARM), proposed to be auto-inhibitory in C. elegans (Chuang and Bargmann, 2005), 
underwent spontaneous cell body and axon degeneration (Figure 3.3-D/E). To assess if 
dsarm∆ARM induced degeneration in Drosophila, we scored the number of intact cell 
bodies and axons in age-matched adults at 1 through 10 days post eclosion (dpe). We 
found that dsarm∆ARM triggered the spontaneous degeneration of cell bodies and axons 
within 2-3 dpe in wild type (Figure 3.3-D/E) and dsarm mutants lacking endogenous 
61 
 
 
dSarm (Figure 3.3-F). This dsarm∆ARM mediated neurodegenerative phenotype was not 
specific to glutamatergic sensory neuron clones in the wing.  We also observed a similar 
phenotype in larva when transiently expressing dsarm∆ARM in ddaC neurons and in adult-
specific postmitotic PDF+ neurons using temperature sensitive Gal80ts ON/OFF system 
to express dsarm∆ARM (data not shown in thesis). In all cell types co-expression of P35, a 
broad apoptosis inhibitor, did not alter neurodegeneration, while co-expression of WldS, a 
potent inhibitor of Wallerian degeneration, was able to partially suppress cell body and 
axon degeneration induced by dsarm∆ARM (Figure 3.3-F). Thus, dsarm∆ARM resembles a 
pro-degenerative gain-of-function allele of dSarm in vivo, similar to versions of the TIR 
domain that can be dimerized for activation (Gerdts et al., 2015; Yang et al., 2015). 
Together our data argue that dSarm∆ARM activates a Wallerian-like program of 
degeneration in vivo, and that WldS either acts downstream of dsarm∆ARM, or in parallel, 
since its activity is sufficient to partially overcome the pro-degenerative effects of dSarm 
activation, as has been found in vitro (Gerdts et al., 2015). Finally, we found that hiw 
mutant clones did not alter the pro-degenerative dsarm∆ARM phenotype at 10 dpe (Figure 
3.3-F), arguing that Hiw acts upstream or in parallel to dSarm. 
To determine the position of axed in the axon death signaling cascade, we 
explored the possibility that Axed might function downstream of dSarm. We expressed 
dsarm∆ARM in clones of axed2094, axed0011 and BSC411, uncovering the axed genomic 
locus, and scored cell body and axon survival at 10 dpe. Loss of Axed function 
completely suppressed dsarm∆ARM–mediated cell body and axonal degeneration at 10 dpe 
and some neurons persisted to 50 dpe, despite continuous dSarm∆ARM production (Figure 
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3.3-F/G). Axed null mutant suppression of dsarm∆ARM appeared complete, with the 
exception of some swelling which more apparent in cell bodies than in axons, and was 
much stronger than afforded by WldS. Axed is required genetically downstream for all 
dSarm-mediated pro-degenerative functions. 
 
Results 3-4: Axed is required downstream of degeneration induced by loss of Nmnat 
The NAD+ biosynthetic enzyme Nmnat is required for axon survival, and one 
isoform in mammals, Nmnat2, functions as a labile axon survival factor whose depletion 
induces Wallerian-like degeneration of even uninjured axons (Fang et al., 2012; Gilley 
and Coleman, 2010). Intriguingly, while mouse Nmnat2-/- knock-out animals die during 
embryonic stages and exhibit short axons, Sarm1-/- knock-out mutations can fully rescue 
Nmnat2-/- animals to adulthood (Gilley et al., 2015). Nmnat2-/- animals likely survive due 
to the NAD+ biosynthetic activity of two additional mammalian Nmnat isoforms, 
Nmnat1 and Nmnat3 (Gilley and Coleman, 2010). A current model posits that activated 
Sarm1 triggers rapid NAD+ destruction and loss of NAD+ then promotes axon 
degeneration (Gerdts et al., 2015). To test this model we used RNA interference (RNAi) 
to knock down the sole Drosophila Nmnat. We analyzed Nmnat knock-down effects in 
clones expressing nmnatRNAi by assessing the integrity of cell bodies and axons over time, 
as described above with dsarm∆ARM: compared to control clones, clones expressing 
nmnatRNAi underwent complete cell body and axon degeneration within 8-10 dpe (Figure 
3.4-A/B). These findings are consistent with previous reports (Fang et al., 2012), but 
knock-down of Nmnat was less potent, probably due to a different Gal4 driver used in 
this study. Interestingly, nmnatRNAi-mediated degeneration of cell bodies and axons was 
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completely suppressed in distinct axed null mutant clones at 10 dpe (Figure 3.4-C). We 
also found suppression, though less robust, in clones lacking dsarm. Importantly, 
nmnatRNAi-mediated degeneration in axed2094,dsarm896 double mutants were similar 
compared to axed single mutants, suggesting that axed is epistatic to dsarm. In contrast, 
loss of hiw was not able to significantly suppress nmnatRNAi-mediated degeneration at 
10dpe, however significantly delayed degeneration compared to wild type at 5dpe, 
consistent with previous findings and supporting a model with Hiw/Phr1 function 
upstream of Nmnat/Nmnat2 depletion (Babetto et al., 2010; Xiong et al., 2012). While 
Nmnat-RNAi induced whole neuron degeneration, we also wanted to see if suppression 
of death was also afforded to severed axons in this background. While we were unable to 
sever control axons at 5 dpe because most were already degenerated, we found 
approximately 90+% and 75% of anucleated axons in null alleles of axed and dsarm, 
respectively, remained intact to 7dpa.  
RNAi-mediated knock-down often leads to partial phenotypes as compared to loss 
of function mutations. To determine the fate of neurons completely devoid of Nmnat 
activity and therefore lacking all NAD+ biosynthetic activity (Rongvaux et al., 2003; 
Sasaki et al., 2016), we analyzed cell body and axon integrity over time in clones of the a 
deletion uncovering most of Nmnat, Nmnat4790-1 (Zhai et al., 2006). As compared to wild 
type, Nmnat4790-1 clones in either wild type, axed heterozygote, or dsarm heterozygote 
backgrounds underwent rapid neurodegeneration within by 5dpe (Figure 3.5-A, right 
arm). Heterozygous Nmnat4790-1 had no effect on uninjured axon or cell body survival and 
did not attenuate axon survival after injury in axed or dsarm null alleles (Figure 3.5-A, 
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left arm & 3.5B). Next, we used a heat-shock mediated approach to stochastically 
generate low numbers of GFP+-labeled Nmnat null clones, additionally homozygous for 
either wild type or unique axed or dsarm alleles. At 5 dpe, while Nmnat clones underwent 
complete neurodegeneration, double clones lacking Nmnat and axed remained 
morphologically preserved (Figure 3.5-C/D), arguing that execution of loss-of-nmnat 
triggered neurodegeneration requires axed. In contrast, loss-of-Nmnat triggered 
neurodegeneration was not altered in dsarm alleles, dsarm896 & dsarm4621, suggesting that 
loss of dsarm is not sufficient to block neurodegeneration induced by cellular depletion of 
Nmnat (Figure 3.5-C/D). Importantly, axed, dsarm double clones completely blocked 
Nmnat-mediated neurodegeneration, supporting a function for axed downstream of 
dsarm. When axedlong was re-expressed in double null clones, Nmnat-loss induced 
degeneration is completely restored, further confirming a requirement for Axed to 
participated in the degenerative process (Figure 3.6-A). We also expressed NmnatRNAi in a 
double null clonal background to ensure all Nmnat was eliminated and still observed 
protection with axed. Neurons lacking axed and Nmnat even remained intact to 30dpe 
(Figure 3.6-D). Taken together, we conclude that Axed is essential for neurodegeneration 
triggered by loss of Nmnat. 
We demonstrated a requirement for Axed downstream of pro-degenerative dSarm 
and also downstream of loss of Nmnat. These two insults are occurring within an axon 
after injury, likely at the same time, and possibly from two parallel signaling pathways. 
In order to determine Axed is required for both processes within a single neuron, we 
expressed dsarm∆ARM in an axed, Nmnat null background and observed no degeneration 
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compared to rapid death in wild type at 5dpe (Figure 3.6-A), confirming both 
degenerative events converge on Axed. 
Our epistatic analyses were derived from manipulated genetic environments, such 
as expression of a gain-of-function-dSarm or knock-down of Nmnat, which caused 
degeneration of whole neurons.  In order to confirm the position of Axed in injury-
induced axon degeneration signaling, we axotomized clones lacking axed and Nmnat, 
additionally expressing GFP or dsarm∆ARM and found the majority of severed axons 
remained morphologically preserved at 7 dpa in (Figure 3.6-B/C). These findings clearly 
suggest that both known axon death events after injury require Axed to promote the 
disassembly of severed axons. 
 
Results 3-5: Genetic interactions with other axon death genes 
Highwire/Phr1 is an ubiquitin E3 ligase that plays an essential role in regulating 
turnover of Nmnat and elimination results in long term suppression of axon death, 
primarily as a result of persistently higher Nmnat levels within the axonal compartment. 
We sought to assess whether overexpressing Hiw, theoretically increasing Nmnat 
proteasomal degradation, could rescue degeneration in severed axed null axons. We 
found overexpression of Hiw to levels sufficient to rescue degeneration in hiwΔN null 
background, had no effect on anucleated axon preservation in axed0011 (Figure 3.7). 
The C. elegans dSarm/Sarm1 homologue tir-1 has been shown to act upstream of 
MAPK as well as c-Jun N terminal kinases (JNKs) during regulation of asymmetric 
odorant receptor expression (Chuang and Bargmann, 2005). Consistent with these 
findings, the mammalian MAPK kinases Mkk4 and Mkk7 as well JNK1-3 were recently 
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implicated in early events of axon death signaling downstream of Sarm1 (Yang et al., 
2015), suggesting that axon degenerative signaling may parallel a signaling cascade in C. 
elegans. We found that the Drosophila null alleles of these genes (MKK4e01485, 
MKK4Exel6149, MKK7/hepr75, JNK/bskflp170B & bsk2, respectively) were not able to suppress 
pro-degenerative dsarm∆ARM signaling at 10 dpe, nor were they defective in axon death in 
our wing assay at 7 dpa (Glise et al., 1995; Sluss et al., 1996; Thibault et al., 2004) (Table 
3.2). Given that Drosophila has a single JNK ortholog (bsk), our data argue strongly 
against a requirement for JNK signaling in axon death in vivo.  
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Chapter III: Materials & Methods 
 
Wing injury assays: 
See Materials & Methods in Chapter II. 
 
Immunohistochemistry: 
Immunolabeling: Anti HRP (Horseradish Peroxidase) antibody (AB) staining of dorsal 
dendrite arborization (dda) sensory neurons was performed as described(Wong et al., 
2013), Anti FasII (Fasciclin II) AB staining of unpruned α/ß MB neurons in(Tasdemir-
Yilmaz and Freeman, 2014), anti PDF (Pigment dispersing factor) AB staining of PDF+ 
neurons in (Muthukumar et al., 2014), and anti GFP staining in (MacDonald et al., 2006). 
GFP and CsChrimson::mVenus detection in adult brains: 1st AB: 1:1,000 Chicken anti-
GFP (Rockland 600-901-215S) at 4° C overnight, 2nd AB: 1:100 Goat anti Chicken 
Dylight® 488 (Abcam ab96947) at room temperature for 1h. 
 
AxedEGFP::FLAG detection in larval brains: the central nervous system was dissected from 
third instar larvae, and fixed for 5 minutes in cold 100% methanol, washed in PBS, and 
subsequently subjected to immunostaining with primary antibodies in PBS + 0.1% Triton 
X-100 (PTX) overnight at 4º C. Brains were washed with PTX, followed by any 
secondary antibody incubation in PTX at 4º C overnight. AxedEGFP::FLAG signals were not 
enhanced with antibodies. The following ABs were used for colocalization with 
AxedeGFP::FLAG: 1st ABs: Cy5 conjugated goat anti-HRP (Jackson ImmunoResearch 
Laboratories, 1:500), mouse anti-Bruchpilot (nc82, Developmental Studies Hybridoma 
Bank, 1:20), and rabbit anti-GAT ((Stork et al., 2014),1:3,000). The following Cy5 
conjugated 2nd ABs were used: goat anti-mouse (nc82) and goat anti-rabbit (GAT) 
(Jackson ImmunoResearch). CNS samples were washed in PTX and mounted in 
Vectashield mounting medium reagent (Vector Laboratories). Confocal images were 
obtained on Innovative Imaging Innovations (3I) spinning-disc confocal microscope 
equipped with a Yokogawa CSX-X1 scan head. 
 
AxedEGFP::FLAG detection in adult brains: the third antennal segments of adult Drosophila 
were unilaterally removed using a pair of #5 forceps under a dissection microscope. Flies 
were decapitated at 2, 4, 6, and 24 h post antennal ablation, as well as without injury for 
non-injury controls (y,w ; ; axedEGFP::FLAG  and y,w). Heads were fixed and permeabilized 
in 4% formaldehyde in PTX for 20 min at room temperature, and washed with PTX. 
Brains were dissected in cold PTX, and incubated with 1st AB (mouse anti-Bruchpilot 
(nc82, Developmental Studies Hybridoma Bank, 1:20)) in PTX at 4° C overnight, washed 
with PTX, and incubated with Cy3 conjugated 2nd AB goat anti-mouse at 4º C in PTX 
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overnight. Brains were washed with PTX, mounted with Vectashield mounting medium 
(Vector Laboratories), and ipsilateral antennal lobes were imaged on the 3I spinning-disc 
confocal. 
 
Western Blot: Primary antibodies (AB) were applied at 4°C overnight, secondary 
antibodies at room temperature for 1h. GFP detection: 1st AB: 1:2000 Rabbit anti-GFP 
(Abcam ab6556), 2nd AB: 1:5000 Goat anti-rabbit HRP (Abcam ab6721). FLAG 
detection: 1st AB: 1:1000 Mouse anti FLAG (Sigma F1804), 2nd AB: 1:2000 Rabbit anti 
Mouse HRP (Abcam ab6728). Tubulin detection: 1st AB: 1:5000 Mouse anti-Tubulin 
(Sigma, clone DM1A, T9026), 2nd AB: 1:2000 Rabbit anti-Mouse HRP (Abcam 
ab6728). 
 
Confocal microscopy: 
See Materials & Methods in Chapter II. 
 
Heat shock treatment: 
Crosses for MARCM double clones were passed every day, and 1 h heat shock 
application at 37° C performed at 5 days post initial cross set up. 
 
Drosophila Stocks and Genotypes in Display Items: 
In addition to stocks listed in Materials & Methods section of Chapter II, stocks used in 
Chapter III are listed below. 
 
X chromosome:  
5xUAS-WldS (Hoopfer et al., 2006), Mkk7 allele: hepr75 (Glise et al., 1995). 
 
Chromosome 2:  
GMR-hid10 (Bergmann et al., 1998), 5xUAS-P35 (Hay et al., 1994), 5xUAS-Dcr-2 (Dietzl 
et al., 2007), 5xUAS-NmnatRNAi(GD32255) (Dietzl et al., 2007), bacterial artificial chromosome 
containing genomic dsarm (landing site: VK00037): BACCH321-38D07 (Osterloh et al., 2012), 
5xUAS-dsarmP862Q (Lukas Neukomm), 5xUAS-dsarm∆ARM::myc (based of cDNA, isoform 
D(Amy Sheehan)), JNK alleles: bskflp170B & bsk2 (Sluss et al., 1996), 10xUAS-IVS-
myr::smGdP-cMyc(Nern et al., 2015).  
 
Chromosome 3:  
droncI29 (Xu et al., 2005), Nmnat∆4790-1 (Zhai et al., 2006), nSyb-Gal4 
{NagarkarJaiswal:2015gp}, 5xUAS-P35 (Hay et al., 1994), 5xUAS-WldS (Hoopfer et al., 
2006), ase-FLP3a & ase-FLP3b (Neukomm et al., 2014), 5xUAS-dsarm∆ARM::EGFP (based 
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of cDNA, isoform D (Amy Sheehan)), Mkk4 alleles: Mkk4e01458 and Df(3R)Exel6149 
(Rallis et al., 2010), dsarm896 & dsarm4621 (Osterloh et al., 2012), Tdc2-Gal4(Cole et al., 
2005), 5xUAS-CD8::mCherry(Roy et al., 2011). 
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Chapter III: Figures & Tables 
 
Figure 3.1: Axed is expressed in neurons 
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Figure 3.1: 
A. Generation of a functional EGFP::FLAG tag knock-in to the genomic locus of Axed. 
Recombination Mediated Cassette Exchange (RMCE) of 3xStop with an EGFP::FLAG 
tag. While axedMI13270 mutants are homozygous lethal & axon death defective, 
axedEGFP::FLAG flies regain viability & the ability to drive axon degeneration. 
B. Western blots of axedEGFP::FLAG fly heads confirm the expression of both long and short 
Axed isoforms. 
C. Axed is enriched in the larval neuropil. Top: AxedEGFP::FLAG and merge with HRP 
staining. Bottom: Axed is found in close proximity to synapses (nc82 staining, top), and to 
mostly excluded from glia (astrocytes & cortex glia, middle & bottom, respectively). Scale 
bar, 10µm. 
D. Axed is expressed in nerves. Top to bottom: AxedEGFP::FLAG, larval ventral abdominal 
nerves (HRP staining) and merge. Scale bar, 10µm. 
E. Tdc2-Gal4 driven overexpression of AxedsmGdP-cMyc in Tdc2 positive neurons localizes 
to axons and in punctate clusters in cell soma. Top to bottom: AxedsmGdP-cMyc, 
CD8::cherry, and merge. Scale bar, 10µm. 
F. Axed is upregulated upon axon injury in adult brains. Bilateral antennal ablation was 
performed to sever cell bodies from axons, and the antennal lobe in brains analyzed 
before, and 2, 4, 6 & 24 hour post axotomy (hpa). Green: AxedEGFP::FLAG, Blue: nc82 
staining. Scale bar, 20µm. 
G. Quantification of AxedEGFP::FLAG levels pre- and post-injury. Ordinary one-way 
ANOVA with multiple comparisons test (* = p < 0.05, ** = p < 0.01, *** = p < 0.001, 
**** = p < 0.0001). 
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Figure 3.2: Axed is not involved in programmed cell death or developmental neurite 
pruning of MB γ neurons 
 
 
73 
 
 
Figure 3.2:  
A. Axed is not required for programmed cell death in the eye. GMR-hid induced pro-
apoptotic signaling in the eye destroys eye morphology. Clones of the null allele droncI29, 
the Drosophila Nedd2-like initiator caspase, suppress this phenotype, while wild type or 
axed2094 mutant clones do not. 
B. Axed is not required for developmental pruning of mushroom body (MB) γ neurons. 
Time points: 3rd larval stage, 18h & 48h after puparium formation (APF). MARCM clones 
of wild type and axed0011 mutants, showing cell bodies (cb), proximal dendritic arbors (den) 
and distal bifurcated axons projecting both medially and dorsally (m & d, respectively). In 
both genotypes, at 18h APF, dendrites and distal axons undergo fragmentation and are 
cleared. By 48h APF, medial axons regrow to form the adult-specific medial lobe. 
Red/grey: adult, unpruned α/ß MB neurons (anti-FasII staining). 
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Figure 3.3: Axed functions downstream of dSarm pro-degenerative signaling  
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Figure 3.3:  
A. Complementation test in axon degeneration assays. Glutamatergic axons (OK371-Gal4, 
5xUAS-mCD8::GFP) were severed, and the onset of axon fragmentation visualized 7 days 
post axotomy (7 dpa). Severed axons either heterozygous for dsarm4621, heterozygous for 
axed0011, or trans-heterozygous for dsarm4621/axed0011 underwent fragmentation at 7 dpa.  
B. Genomic dsarm fails to rescue axon degeneration in axed mutant alleles. Degeneration 
of axons, homozygous for wild type, dsarm4314, axed0011 or axed2094, was assessed at 7 dpa, 
with or without an extra copy of a bacterial artificial chromosome (BAC) containing 
genomic dsarm (BACCH321-38D07). Uninjured axons served as internal controls (white bars). 
C. Overexpression of dsarm fails to rescue axon degeneration in axed mutant alleles. 
Degeneration of axons homozygous for wild type, dsarm4314, axed0011 or axed2094, was 
assessed at 7 dpa, with dsarm* (5xUAS-dsarmP862Q). Uninjured axons served as internal 
controls (white bars).  
D. dsarm∆ARM-mediated degeneration of sensory neuron cell bodies. Left side: top, intact 
control neuron; center and bottom, early and late examples of degenerative neurons. 
Dendrites and axons, left and right, respectively. Scale bar, 5 µm. Right side: the average 
numbers of intact cell bodies are plotted on each day post eclosion (dpe) expressing either 
dsarm∆ARM or GFP as a control (n = 10 wings each). Lines: interpolation of 95% confidence 
interval (CI). 
E. dsarm∆ARM-mediated degeneration of sensory axons. Left side: top, intact control axons; 
center and bottom, early and late examples of degenerative axons. Scale bar, 5 µm. Right 
side: the average numbers of intact axons are plotted at each dpe, expressing either 
dsarm∆ARM or GFP as a control (n = 10 each). Lines: interpolation of 95% CI. 
F. Axed functions downstream of dsarm∆ARM-mediated degeneration. Axons undergo 
Wallerian-like degeneration after dSarm∆ARM expression, they are partially protected by 
WldS. At 10 dpe, clones of both axed2094 and the deficiency BSC411 suppress dsarm∆ARM-
mediated degeneration of sensory neurons and their axons (n = 20 each). 
G. Axons are morphologically preserved to 50 dpe in axed0011 mutant alleles expressing 
dsarm∆ARM (n = 10 each). Inset: top and bottom, representative cell body and axons at 50 
dpe, respectively. Wild type at 10, 14, and 21 dpe data not shown; 100% of cell bodies and 
axons are degenerated at these time points.  
 
F. 2-way ANOVA with Sidak’s multiple comparisons test (* = p < 0.05, ** = p < 0.01, *** 
= p < 0.001, **** = p < 0.0001). 
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Figure 3.4: Axed functions downstream of Nmnat depletion  
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Figure 3.4:  
A. RNAi-mediated knock-down of Nmnat (NmnatRNAi) induces degeneration of sensory 
neuron cell bodies. Left side: top, intact control axons; center and bottom, early and late 
examples of degenerative axons. Scale bar, 5 µm. Right side: the average numbers of intact 
axons are plotted at each dpe, expressing either dsarm∆ARM or GFP as a control (n = 20 
each). Lines: interpolation of 95% CI.  
B. NmnatRNAi & Dcr2-mediated degeneration of axons. Left side: top, intact control axons; 
center and bottom, early and late examples of degenerative axons. Scale bar, 5 µm. Right 
side: the average numbers of intact axons are plotted at each dpe, expressing either 
dsarm∆ARM or GFP as a control (n = 20 each). Lines: interpolation of 95% CI. 
C. Axed functions downstream of NmnatRNAi-mediated neurodegeneration. To 10 dpe, 
axed2094 and axed, dsarm double mutants suppress Nmnat RNAi-mediated cell body and 
axonal degeneration. At 10 dpe dsarm896 mutants show axonal degeneration (n = 20 each). 
D. Hiw cannot suppress NmnatRNAi-mediated neurodegeneration (n = 20 each). 
E. Severed axed or dsarm mutant axons expressing NmnatRNAi & Dcr2 are preserved at 7 
dpa (n = 15 each). 
F. Representative pictures of severed axons at 7 dpa. Number of cb proximal to cut site is 
indicated in the upper right.  Scale bar, 5 µm. 
 
C-D. 2-way ANOVA with Sidak’s multiple comparisons test on either cell bodies or 
axons, degenerating cell bodies and axons were excluded. (* = p < 0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001). 
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Figure 3.5: Death induced by complete loss of Nmnat is suppressed in axed nulls, but not 
dSarm. 
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Figure 3.5:  
A. Neurons in all backgrounds are morphologically unaffected by loss of one copy of 
Nmnat (left arm, mutant alleles, is flipped homozygous, purple).  Conversely, complete 
neuron death in Nmnat mutant clones is unaffected by removal of one copy of axed or 
dsarm (right arm, Nmnat, is flipped homozygous, red).  (n = 15 wings each).  
B. Severed axed & dsarm axons heterozygous for Nmnat remain intact at 7 dpa. (n = 15 
wings each). 
C. Axed functions downstream of Nmnat-mediated neurodegeneration. Two unique 
alleles of axed block Nmnat∆4790-mediated neurodegeneration, while two separate alleles 
of dsarm fail to do so. Axed, dsarm double mutant clones also block Nmnat-mediated 
neurodegeneration. Percentage of clones with intact cell bodies & axons at 5 dpe (n = 15 
wings each). 
D. Representative images of cell bodies and axons double mutant clones Scale bar, 5 µm. 
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Figure 3.6: Axed, Nmnat double null axons are preserved in multiple contexts. 
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Figure 3.6:  
A. Axed, Nmnat double null neuronal clones expressing GFP, dsarmΔARM, or NmnatRNAi 
& Dcr2 are preserved to 5 dpe, while those expressing Axedlong(attP40) degenerate. 
Percentage of clones with intact cell bodies & axons. (n = 15 wings each) 
B. Axon death is suppressed in severed axed, Nmnat double null axons expressing GFP, 
dsarmΔARM at 7 dpa.  (n = 10-15 wings each) 
C. Wild type axons: Uninjured at 5dpe and 7dpa. Axed, Nmnat double null axons 
expressing GFP or dsarmΔARM. Scale bar, 5µm. 
D. Axed, Nmnat double null neuronal clones expressing GFP remain morphologically 
intact at 30 days post eclosion. Scale bar, 5µm. 
 
 
Figure 3.7: Hiw expression cannot rescue axon death in axed nulls 
 
 
 
Figure 3.7: 
A. Severed axed axons expressing hiw remain intact at 7 dpa. (n = 10 wings each). 
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Table 3.1: Axed alleles suppress axon degeneration downstream of dSarm & Nmnat 
 
Axed allele Detailed description 
dsarm∆ARM 
suppression 
NmnatRNAi 
or null 
suppression 
axed0011 EMS mutagenesis, 16bp deletion exon 3 yes yes 
axed2094 EMS mutagenesis yes yes 
BSC411 Deficiency uncovering genomic axed yes ND 
axedMI13270 Minos transposon Mi{MIC}CG8398MI13270 yes ND 
axedEx05 Precise Minos excision no ND 
axedEx07 Imprecise Minos excision yes ND 
axedEx65 Imprecise Minos excision yes ND 
axedEx96 Imprecise Minos excision yes ND 
axedeGFP::FLAG Functional endogenous eGFP::FLAG fusion no ND 
axedCrisprA CRISPR/Cas9, 194bp deletion, exon 2 yes ND 
axedCrisprB CRISPR/Cas9, 14bp deletion, exon 2 yes ND 
axedCrisprC CRISPR/Cas9, 14bp deletion, exon 2 yes ND 
 
Table 3.1:  
Summary of all axed alleles generated and their abilities to suppress dsarm∆ARM-mediated 
Wallerian-like degeneration or NmnatRNAi-triggered degeneration. If known, the 
molecular nature of each lesion is indicated. ND, not determined. 
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Table 3.2: MAPK alleles tested for deficits in axon death 
 
Gene / allele Detailed description 
Axon death 
phenotype 
dsarm∆ARM 
suppression 
MAPK alleles 
bsk2 JNK null allele, early stop mutation no no 
bskflp170B Deficiency uncovering JNK no no 
MKK4e01485 P element transposon no no 
Df(3R)Exel6149 Deficiency uncovering MKK4 no no 
hepr75 MKK7 null allele no no 
 
Table 3.2:  
The MAPK genes in the table tested were null alleles or deficiencies recombined with 
FRT sites. Each was assessed for an axon death at 7 dpa and whole cell death after 
expression of dsarm∆ARM.  
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Table 3.3: Genotypes in figures/experiments 
 
Abbreviations: Y: Y chromosome, w: w1118 or w-, OK371: OK371-Gal4, mCD8::GFP: 
5xUAS-mCD8::GFP 
Figure 3.1: 
wild type: yw ; + ; + 
AxedEGFP::FLAG: yw ; + ; axedEGFP-FlAsH-StrepII-TEV-3xFlag 
w/Y ; 5xUAS-axed::smGdP-cMyc ; Tdc2-Gal4,5xUAS-CD8::mCherry 
Spaghetti monster control: w/Y ; 10xUAS-IVS-myr::smGdP-cMyc ; Tdc2-Gal4,5xUAS-CD8::mCherry 
Spaghetti monster axed: w/Y ; 5xUAS-axed::smGdP-cMyc ; Tdc2-Gal4,5xUAS-CD8::mCherry 
Figure 3.2: 
A. wild type:  Canton S 
A. GMR-hid10 wild type:  w,eyFLP2/Y ; GMR-hid10/+ ; FRT2A/tub-Gal80,FRT2A 
A. GMR-hid10 droncI29:  w,eyFLP2/Y ; GMR-hid10/+ ; droncI29,FRT2A/tub-Gal80,FRT2A 
A. GMR-hid10 axed2094:  w,eyFLP2/Y ; GMR-hid10/+ ; axed2094,FRT2A/tub-Gal80,FRT2A 
B. wild type:  w,hs-FLP12/Y ; 201Y-gal4,mCD8::GFP/+ ; FRT2A/tub-Gal80,FRT2A 
B. axed0011:  w,hs-FLP12/Y ; 201Y-gal4,mCD8::GFP/+ ; axed0011,FRT2A/tub-Gal80,FRT2A 
Figure 3.3: 
A. axed0011/+:  w/Y ; OK371,mCD8::GFP/+ ; axed0011,FRT2A/FRT2A 
A. +/dsarm4621:  w/Y ; OK371,mCD8::GFP/+ ; FRT2A/FRT2A,dsarm4621 
A. axed4621/dsarm4621:  w/Y ; OK371,mCD8::GFP/+ ; axed4621,FRT2A/dsarm4621,FRT2A 
B. wild type: w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; FRT2A/tub-Gal80,FRT2A 
B. wild type + genomic dsarm: w/Y ; OK371,mCD8::GFP,aseFLP2e/BACCH321-38D077; FRT2A/tub-Gal80,FRT2A 
B. dsarm4314: w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; dsarm4314,FRT2A/tub-Gal80,FRT2A 
B. dsarm4314 + genomic dsarm: w/Y ; OK371,mCD8::GFP,aseFLP2e/BACCH321-38D07; dsarm4314,FRT2A/tub-Gal80,FRT2A 
B. axed0011 & axed2094: as above 
C. wild type + 5xUAS-dsarm: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarmP862Q; FRT2A/tub-Gal80,FRT2A 
C. dsarm4314 + 5xUAS-dsarm: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarmP862Q; dsarm4314,FRT2A/tub-Gal80,FRT2A 
C. axed0011 + 5xUAS-dsarm: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarmP862Q; axed0011,FRT2A/tub-Gal80,FRT2A 
D-E. GFP:  w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; FRT2A/tub-Gal80,FRT2A 
D-E. dsarm∆ARM:  w/Y ; OK371,mCD8::GFP,aseFLP2e//5xUAS-dsarm∆ARM::myc ; FRT2A/tub-Gal80,FRT2A 
F. wild type + mCD8::GFP: w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; FRT2A/tub-Gal80,FRT2A 
F. wild type + 5xUAS-dsarm∆ARM::myc: w/Y ; OK371,mCD8::GFP,aseFLP2e//5xUAS-dsarm∆ARM::myc ; FRT2A/tub-Gal80,FRT2A 
F. P35:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc,5xUAS-P35 ; FRT2A/tub-Gal80,FRT2A 
F. WldS:  w,5xUAS-WldS/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; FRT2A/tub-Gal80,FRT2A 
F. dsarm896:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; dsarm896,FRT2A/tub-Gal80,FRT2A 
F. hiw∆N:  w,tub-Gal80,FRT19A/w,hiw∆N,FRT19A ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; mCD8::GFP,aseFLP3b/+ 
F. axed2094:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; axed2094,FRT2A/tub-Gal80,FRT2A 
F. BSC411:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; BSC411,FRT2A/tub-Gal80,FRT2A 
G. wild type + 5xUAS-dsarm∆ARM::myc: w/Y ; OK371,mCD8::GFP,aseFLP2e//5xUAS-dsarm∆ARM::myc ; FRT2A/tub-Gal80,FRT2A 
G. axed2094:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; axed2094,FRT2A/tub-Gal80,FRT2A 
Figure 3.4: 
A-B. control:  w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; FRT2A/tub-Gal80,FRT2A 
A-B. NmnatRNAi:  w/Y ; OK371,mCD8::GFP,aseFLP2e/10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr-2 ; FRT2A/tub-Gal80,FRT2A 
C. wild type:  w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; FRT2A/tub-Gal80,FRT2A 
C. NmnatRNAi:  w/Y ; OK371,mCD8::GFP,aseFLP2e/10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2 ; FRT2A/tub-Gal80,FRT2A 
C. axed0011:  w/Y ; OK371,mCD8::GFP,aseFLP2e/10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2 ; axed0011,FRT2A/tub-Gal80,FRT2A 
C. axed2094, dsarm896 & axed2094,dsarm896:  as above 
D. wild type:  w,19A/w,tubGal80,19A; 10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2/Ok371-Gal4,mCD8::GFP ; aseFLP3b/+ 
D. hiw∆N:  w,hsFLP,hiw∆N,19A/w,tubGal80,19A; 10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2/Ok371-Gal4,mCD8::GFP ; aseFLP3b/+ 
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E-F. axed0011, axed2094, dsarm896 & axed2094,dsarm896:  as above in C. 
Figure 3.5: 
A. Nmnat Δ4790-1/+ and wild type 3L clones: w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; FRT2A,FRT82B,NmnatΔ4790-1/tub-Gal80,FRT2A 
A. Nmnat Δ4790-1 and wild type/+ 3R clones: w/Y ; OK371,mCD8::GFP,aseFLP2a/+ ; FRT2A,FRT82B,NmnatΔ4790-1/FRT82B,tub-Gal80 
A. Nmnat Δ4790-1/+ and axed0011 3L clones: w/Y ; OK371,mCD8::GFP,aseFLP2e/+ ; axed0011,FRT2A,FRT82B,NmnatΔ4790-
1/tub-Gal80,FRT2A 
A. Nmnat Δ4790-1 and axed0011/+ 3R clones: w/Y ; OK371,mCD8::GFP,aseFLP2a/+ ; axed0011,FRT2A,FRT82B,NmnatΔ4790-
1FRT82B,tub-Gal80 
A. Nmnat Δ4790-1/+ OR Nmnat axed0011, axed2094, dsarm896, dsarm896, & dsarm896 & axed2094 3L OR 3R clones:  as above 
B. Axotomy in Nmnat Δ4790-1/+ and wild type, axed0011, axed2094, dsarm896, dsarm4621, & dsarm896 & axed2094 3L clones:  as above 
C-D. wild type 3L & 3R double clones: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/+ ;  
FRT2A,FRT82B/tubGal80,FRT2A,FRT82b,tubGal80 
C-D. wild type and Nmnat Δ4790-1 3L & 3R double clones: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/+ ; FRT2A,FRT82B,NmnatΔ4790-
1/tubGal80,FRT2A,FRT82b,tubGal80 
C-D. axed0011 and Nmnat Δ4790-1 3L & 3R double clones: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/+; FRT2A,FRT82B,NmnatΔ4790-
1/tubGal80,FRT2A,FRT82b,tubGal80 
C-D. axed2094, dsarm896, dsarm4621, & dsarm896 & axed2094 3L & 3R double clones:  as above 
Figure 3-6: 
A-D. wild type 3L & 3R double clones + GFP: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/mCD8::GFP ;  
FRT2A,FRT82B/tubGal80,FRT2A,FRT82b,tubGal80 
A-D. wild type and Nmnat Δ4790-1 3L & 3R double clones + GFP: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/mCD8::GFP ; 
FRT2A,FRT82B,NmnatΔ4790-1/tubGal80,FRT2A,FRT82b,tubGal80 
A-D. axed0011 and Nmnat Δ4790-1 3L & 3R double clones + GFP: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/mCD8::GFP ; 
FRT2A,FRT82B,NmnatΔ4790-1/tubGal80,FRT2A,FRT82b,tubGal80 
A-D. axed2094, & dsarm896 & axed2094 and Nmnat Δ4790-1 3L & 3R double clones + GFP:  as above 
A-D. wild type 3L & 3R double clones + ΔARM: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/5xUAS-dsarm∆ARM::myc ;  
FRT2A,FRT82B/tubGal80,FRT2A,FRT82b,tubGal80 
A-D. wild type and Nmnat Δ4790-1 3L & 3R double clones + ΔARM: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/5xUAS-dsarm∆ARM::myc ; 
FRT2A,FRT82B,NmnatΔ4790-1/tubGal80,FRT2A,FRT82b,tubGal80 
A-D. axed0011 and Nmnat Δ4790-1 3L & 3R double clones + ΔARM: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/5xUAS-dsarm∆ARM::myc ; 
FRT2A,FRT82B,NmnatΔ4790-1/tubGal80,FRT2A,FRT82b,tubGal80 
A-D. axed2094, & dsarm896 & axed2094 and Nmnat Δ4790-1 3L & 3R double clones + ΔARM:  as above 
A. wild type 3L & 3R double clones + axedlong(attp40): y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/5xUAS-axedfl(attP40) ;  
FRT2A,FRT82B/tubGal80,FRT2A,FRT82b,tubGal80 
A. wild type and Nmnat Δ4790-1 3L & 3R double clones + axedlong(attp40): y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/5xUAS-axedfl(attP40); 
FRT2A,FRT82B,NmnatΔ4790-1/tubGal80,FRT2A,FRT82b,tubGal80 
A. axed0011 and Nmnat Δ4790-1 3L & 3R double clones + axedlong(attp40): y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/5xUAS-axedfl(attP40); 
FRT2A,FRT82B,NmnatΔ4790-1/tubGal80,FRT2A,FRT82b,tubGal80 
A. axed2094, & dsarm896 & axed2094 and Nmnat Δ4790-1 3L & 3R double clones + axedlong(attp40):  as above 
A. wild type 3L & 3R double clones + Nmnat-RNAi: y,w,hsFLP ; Ok371,mCD::GFP,aseFLP2a/10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2 ; 
FRT2A,FRT82B,NmnatΔ4790-1/tubGal80,FRT2A,FRT82b,tubGal80 
A. wild type and Nmnat Δ4790-1 3L & 3R double clones + Nmnat-RNAi: y,w,hsFLP ; 
Ok371,mCD::GFP,aseFLP2a/10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2 ; FRT2A,FRT82B,NmnatΔ4790-
1/tubGal80,FRT2A,FRT82b,tubGal80 
A. axed0011 and Nmnat Δ4790-1 3L & 3R double clones + Nmnat-RNAi: y,w,hsFLP ; 
Ok371,mCD::GFP,aseFLP2a/10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2 ; FRT2A,FRT82B,NmnatΔ4790-
1/tubGal80,FRT2A,FRT82b,tubGal80 
Table 3-1: 
dsarm∆ARM:  w/Y ; OK371,mCD8::GFP,aseFLP2e//5xUAS-dsarm∆ARM::myc ; axedalleles,FRT2A/tub-Gal80,FRT2A 
NmnatRNAi:  w/Y ; OK371,mCD8::GFP,aseFLP2e/10xUAS-NmnatRNAi(GD32255),5xUAS-Dcr2 ; axedalleles,FRT2A/tub-Gal80,FRT2A 
Figure 3-7: 
A. wild type + 5xUAS-hiw: w,19A/w,tubGal80,19A ; Ok371-Gal4,mCD8::GFP/5xUAS-hiwfl ; aseFLP3b/+ 
A. hiw∆N + 5xUAS-hiw: w,hsFLP,hiw∆N,19A/w,tubGal80,19A; Ok371-Gal4,mCD8::GFP /5xUAS-hiwfl ; aseFLP3b/+ 
A. axed0011 + 5xUAS-hiw: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-hiwfl ; axed0011,FRT2A/tub-Gal80,FRT2A 
Table 3-2: 
Axotomy:  
JNK: bskflp170B & bsk2:  w/Y ; JNKallelels,FRT40A/tub-Gal80,FRT40A ; nSyb-Gal4,mCD8::GFP,aseFLP3a/nSyb-Gal4,mCD8::GFP 
Mkk4: Mkk4e01485 & Df(3R)Exel6149:  w/Y ; OK371,mCD8::GFP,aseFLP2a/mCD8::GFP ; FRT82B,Mkk4alleles/FRT82B,tub-Gal80 
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Mkk7: hepr75:  w,hs-FLP12,tub-Gal80,FRT19A/w,hepr75,FRT19A; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b/+ 
dsarm∆ARM suppression: 
JNK: bskflp170B & bsk2:  w/Y ; JNKallelels,FRT40A/tub-Gal80,FRT40A ; nSyb-Gal4,mCD8::GFP,aseFLP3a/5xUAS-dsarm∆ARM::EGFP 
Mkk4: Mkk4e01485 & Df(3R)Exel6149:  w/Y ; OK371,mCD8::GFP,aseFLP2a/5xUAS-dsarm∆ARM::myc ; 
FRT82B,Mkk4alleles/FRT82B,tub-Gal80 
Mkk7: hepr75:  w,hs FLP12,tub Gal80,FRT19A/w,hepr75,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; 5xUAS dsarm∆ARM::EGFP 
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CHAPTER IV: Defining Axed Domains & Molecular Partners 
Required for Axon Death. 
 
This work was conducted in the laboratory of Marc Freeman. I performed all of the 
Drosophila experiments in this chapter. Amy Sheehan cloned axed domain deletions 
constructs and Jon Farley tested expression in S2 cells. 
 
The following publication is in preparation as follows: 
Axon death pathways converge on Axed to promote functional and structural axon 
disassembly 
Lukas J. Neukomm* & Thomas C. Burdett*, Jaeda Coutinho-Budd, Andrew M. Seeds, 
Stefanie Hampel, Jack Wong, Yonca Karadeniz, Jeannette M. Osterloh, Amy E. Sheehan, 
and Marc R. Freeman 
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Abstract 
 
 In the previous two chapters we identified and defined a downstream role for 
Axed within an axon death program activated after injury. In this chapter, I present 
experiments designed to elucidate which structural features of Axed are required for 
degenerative function. To do this we attempted to rescue degeneration in an axed null 
background with Axed constructs lacking conserved domains and found that the C-
terminal region is essential for function. Additionally, we investigate whether common 
BTB domain protein binding partners are required for function and found that Axed 
likely does not integrate into Cullin-RING-ligase complex, since disrupting complex 
components had no effect on the progression axon death after injury or dSarmΔARM 
induction. Furthermore, we find that the ubiquitin proteasome is not required for 
downstream degenerative processes in axons. 
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Chapter IV: Results & Discussion 
Results 4-1: Defining Axed domains required for function 
Axed contains two evolutionary conserved domains, BTB (bric-à-brac, tramtrack, 
broad complex), and BACK (BTB and C-terminal Kelch), respectively(Stogios and 
Privé, 2004). To determine the domains in Axed essential for axon death, we generated 
deletion constructs lacking either the BTB, the BACK, or the C terminal domain using 
Axedlong as a reference (Figure 4.1-A). To avoid artificial localization or stabilization 
changes we did not tag the deletion constructs, but without a functional antibody, we 
were unable to confirm these constructs resulted in stably expressed protein. To confirm 
the protein was actually produced we tagged each deletion construct with N-terminal 
FLAG tags and expressed them in S2 cells under the actin promotor. Western blot 
revealed each construct produced protein of the expected size (Figure 4.1-B). FLAG-
tagged constructs will be retested for function and subcellular localization in vivo in the 
future. Each deletion construct was site specifically inserted and expressed in wild type 
clones, as well as in several distinct axed mutant backgrounds, and assayed for axon 
death (Figure 4.1C/D/E/F). While full length Axedlong was able to entirely rescue axon 
death, constructs lacking either BTB or BACK domains were only partially functional, 
whereas expression of Axed lacking the C terminus completely failed to rescue axon 
death. Our findings suggest that the BTB and BACK domains are important, but partially 
redundant for Axed function, while the C terminus, which harbors a substrate binding 
domain in many BTB molecules, is absolutely required for axon death signaling or 
protein stability in vivo.  
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Many BTB-containing proteins are involved in the recruitment of substrates to 
Cullin-RING ligase (CRL) complexes for ubiquitin tagging and proteasome 
degradation(Bennett et al., 2010; Pintard et al., 2004; Zhuang et al., 2009). We tested an 
array of Drosophila CRL complex mutants in our wing axotomy assay, we found none of 
them to be defective in axon death (Table 4.1). These data suggest CRL complexes are 
not involved in axon death, or that genetic redundancy among CRL components might 
mask their axon death involvement.  
 
Results 4-2: Disrupting the proteasome fails to suppress axon death in multiple contexts 
Despite the Cullin-RING-ligase complex components failing to display any axon 
death defects at all, we thought Axed may still play a role in the ubiquitin proteasome 
system with functionally redundant cullins or other E3 ligases. In order bypass an 
extensive candidate survey of Drosophila E3 ligase genes, we decided to alter the UPS 
itself, reasoning that if Axed functions within the UPS, disruptions should phenocopy 
axed null alleles. Previous studies have demonstrated pharmacological blockade of the 
UPS moderately preserves axons in vivo and antagonizing ubiquitin chain formation with 
yeast de-ubiquitinating yeast UBP2 strongly protects axons in vivo (Baker et al., 1992; 
Xiong et al., 2012; Zhai et al., 2003).   
We first attempted to replicate UBP2 axon protection in adult glutamatergic 
neurons in the wing. We found the overexpressing UBP2 in adult glutamatergic sensory 
neurons led to spontaneous whole cell loss over the course of 5 days, not seen in axons 
expressing a GFP control (Figure 4.2-A), that could be almost fully suppressed by co-
expression of apoptotic inhibitor P35 (Figure 4.2-B/D, uninjured at 5dpe). While death is 
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suppressed, cells are still morphologically altered with swollen and enlarged cell bodies 
and axonal membranes that are irregular compared to wild type (Figure 4.2-C). Since 
degeneration of axons and cell bodies before injury, expression of dsarmΔARM, or knock 
out of Nmnat would complicate our interpretation of suppression of a Wallerian-like 
death program, we co-expressed P35 with UBP2 or a control GFP in all experiments. 
Consistent with previous reports, we found UBP2 strongly suppressed injury-induced 
axon death after injury for at least 7 dpa (Figure 4.2-B/C). 
We next wanted to assess whether this protective effect was applicable to 
downstream pro-degenerative processes. To do this we co-expressed UBP2 & P35 in an 
Nmnat null background and found that while UBP2 could delay spontaneous 
degeneration at 1 day, the majority of cell bodies and axons fully degenerated by 5 days 
(Figure 4.2-D).  The few surviving cell bodies were severely swollen, while the axons 
were dimmer and thinned compared to controls, indicating a progressive degeneration 
(Figure 4.2-E). Additionally, we assessed whether UBP2 & P35 could suppress 
dsarmΔARM induced degeneration and found no significant suppression of neuron death 
(Figure 4.2-F/G). The small amount of remaining neurons in control and UBP2 clones is 
likely due to the dilution of dsarmΔARM production when using four UAS constructs. 
These data argue that axon protective effects of UBP2 occur upstream of dsarm 
activation and Nmnat loss. 
Since UBP2 only reversed ubiquitination processes, we wanted to determine if 
whole proteasome disruption led to stronger axon protective effects possibly extending 
further downstream in the axon pathway. To do this we used ovexpression of temperature 
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sensitive dominant negative 20S proteasomal subunits, prosβ61 & prosβ21, or 20S 
proteasome particle repressor 31kDA (PI31) (Cho-Park and Steller, 2013; Schweisguth, 
1999).  Previous reports demonstrated that proteasome disruption increased Nmnat levels 
modestly, but less than levels induced by UBP2. However, they did not test whether the 
Nmnat increase resulted in axon survival after injury. To our surprise none of the 
proteasome disruptions we attempted led to persistence of intact anucleated axons after 
axotomy or suppression of whole neuron death after gain of function dsarm signaling or 
loss of Nmnat (Figure 4.5). Even expression of prosβ61 & prosβ21 together failed to 
produce even partial suppression of axon death after injury at 7 dpa (Figure 4.3-A). As 
we could not directly assess proteasome activity within sensory neurons, it is possible 
some residual proteasome activity remained. However, taken together these data suggest 
that the proteasome plays no essential role in axon death and that the ubiquitin addition 
process may play essential roles beyond proteasomal degradation as proposed in previous 
reports (Xiong et al., 2012). 
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Chapter IV: Materials & Methods 
 
Wing injury & assays and Confocal Microscopy: 
See Materials & Methods in Chapter II. 
 
Temperature sensitive alleles: 
Use of temperature sensitive alleles to disrupt the proteasome is noted in figures. When 
assessing injury induced axon death, adult flies were shifted to 29°C immediately post 
eclosion for 5 days. Axotomy was applied and flies were maintained at 29°C for the 
remainder of the testing period. When assessing death induced by dSarmΔARM or loss of 
Nmnat, both crosses and adults were maintained at 29°C. 
 
Cloning: 
For structure/function analyses, Gibson assembly was used to clone the axedlong PCR 
product into pUAST(attB) (Bischof et al., 2007) using the following primers:  
pLN292 p(5x)UAST-axedlong,w+,attB 
5’ primer: GCTAGCGGATCCAAAAGCTTtccggatccaagcttgcatgcc,  
3’ primer: GGTACCCTCGAGCCGCGGCCGCggatccgatccagacatgataag 
Domain deletion versions as indicated:  
pLN297 p(5x)UAST-axed∆BTB(aa157-258),w+,attB;  
pLN298 p(5x)UAST-axed∆BACK(aa348-442),w+,attB;  
pLN299 p(5x)UAST-axedNterm(aa442-537),w+,attB.  
Phi31-mediated integration was performed by (Bestgene). 
 
S2 cells: 
8x105 cells were plated out in 12-well plate 24 hr prior to transfection. Cells were co-
transfected with 5xUAS deletion constructs and pAc-GAL4 to a final concentration of 1 
µg DNA using Mirus TransIT-Insect (Mirus Bio, Madison, WI). Cells were harvested 48 
hours after transfection and protein expression was assessed using Western blot. (pAC-
GAL4 was a gift from Liqun Luo - Addgene plasmid # 24344 - ). 
 
Immunohistochemistry 
Western Blot: Primary antibodies (AB) were applied at 4°C overnight, secondary 
antibodies at room temperature for 1h. FLAG detection: 1st AB: 1:1000 Mouse anti 
FLAG (Sigma F1804), 2nd AB: 1:2000 Rabbit anti Mouse HRP (Abcam ab6728). 
 
Drosophila Stocks and Genotypes in Display Items 
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In addition to stocks listed in Materials & Methods section of Chapter II & III, stocks used 
in Chapter IV are listed below. 
 
X chromosome:  
Df(1)G1 (uncovering Roc1aG1) (Noureddine et al., 2002). 
 
Chromosome 2:  
axed structure/function (including endogenous 5’ & 3’ UTR, landing site: attP40): 
5xUAS-axedlong, 5xUAS-axed∆BTB, 5xUAS-axed∆BACK, 5xUAS-axed∆Cterm (Amy Sheehan), 
cul1K01207 (Spradling et al., 1999), cul3gft2 (Ou et al., 2002), cul306430 (Mistry et al., 2004), 
cul3EY11031(Bellen et al., 2004), cul411L (Hu et al., 2008), cul4KG02900 (Lin et al., 2009), 
Uba1S3484 (Spradling et al., 1999), Uba1LL03617 (Schuldiner et al., 2008), Nedd8KG03071 
(Spradling et al., 1999), 5xUAS- UAS-UBP2.D (Liqun Luo), 5xUAS-ProsB61 (Belote and 
Fortier, 2002), 5xUAS-PI31::HA (Bader et al., 2011). 
 
Chromosome 3:  
Roc1bdc3 (Donaldson et al., 2004), 5xUAS-GFP::gftK717R (Zhu et al., 2005), 5xUAS-
ProsB21 (Belote and Fortier, 2002), 5xUAS-PI31 (Provided by the Stellar Lab), sina2 
(Carthew and Rubin, 1990), effS1782 (Fauvarque et al., 2001). 
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Chapter IV: Figures & Tables 
Figure 4.1: Axed conserved domains required for function 
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Figure 4.1:  
A. Depicted are the conserved domains of Axedlong (537 amino acids (aa)), * indicates the 
start codon of Axedshort (434 aa). Indicated deletions are shown below (aa deleted: 
∆BTB(157-258), ∆BACK(348-442), ∆CTerm(442-537)).  
B. N-terminal FLAG tagged deletion constructs under an actin promoter produce stable 
protein species S2 cells. Deletions constructs were co-transfected with a pAc in S2 cells, 
lysed, and assessed using Western blot and anti-FLAG (Expected molecular weights: 
Axedlong: ~60kDa, AxedΔBTB: ~49kDa, AxedΔBACK: ~49.5kDa, AxedΔCTerm: ~49.5kDa). 
C-F. To determine if Axedlong or Axed deletion constructs caused spontaneous 
degeneration or dominant negative effects, or could rescue axon degeneration we 
assessed axon integrity in uninjured axons and axons at 7dpa in wild type, axed null, 
dsarm null, and hiw null clones: 
C. Axedlong recues axon death at 7dpa in axed null clones, yet fails to attenuate axon 
protection afforded in severed dsarm or hiw null axons. Expression in wild type has no 
effect on uninjured neuronal morphology or on the progression of axon death after injury 
(n = 15 wings each). 
D. AxedΔBTB partially recues axon death at 7dpa in axed null clones and fails to attenuate 
axon protection afforded in severed dsarm or hiw null axons. Expression in wild type has 
no effect on uninjured neuronal morphology or on the progression of axon death after 
injury (n = 15 wings each). 
E. AxedΔBACK partially recues axon death at 7dpa in axed null clones and fails to 
attenuate axon protection afforded in severed dsarm or hiw null axons. Expression in wild 
type has no effect on uninjured neuronal morphology or on the progression of axon death 
after injury (n = 15 wings each). 
F. AxedΔCTerm fails to rescue axon death at 7dpa in axed, dsarm, or hiw null axons. 
Expression in wild type has no effect on uninjured neuronal morphology or on the 
progression of axon death after injury (n = 15 wings each). 
G. Axed deletion constructs, as well as Axedlong, fail to attenuate neuronal death induced 
by dsarmΔARM (n = 10 wings each). 
H. Axed deletion constructs, as well as Axedlong, fail to attenuate neuronal death in 
Nmnat null clones (n = 15 wings each). 
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Figure 4.2: Disrupting the proteasome with UBP2 suppresses axon death induced by 
injury, but not by Nmnat depletion or dSarmΔARM. 
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Figure 4.2:  
A. Expression of the yeast de-ubiquitinating enzyme UBP2 in neurons causes 
spontaneous progressive degeneration of both cell bodies and axons. Intact cell bodies 
and axons were scored wild type expressing GFP or UBP2 (n = 10 wings each). 
B. UBP2 completely inhibits axon degeneration to 7 days post axotomy. Apoptotic 
inhibitor P35 has no effect on axon degeneration and suppresses spontaneous neuronal 
death induced by UBP2 (n = 15 wings each). 
C. Representative images of cell bodies (cb), uninjured axons at 5 dpe and severed axons 
at 7 days (expected axons, #cb). Scale bar, 5µm.  
D. UBP2 delays neuronal death induced by deletion of Nmnat. Intact cell bodies and 
axons were scored wild type or Nmnat clones co-expressing P35 and either GFP or UBP2 
(n = 15 wings each). 
E. Representative image of partially (upper) and fully degenerated (lower) Nmnat null 
cell bodies and axons expressing P35 and UBP2 at 5 dpe. Scale bar, 5µm. 
F. Expression of UBP2, P35, or both in tandem fail to attenuate death induced by 
dsarmΔARM. Intact cell bodies and axons were scored wild type clones co-expressing P35 
and either GFP or UBP2 (n = 10 wings each). 
G. Representative image of degenerated cell bodies and axons expressing P35, UBP2, 
dsarmΔARM at 5 dpe. Scale bar, 5µm 
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Figure 4.3: Disrupting the proteasome with prosβ21, prosβ61, or PI31 overexpression 
fails suppress axon death induced by injury, Nmnat depletion, or dSarmΔARM.  
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Figure 4.3:  
A. Dual expression of temperature sensitive dominant negative proteasome 20S subunits 
prosβ21 & prosβ61 fails to inhibit axon degeneration at 29C. (n = 15 wings each). 
B. Axon death is unaffected by expression of either prosβ61 at 29C or PI31. (n = 15 
wings each). 
C. Overexpression of prosβ61 at 29C or PI31 fail to inhibit neuronal death in Nmnat null 
clones. (n = 15 wings each). 
D. dsarmΔARM induced neuronal death is unaffected by expression of either prosβ61 at 29C 
or PI31. (n = 10 wings each) 
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Table 4.1: Cullin-RING-ligase complex component alleles tested for deficits in axon 
death 
 
Gene / allele Detailed description 
Axon 
death 
phenotype 
dsarm∆ARM 
suppression 
Cullin-RING ligase complex mutants 
cul1K01207 P element transposon no no 
cul3gft2 EMS mutant no no 
cul306430 P element transposon no no 
cul3EY11031 P element transposon no no 
UAS-GFP::gftK717R 
Cul3 mutation in Nedd8 conjugation 
site 
no nd 
cul411L Imprecise excision no no 
cul4KG02900 P element transposon no no 
Df(3R)Exel6211 Deficiency uncovering cul5 no no 
Df(3R)BSC3450 Deficiency uncovering cul5 no no 
Df(3R)BSC413 Deficiency uncovering CG11261 no no 
Df(3R)ED4486 Deficiency uncovering CG11261 no no 
Uba1S3484 P element transposon no no 
Uba1LL03617 P element transposon no no 
Df(1)G1 Deletion uncovering Roc1a no no 
Roc1bdc3 Deletion uncovering Roc1b no no 
Df(3L)BSC247 Deficiency uncovering Roc1b no no 
effS1782 P element transposon no no 
sina2 EMS mutant no no 
Df(3L)Exel9004 Deficiency uncovering sinah & sina no no 
Nedd8KG03071 P element transposon no no 
 
Table 4.1:  
 
The Cullin-RING-ligase complex genes in the table tested were null alleles or 
deficiencies recombined with FRT sites. Each was assessed for an axon death at 7 dpa 
and whole cell death after expression of dsarm∆ARM.  
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Table 4.2: Genotypes in figures/experiments 
Abbreviations: Y: Y chromosome, w: w1118 or w-, OK371: OK371-Gal4, mCD8::GFP: 
5xUAS-mCD8::GFP  
Figure 4-1: 
A. - 
B. wild type + axedlong: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axedlong(attP40) ; FRT2A/tub-Gal80,FRT2A 
B. axed0011 + axedlong: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axedlong(attP40) ; axed0011,FRT2A/tub-Gal80,FRT2A 
B. axed2094, axedMI13270, BSC411, & dsarm896 + axedlong : as above 
B. wild type + axedlong: w,19A/w,tubGal80,19A ; Ok371-Gal4,mCD8::GFP/5xUAS-axedlong(attP40) ; aseFLP3b/+ 
B. hiw∆N + axedlong: w,hsFLP,hiw∆N,19A/w,tubGal80,19A; Ok371-Gal4,mCD8::GFP /5xUAS-axedlong(attP40) ; aseFLP3b/+ 
C. wild type + axed∆BTB: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axed∆BTB(attP40 ); FRT2A/tub-Gal80,FRT2A 
C. axed0011 + axed∆BTB: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axed∆BTB(attP40) ; axed0011,FRT2A/tub-Gal80,FRT2A 
C. axed2094, axedMI13270, BSC411, & dsarm896 + axed∆BTB: as above 
C. wild type + axed∆BTB: w,19A/w,tubGal80,19A ; Ok371-Gal4,mCD8::GFP/5xUAS-axed∆BTB(attP40) ; aseFLP3b/+ 
C. hiw∆N + axed∆BTB: w,hsFLP,hiw∆N,19A/w,tubGal80,19A; Ok371-Gal4,mCD8::GFP /5xUAS-axed∆BTB(attP40) ; aseFLP3b/+ 
D. wild type + axed∆BACK: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axed∆BACK(attP40) ; FRT2A/tub-Gal80,FRT2A 
D. axed0011 + axed∆BACK: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axed∆BACK(attP40) ; axed0011,FRT2A/tub-Gal80,FRT2A 
D. axed2094, axedMI13270, BSC411, & dsarm896 + axed∆BTB: as above 
D. wild type + axed∆BACK: w,19A/w,tubGal80,19A ; Ok371-Gal4,mCD8::GFP/5xUAS-axed∆BACK(attP40) ; aseFLP3b/+ 
D. hiw∆N + axed∆BACK: w,hsFLP,hiw∆N,19A/w,tubGal80,19A; Ok371-Gal4,mCD8::GFP /5xUAS-axed∆BACK(attP40) ; aseFLP3b/+ 
E. wild type + axed∆Cterm: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axed∆Cterm(attP40) ; FRT2A/tub-Gal80,FRT2A 
E. axed0011 + axed∆Cterm: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axed∆Cterm(attP40) ; axed0011,FRT2A/tub-Gal80,FRT2A 
E. axed2094, axedMI13270, BSC411, & dsarm896 + axed∆Cterm: as above 
E. wild type + axed∆Cterm: w,19A/w,tubGal80,19A ; Ok371-Gal4,mCD8::GFP/5xUAS-axed∆Cterm(attP40) ; aseFLP3b/+ 
E. hiw∆N + axed∆Cterm: w,hsFLP,hiw∆N,19A/w,tubGal80,19A; Ok371-Gal4,mCD8::GFP /5xUAS-axed∆Cterm(attP40) ; aseFLP3b/+ 
F. GFP + axedlong: FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/5xUAS-axedlong(attP40) ; 
mCD8::GFP,aseFLP3b/mCD8::GFP 
F. GFP + axed∆BTB, axed∆BACK, & axed∆Cterm: as above 
F. ΔARM + axedlong: FRT19A/tubGal80,hsFLP,FRT19A ; OK371,mCD8::GFP,aseFLP2a/5xUAS-axedlong(attP40) ; 
mCD8::GFP,aseFLP3b/5xUAS-dsarm∆ARM::EGFP 
F. ΔARM + axed∆BTB, axed∆BACK, & axed∆Cterm: as above 
G. wild type + GFP:  w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; FRT82B/FRT82B,tub-Gal80 
G. NmnatΔ4790-1 + GFP:  w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; FRT82B,NmnatΔ4790-1/FRT82B,tub-Gal80 
G. wild type + axedlong:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axedlong(attP40); FRT82B/FRT82B,tub-Gal80 
G. wild type + axed∆BTB, axed∆BACK, & axed∆Cterm: as above 
G. NmnatΔ4790-1 + axedlong:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-axedlong(attP40); FRT82B,NmnatΔ4790-1/FRT82B,tub-Gal80 
G. NmnatΔ4790-1 + axed∆BTB, axed∆BACK, & axed∆Cterm: as above 
Table 4-1: 
Axotomy: 
Cul1: cul1k01207:  w/Y ; FRT42D,tub-Gal80/FRT42D,cul1k01207 ; nSyb-Gal4,mCD8::GFP,aseFLP3a/mCD8::GFP 
Cul3: cul3gft2, cul306430, cul3EY11031:  w/Y ; cul3alleles,FRT40A/tub-Gal80,FRT40A ; nSyb-Gal4,mCD8::GFP,aseFLP3a/mCD8::GFP 
Cul3: 5xUAS-GFP::gftK717R:  w/Y ; FRT40A/tub-Gal80,FRT40A ; nSyb-Gal4,mCD8::GFP,aseFLP3a/5xUAS-GFP::gftK717R 
Cul4: cul411L:  w,elavC155-Gal4/Y ; FRTG13,tub-Gal80/FRTG13,cul411L ; aseFLP3b,mCD8::GFP/mCD8::GFP 
Cul4: cul4KG02900:  w/Y ; FRT42D,tub-Gal80/FRT42D,cul4KG02900 ; nSyb-Gal4,mCD8::GFP,aseFLP3a/mCD8::GFP 
Cul5: Df(3R)Exel6211 & Df(3R)BSC3450:  w/Y ; OK371,mCD8::GFP,aseFLP2a/mCD8::GFP ; FRT82B,Cul5alleles/FRT82B,tub-Gal80 
CG11261: Df(3R)BSC413 & Df(3R)ED4486:  w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; 
CG11261alleles,FRT2A/tub-Gal80,FRT2A 
Uba1: uba1LL03617:  w,elavc155-Gal4/Y ; FRTG13,tub-Gal80/FRTG13,uba1LL03617 ; aseFLP3b,mCD8::GFP/mCD8::GFP 
Uba1: uba1S3484:  w/Y ; FRT42D,tub-Gal80/FRT42D,uba1S3484 ; nSyb-Gal4,mCD8::GFP,aseFLP3a/mCD8::GFP 
Roc1a: Df(1)G1:  Df(1)G1,w,sn1,FRT19A/w,hs-FLP12,tub-Gal80,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; mCD8::GFP,aseFLP3b 
Roc1b: roc1bdc3 & Df(3L)BSC247:  w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; Roc1balleles,FRT2A/tub-Gal80,FRT2A 
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Eff: w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; effS1782,FRT2A/tub-Gal80,FRT2A  
Sina: w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; sina2,FRT2A/tub-Gal80,FRT2A sina2 
Sina & Sinah: w/Y ; OK371,mCD8::GFP,aseFLP2e/mCD8::GFP ; Df(3L)Exel9004,FRT2A/tub-Gal80,FRT2A  
Nedd8: nedd8KG03071:  w/Y ; nedd8KG03071,FRT40A/tub-Gal80,FRT40A ; nSyb-Gal4,mCD8::GFP,aseFLP3a/mCD8::GFP 
dsarm∆ARM suppression: 
Cul1: cul1k01207:  w/Y ; FRT42D,tub-Gal80/FRT42D,cul1k01207 ; nSyb-Gal4,mCD8::GFP,aseFLP3a/5xUAS-dsarm∆ARM::EGFP 
Cul3: cul3gft2, cul306430, cul3EY11031:  w/Y ; cul3alleles,FRT40A/tub-Gal80,FRT40A ; 
nSyb-Gal4,mCD8::GFP,aseFLP3a/5xUAS-dsarm∆ARM::EGFP 
Cul4: cul411L:  w,elavc155-Gal4/Y ; FRTG13,tub-Gal80/FRTG13,cul411L ; aseFLP3b,mCD8::GFP/5xUAS-dsarm∆ARM::EGFP 
Cul4: cul4KG02900: w/Y ; FRT42D,tub-Gal80/FRT42D,cul4KG02900 ; nSyb-Gal4,mCD8::GFP,aseFLP3a/5xUAS-dsarm∆ARM::EGFP 
Cul5: Df(3R)Exel6211 & Df(3R)BSC3450:  w/Y ; OK371,mCD8::GFP,aseFLP2a/5xUAS-dsarm∆ARM::myc ; 
FRT82B,Cul5alleles/FRT82B,tub-Gal80 
CG11261: Df(3R)BSC413 & Df(3R)ED4486:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; 
CG11261alleles,FRT2A/tub-Gal80,FRT2A 
Uba1: uba1LL03617:  w,elavc155-Gal4/Y ; FRTG13,tub-Gal80/FRTG13,uba1LL03617 ; aseFLP3b,mCD8::GFP/5xUAS-dsarm∆ARM::EGFP  
Uba1: uba1S3484:  w/Y ; FRT42D,tub-Gal80/FRT42D,uba1S3484 ; nSyb-Gal4,mCD8::GFP,aseFLP3a/5xUAS-dsarm∆ARM::EGFP 
Roc1a: Df(1)G1:  Df(1)G1,w,sn1,FRT19A/w,hs-FLP12,tub-Gal80,FRT19A ; OK371,mCD8::GFP,aseFLP2a/+ ; 5xUAS-dsarm∆ARM::EGFP 
Roc1b: roc1bdc3 & Df(3L)BSC247:  w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; Roc1balleles,FRT2A/tub-Gal80,FRT2A 
Eff: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; effS1782,FRT2A/tub-Gal80,FRT2A  
Sina: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; sina2,FRT2A/tub-Gal80,FRT2A sina2 
Sina & Sinah: w/Y ; OK371,mCD8::GFP,aseFLP2e/5xUAS-dsarm∆ARM::myc ; Df(3L)Exel9004,FRT2A/tub-Gal80,FRT2A  
Nedd8: nedd8KG03071:  w/Y ; nedd8KG03071,FRT40A/tub-Gal80,FRT40A ; nSyb-Gal4,mCD8::GFP,aseFLP3a/5xUAS-dsarm∆ARM::EGFP 
Figure 4-2: 
A. GFP: w,FRT19A/w,hsFLP,tubGal80,FRT19A ; mCD8::GFP/ OK371,mCD8::GFP ; mCD8::GFP/mCD8::GFP,aseFLP3b 
A. UBP2: w,FRT19A/w,hsFLP,tubGal80,FRT19A ; 5xUAS-UBP2.D/ OK371,mCD8::GFP ; mCD8::GFP/mCD8::GFP,aseFLP3b 
B-C. GFP,P35: w/Y ; OK371,mCD8::GFP,5xUAS-P35/mCD8::GFP ; FRT2A,FRT82b / FRT82b, tubGal80 
B-C. GFP,UBP2: w/Y ; OK371,mCD8::GFP,5xUAS-P35/5xUAS-UBP2 ; FRT2A,FRT82b / FRT82b, tubGal80 
D-E. wild type + GFP,P35: w/Y ; OK371,mCD8::GFP,5xUAS-P35/mCD8::GFP ; FRT2A,FRT82b / FRT82b, tubGal80 
D-E. wild type + GFP,P35: GFP,UBP2: w/Y ; OK371,mCD8::GFP,5xUAS-P35/5xUAS-UBP2 ; FRT2A,FRT82b / FRT82b, tubGal80 
D-E. NmnatΔ4790-1 + GFP,P35: w/Y ; OK371,mCD8::GFP,5xUAS-P35/mCD8::GFP ; FRT82b,NmnatΔ4790-1  / FRT82b, tubGal80 
D-E. NmnatΔ4790-1  + GFP,P35: w/Y ; OK371,mCD8::GFP,5xUAS-P35/5xUAS-UBP2 ; FRT82b,NmnatΔ4790-1/FRT82b, tubGal80 
F-G. GFP,P35: w,FRT19A/ w,hsFLP,tubGal80,FRT19A ; mCD8::GFP/mCD8::GFP,OK371,mCD8::GFP ; 5xUAS-P35/mCD8::GFP, 
aseFLP3b 
F-G. GFP,UBP2: w,FRT19A/ w,hsFLP,tubGal80,FRT19A ; 5xUAS-UBP2/mCD8::GFP,OK371,mCD8::GFP ; 5xUAS-P35/mCD8::GFP, 
aseFLP3b 
F-G. ΔARM,P35: w,FRT19A/ w,hsFLP,tubGal80,FRT19A ; mCD8::GFP/mCD8::GFP,OK371,mCD8::GFP ; 5xUAS-
P35/5xUAS-dsarm∆ARM::EGFP 
F-G. UBP2,ΔARM,P35: w,FRT19A/ w,hsFLP,tubGal80,FRT19A ; 5xUAS-UBP2/mCD8::GFP,OK371,mCD8::GFP ; 5xUAS-
P35/5xUAS-dsarm∆ARM::EGFP 
Figure 4-3: 
A. GFP: w,hsFLP,FRT19/w,tubGal80,FRT19 ; OK371,mCD8::GFP/mCD8::GFP; aseFLP3b,mCD8::GFP / + 
A. Proβ61 + Prosβ21: w,hsFLP,FRT19/w,tubGal80,FRT19 ; OK371,mCD8::GFP/5xUAS-ProsB61 ; aseFLP3b/5xUAS-ProsB21 
B. GFP: w/Y ; OK371,mCD8::GFP,5xUAS-P35/mCD8::GFP; FRT2A,FRT82b/FRT82b, tubGal80 
B. Proβ61: w/Y ; OK371,mCD8::GFP,5xUAS-P35/5xUAS-Proβ61; FRT2A,FRT82b/FRT82b, tubGal80 
B. PI31::HA: w/Y ; OK371,mCD8::GFP,5xUAS-P35/5xUAS-PI31::HA ; FRT2A,FRT82b/FRT82b, tubGal80 
C. GFP, Proβ61, & PI31::HA: as above (B)  
C. NmnatΔ4790-1 + GFP: w/Y ; OK371,mCD8::GFP,5xUAS-P35/mCD8::GFP; FRT82b,NmnatΔ4790-1/FRT82b, tubGal80 
C. NmnatΔ4790-1 + Proβ61: w/Y ; OK371,mCD8::GFP,5xUAS-P35/5xUAS-Proβ61; FRT82b,NmnatΔ4790-1/FRT82b, tubGal80 
C. NmnatΔ4790-1 + PI31::HA: w/Y ; OK371,mCD8::GFP,5xUAS-P35/5xUAS-PI31::HA ; FRT82b,NmnatΔ4790-1/FRT82b, tubGal80 
D. GFP (-): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/mCD8::GFP ; aseFLP3b/mCD8::GFP 
D. Prosβ21(-): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/mCD8::GFP ; aseFLP3b/5xUAS-Prosβ21 
D. Proβ61(-): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/5xUAS-Proβ61; aseFLP3b/mCD8::GFP 
D. PI31(-): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/mCD8::GFP ; aseFLP3b/5xUAS-PI31 
D. PI31::HA(-): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/5xUAS-PI31::HA; aseFLP3b/mCD8::GFP 
104 
 
 
D. GFP (+): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/5xUAS-dsarm∆ARM::myc; aseFLP3b/mCD8::GFP 
D. GFP (+’): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/mCD8::GFP ; aseFLP3b/5xUAS-dsarm∆ARM::EGFP 
D. Prosβ21(+): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/5xUAS-dsarm∆ARM::myc; aseFLP3b/5xUAS-Prosβ21 
D. Proβ61 (+’): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/5xUAS-Proβ61 ; aseFLP3b/5xUAS-dsarm∆ARM::EGFP 
D. PI31 (+): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/5xUAS-dsarm∆ARM::myc; aseFLP3b/5xUAS-PI31 
D. PI31::HA (+’): w,hsFLP,FRT19/w,tubGal80,FRT19 ;OK371,mCD8::GFP/5xUAS-PI31::HA ; aseFLP3b/5xUAS-dsarm∆ARM::EGFP 
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CHAPTER V: Discussion 
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Discussion 5-1: Screening for regulators of axon death and maintenance 
In this thesis I describe the identification axed, a novel essential component of the 
axon death signaling pathway in Drosophila. In addition, I uncovered and identified two 
other mutant genes, one required for axon maintenance, the other required for normal 
axon death progression. Two distinct, unbiased forward genetic screens of axotomized 
neuronal clones in the Drosophila wing, combined with NGS technology and 
conventional genetic mapping, were used to identify these mutations. Unbiased 
screening, in contrast to a candidate screening approach, has the advantage of uncovering 
unexpected genes of interest. In retrospect, taking this strategy seems especially useful in 
the search for genes required for axon death, since no previous evidence would implicate 
a SAM/TIR domain- or a BTB domain-containing protein as pro-degenerative molecules, 
dsarm and axed, although a candidate strategy utilized by myself and others in the lab has 
ruled out a large swath of genes from essential participation in axon death signaling. 
I first attempted to screen using chromosomal deficiency lines recombined with 
FRT sites that were generously provided by the Doe Lab (Oregon). Only one of 169 
tested deficiencies was defective for axon death and this deficiency, Df(1)ED7289, 
uncovered hiw, a gene previously described for its role in axon death by the Collins Lab 
(Xiong et al., 2012) (Table 2.1). Lines were tested for an axon defective phenotype at 5-7 
dpa, so it is possible we may have missed more subtle phenotypes. Although this strategy 
failed to uncover any novel candidates, it still provides evidence that genes within tested 
deficiencies are not essential for axon death to proceed and is therefore a useful resource 
to cross reference genes and proteins that may turn up as candidates in additional screens 
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for axon death, other degenerative screens, or protein interaction experiments. For more 
definitive evidence however, well characterized null mutations of individual genes would 
have to be tested.  
Another group in lab, including myself, used ethyl methanesulfonate to induce 
random mutations across the Drosophila genome in the hope of disrupting a gene 
required for axon death.  We attempted to saturate the genome and screened 40,000+ 
unique mutants. I recovered gene-of-interest-#1345x (Figure 2.2) and axed0011, while Lukas 
Neukomm recovered axed2094 (Figure 2.4).  There is also an axon death gene on 
chromosome 2L, or possibly a dominant mutation located elsewhere, where both I and 
Jon Farley acquired in the screen, but failed to recover. I also recovered two alleles of a 
single gene required for axon maintenance, gene-of-interest-#2596x &1013x (Figure 2.3). 
Taken together combination of screening approaches attempted to test most 
Drosophila genes, however we may have missed some genes required for axon death for 
a few reasons. First, due to MARCM technical constraints we could not screen genes 
located between FRTs and telomeres as well as on the Y and 4th chromosomes, missing 
~18% of the Drosophila genome, although Wallerian degeneration proceeds identically 
in males and females, so genes on the Y chromosome are unlikely to contribute to axon 
death. Second, it is also possible we could not recover more candidates because some 
axon death genes may have functionally redundant duplicates. For example, it would not 
have been surprising to recover a calcium activated protease (Glass et al., 2002; Ma et al., 
2013; Yang et al., 2013), but Drosophila have three to four possibly redundant calpains 
on different chromosomes. Third, some genes may have failed to meet our stringent 
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requirements that axons survive to 7 dpa, thus limiting ‘hits’ to strong mutations in genes 
absolutely essential for axon death, but missing mutations with phenotypes that slightly 
delayed axon death. We also might miss phenotypes where only a subset of axons 
remained intact, especially in the F1 screen, where only one or two injured wings can be 
assessed. Successful recovery of partially protective gene-of-interest-#1345x may have 
been due the X chromosome requiring an F2 screen and thus allowing several injured 
wings to be analyzed. On other chromosomes, we failed to recover any mutations in 
genes reported to participate in axon death such as SkpA/Skp1a, DFsn/Fbxo45, wnd/Dlk, 
Mkk4, hep/Mkk7, and bsk/Jnk, possibly due to very weak phenotypes and some MAPK 
redundancy (Brace et al., 2014; Miller et al., 2009; Wu et al., 2007; Yamagishi and 
Tessier-Lavigne, 2016; Yang et al., 2015). Df(1)ED6443 is an example of a deficiency 
which uncovered a noted axon death gene in mammals, SkpA/Skp1a, but displayed no 
axon death deficit, possibly due to redundancy in the fly (Brace et al., 2014).  In the 
future, it might be possible to use several RNAi constructs or Cas9/CRISPR multiple 
gene knockouts within clones, possibly in combination with null alleles to test 
functionally redundant genes. Also, weak genes in an axon death might be uncovered by 
screening in a sensitized background, such as one lacking one copy axed or dsarm or both 
or very slightly overexpressing nmnat. Going forward, it may also be prudent to use 
different methods to screen as certain chromosomal regions vary in susceptibility 
mutagens and other groups have pulled out non-overlapping groups of candidate genes 
using distinct methods (Yamamoto et al., 2014).  
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False negative results are also possible if certain genes, either within a tested 
deficiency or altered by mutagen, negate the phenotype of an axon death candidate gene 
by causing non-Wallerian cell death before axonal injury. This type of cell death, defects 
in neuronal differentiation, or the suppression of components required for MARCM in 
deficiency clones may produce no detectable neurons in wings or ORNs and render them 
untestable for axon death phenotypes. Indeed, some deficiencies produced no clones and 
were omitted.  
 
Discussion 5-2: A novel gene required for axon maintenance 
Mutagenesis screening on the 1st chromosome uncovered two distinct sets of 
missense mutations within the accessory and catalytic domain of GOI#2 causing severe 
axonal membrane dysfunction and a progressive ‘dying-back’ from distal to proximal 
axonal regions. These mutations phenocopy available loss-of-function alleles and RNAi 
knockdown of GOI#2 in wing sensory neurons. It remains to be determined how long 
wild type GOI#2 protein remains after clone induction and if this is responsible for the 
‘dying back’ pattern of degeneration. Since distal axonal regions display dysfunction 
before proximal regions and cell bodies appear normal, we might hypothesize GOI#2 
must be transported from a remaining and diminishing pool of wild type protein in null 
clone cell somas. It will be interesting in the future to probe how product of GOI#2 
governs membrane structural integrity. Since I will not continue this project, only the 
basic phenotype of GOI#2 loss is presented in this thesis. 
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Discussion 5-3: A single mutation partially suppresses axon degeneration 
I identified a splice site mutation within the transcription factor, GOI#1, that 
results in a subset of axons remaining intact post injury as well as a delayed 
fragmentation in severed axon that do degenerate. Since GOI#1 is a transcription factor 
we might hypothesize that it regulates levels of components in the axon death pathway 
and its loss leads to decrease of pro-degenerative factors such as MAPKs, hiw, dsarm, 
and/or axed  or an increase of pro-survival Nmnat. In theory, reducing Nmnat or 
overexpressing other genes should rescue degeneration if this hypothesis is correct. If 
none of these experiments rescue degeneration, it is possible GOI#1 may have other 
unknown targets required for axon death or have other non-transcriptional regulatory 
roles. Since this line of inquiry will be continued by Jon Farley, only the basic phenotype 
of GOI#1 null is presented in this thesis. 
 
Discussion 5-4: Axed is essential for axon death after injury 
Two mutants were identified on 3L left chromosome that displayed strong 
suppression of axon degeneration in both wing glutamatergic sensory neurons and ORNs 
(Figure 2.4). In wing neurons, nearly 100% of severed axons were morphologically intact 
at 7 days, while in anucleated olfactory receptor axons persisted intact for 50 days post 
injury (Figure 2.4-C/D). The near complete suppression of axon death, for almost the 
lifetime of the fly, is only comparable to loss of function mutations dSarm and hiw, as 
well as expression of Wlds, suggesting the mutations affected a gene or genes that were 
essential for axon death to proceed after injury (MacDonald et al., 2006; Osterloh et al., 
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2012; Xiong et al., 2012). Since both mutations on the same chromosomal arm caused 
lethality at early larval stage 1 and were linked to the axon death defective phenotype 
through multiple outcrossed generations, we used lethality complementation testing to 
map both mutations to a single BTB domain containing gene CG8398, renamed 
axundead or axed (Figure 2.5-A/B). Importantly, genetic elements that disrupted axed, 
such as Df BSC411 and axedMI13270, were also defective for axon degeneration at 7 dpa 
(Figure 2.5-D). Furthermore, when the transposon in axedMI13270 was precisely excised, 
removing an artificial intron containing stop codons, but not altering axed exons, the 
resulting animals are homozygous viable and have wild type axon death in contrast to 
imprecise Minos excision, which resulted in lethal, axon death defective, deletions in 
axed.  
We also used two CRISPR guides co-injected with Cas9 to generate three distinct 
alleles, all harboring lethal deletion mutations in exon 2 of axed. While these mutations 
caused early frameshift deletions with early predicted stops, they only had a partial 
suppression of axon death in clones. Since our Axed antibody failed, we could not assess 
if any Axed protein was produced in the animals, however one of three ATG sites C-
terminal to the last CRISPR guide site might produce a truncated protein containing the 
BACK and C-terminal regions that could phenocopy the partial axon death phenotype 
observed in our structural analyses (Figure 4.1). In the future, we might assess production 
of a truncated transcript in these animals with RT-PCR. It is also possible that the guides 
had one or more off targets in genes required for neuronal maintenance or metabolism, 
and axons were more susceptible to degeneration after injury.  
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To further confirm that the mutations in axed were responsible for the axon death 
phenotype, we re-expressed either axedlong or axedshort isoforms in axed null clones and 
fully rescued axon degeneration (Figure 2.5-D). Both isoforms are also expressed 
endogenously as detected in western blot for AxedEGFP::FLAG (Figure 3.1-B). Neither 
isoform when overexpressed in wild type or axed null clones caused any spontaneous 
degeneration, so there must be some injury-induced upstream post-translational 
modification to Axed or required co-factors for Axed to exert its pro-degenerative 
function. It remains to be determined if the isoforms serve any differential roles besides 
an alternative start site, but the 103 amino acids in the N-terminal region are completely 
dispensable for axon death and contain no conserved domains (Figure 4.1). 
While we had strong genetic evidence that axed dysfunction was responsible for 
our phenotype, whole genome sequencing using NGS technology failed any 
chromosomal anomalies in the CG8398 region. This could be due to low depth of 
sequencing coverage, miscalls of nucleotide variants or deletions compared to the 
reference genome, or complex rearrangements that are difficult to assemble with 
available software. Thus, we used focused Sanger sequencing identify a 16bp deletion in 
the 3rd exon of CG8398, in axed0011, yet we still could not detect a causative mutation in 
the sequence of axed2094. The 16bp deletion is exactly the type of small indel mutation 
that alignment-based software struggles to detect with NGS, while the Sanger method is 
more reliable due to longer sequencing reads (Abel and Duncavage, 2013). It might be 
plausible to assume the mutation affecting axed2094 may alter a distant regulatory region, 
since, both Sanger and NGS failed to detect any mutation within axed coding regions. In 
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the future, we may return to whole genome sequencing data with new algorithms to 
detect indels in axed2094 or assess expression levels of Axed in this mutant, however 
between genetic rescue and generation of new alleles, we were confident loss of function 
mutations in axed were responsible for the lack of axon degeneration after injury.  
We also attempted to target BTBD2, the closest mammalian homolog of axed, 
using lentivirus delivered short hairpin RNA knockdown in axotomized mammalian 
dorsal root ganglia neuron culture, but failed to confirm sufficient knockdown (data not 
in thesis). In addition, collaborators tried similar knock-down strategies as well as testing 
BTBD2 knockouts generated with CRISPR/Cas9 with mixed results that failed upon 
repetition (Nick Hertz, Tessier-Lavigne Lab). It’s possible that loss of BTBD2 function is 
compensated by closely related proteins BTBD3, BTBD6 or BTBD1. I also tried the 
reverse, but failed in an attempt to rescue degeneration in axed null clones with murine 
BTBD2. It is possible that BTBD2 is too structurally diverged from Axed for rescue, 
however a follow up failed to detect strong expression of BTBD2 with antibody staining 
(data not in thesis) which could be the result of technical issues such as non-optimized 
codons for Drosophila or lack of intron for splicing to enhance expression (Le Hir et al., 
2003; Powell and Dion, 2015). If the former is the case, the negative result may still be 
informative by comparing structures between Axed and BTBD2. Notably, the BTBD2 
includes a PHR/Hiw-like domain that is not present in Axed. PHR domains can interact 
with a variety of protein species (Grill et al., 2016) and may have evolved some 
regulatory mechanism in mammalian BTBD2, possibly hindering its function in 
Drosophila.  
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While the mammalian experiments above aimed primarily to demonstrate 
conservation, we also hoped to utilize a neuronal cell culture system to assess metabolic 
state and cytoskeletal structural integrity of axons after injury using a variety of markers, 
which we are unfortunately unable to assess in Drosophila. These culture systems allow 
for the axotomy of a large swath of axons, which can be collected over various time 
points and subjected to biochemical analyses. If we successfully knocked out Axed’s 
mammalian equivalent (Axedm) in this system, we would have assessed following: 1) 
Cytoskeletal integrity by assessing neurofilament light, medium, and heavy chains as 
well microtubule markers such as β-tubulin class III; 2) metabolic state by measuring 
levels of NAD+ & ATP; 3) levels of Nmnat2; 4) phosphorylation status of MAPKs 
especially, pS257/T261-MKK4 & pT183/Y185-JNK (Yang et al., 2015). We would 
expect severed neurons lacking an Axed homolog would definitely maintain cytoskeletal 
integrity, however the results of #2, 3, and 4 could vary and help to further define Axedm 
function. For example, if ATP levels still decline in severed axedm null axons, Axedm may 
destroy axons similar to calpain induction and calcium inflow (Yang et al., 2013).  It 
might be possible that Nmnat2 levels remain elevated in axedm in contrast to Sarm1 
axons, possibly placing in a parallel pathway to Sarm1 action after injury (Gilley et al., 
2015).  Additionally, we could determine if Axedm is regulating basal levels of Nmnat2 
in a similar manner to Phr1 and MAPKs(Babetto et al., 2013; Walker et al., 2017). We 
could also attempt to determine an exact time point after axotomy when an Axedm is 
required by packaging the protein in lentiviral-like particles and adding Axedm back to 
axedm null axons at different times points after injury (Gerdts et al., 2013). This 
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experiment would definitively allow us to place Axedm function in the axon after injury 
and rule out a role regulating basal levels of Nmnat or other factors before injury. It is 
important to note that while these experiments would no doubt provide valuable 
mechanistic insight into Axedm, phenotypes observed in axedm null cell culture models 
may be substantially different than the observations in vivo due to cellular expression 
differences in vitro and lack unique exchange with the extracellular milieu including glia 
cells.  
In order to gain insight into the function of Axed in vivo, we returned to Drosophila 
to visualize endogenous Axed protein. While our attempts to generate immunoreactive 
antibodies against Axed failed, we fluorescently tagged endogenous Axed using 
recombination mediated cassette exchange with axedMI13270 to create axedEGFP::FLAG.  As a 
back-up if Axed protein was expressed at exceedingly low levels, as seems to be the case 
with dSarm, we also generated a UAS controlled axed::smGdP-cMyc, although we must 
be careful interpreting data from this construct as protein overexpression commonly 
causes artificial localization patterns (Prelich, 2012). Available repositories for 
Drosophila expression analysis shows axed expression is favored in nervous tissue as 
well as gut, salivary gland, and very highly expressed in the testis (Broderick et al., 2014; 
Chintapalli et al., 2007; Hu et al., 2017).  We observed robust expression of 
AxedEGFP::FLAG in Drosophila adult brains and in the larval ventral nerve cord (Figure 3.1-
C/F). Axed was particularly enriched the neurite dense neuropil regions and did not co-
localize with markers of astrocytes or cortex glia. BTBD2 and BTBD1 are similarly 
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expressed in mammalian neurons, but also expressed at lower levels in astrocytes, 
oligodendrocytes, and microglia (Zhang et al., 2014).  
Since differentiating between dendritic and axonal arbors within the neuropil is 
challenging, we stained neuronal membranes with HRP to visualize axons in larval 
abdominal nerves and observed strong Axed expression (Figure 3.1-D). Axon targeting is 
also observed in Tdc2 positive neurons expressing Axed::smGdP-cMyc (Figure 3.1-E). 
We cannot observe AxedEGFP::FLAG within wing sensory neuron axons, however low level 
expression could be masked by observation through the thick auto-fluorescing cuticle. It 
is also possible that Axed might be more strongly located towards the distal synaptic ends 
of these long neurons within the thoracic ganglion and outside our field of view, since we 
also observed close association of Axed with synaptic markers in the larval neuropil 
(Figure 3.1-C). This close association to synapse may play a role in axon degeneration or 
have some unknown function, although to date, large scale screens to find determinants 
of synapse maintenance have not observed a role for axed or BTBD2 even after injury 
(Sieburth et al., 2005; Wishart et al., 2012). Both Hiw and Nmnat are also located in and 
around near synaptic compartments, and play roles in synapse formation and maintenance 
seemingly distinct from their roles in axon degeneration (Lauwers and Verstreken, 2013; 
Wan et al., 2000; Wu et al., 2005). In the future, examination of stereotyped larval 
neuromuscular junctions could uncover a role for Axed in synapse formation or 
maintenance.  
Axed is also expressed in neuronal cell bodies, albeit excluded from neuronal nuclei, 
and patterning suggests an enrichment at the plasma membrane in both larval and adult 
117 
 
 
brains. This localization pattern is matched in Tdc2 positive neurons expressing 
Axed::smGdP-cMyc and notable that Axed is still excluded from neuronal nuclei even 
when overexpressed (Figure 3.1-E). ). If we had found Axed located primarily in 
neuronal nuclei, we might more strongly consider the hypothesis that Axed is regulating 
basal levels of axon death pathway components, rather than acting in the axon post 
injury. This is not out of the realm of possibility as BTBD2/1/3 have described roles 
within the nucleus (Matsui et al., 2013; Xu et al., 2002). Additionally, we observe very 
similar punctate membrane localization when comparing Axed::smGdP-cMyc to 
membrane targeted myristoylated smGdP-cMyc (Figure 3.1.-E). Punctate patterning may 
be related to Axed packaging in vesicles for transport to axons, but further analysis is 
required such as co-staining for variety of specific vesicle markers. It would be 
interesting if Axed co-localized to vesicles harboring palmitoylated Nmnat, possibly 
hinting at role for Axed in Nmnat or NAD+ breakdown (Milde et al., 2013). We might 
also assess whether palmitoylation is also plays a role in localizing Axed to membranes 
as it also defines localization of Nmnat and DLK. In fact, Axed has three predicted 
palmitoylation sites at C442, C443, and C528 within the essential C-terminal region, 
while BTBD2 has two predicted sites at C363 and C364, with all sites located C-terminal 
to conserved BACK domain (Ren et al., 2008). Taken together, this evidence supports a 
cell-autonomous role for Axed within the axonal compartment axons after injury.  
The key question remained, what does Axed do in an axon after injury? To 
address this question we ablated antennal cell bodies and found that AxedEGFP::FLAG signal 
significantly increased in antennal lobes from 4 to 6 hours post injury and returned to an 
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uninjured baseline by 24 hours. Increased signal at these time points is particularly of 
note since we have found that the majority of axons undergo explosive fragmentation 
after 4 post injury in multiple Drosophila neuron types (MacDonald et al., 2006; 
Neukomm et al., 2014; Rooney and Freeman, 2014; Xiong and Collins, 2012). The 
observed signal increase may arise for several reasons, not all with biological relevance. 
Since these axons are completely severed from their cell bodies, an actual increased level 
of Axed protein levels could be the result of either local translation or decreased turnover. 
Protein synthesis seems unlikely, as the energy intensive process would require 
ATP/GTP at the same time that levels are rapidly decreasing.  This would be the first 
example of increased production of a pro-degenerative factor after an axon injury, in 
contrast to the auto-inhibited-to-activated strategy employed by dSarm/Sarm1 post injury. 
Interestingly, previous work has demonstrated that Sarm1 is upregulated in response to 
excitotoxic stress or viral infection and one study showed axed upregulation in gut 
epithelial cells by 1-2 fold after infection by several bacterial species (Broderick et al., 
2014; Massoll et al., 2013; Mukherjee et al., 2013), although in these cases cells had 
transcriptional machinery intact.  
It is also possible the increased AxedEGFP::FLAG signal is due to a relocalization or 
clustering of Axed. As noted previously, over-expression of Axed has no spontaneous 
degenerative effects, so some injury-induced cue must ‘activate’ its pro-degenerative 
function. It could be that activation requires a re-localization to some unknown organelle 
or intracellular complex that increases AxedEGFP::FLAG signal, however we could not 
resolve distinct clustering after injury. While localization to vesicular membranes plays a 
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role in neuroprotective ability and basal turnover of Nmnat2, active of relocalization after 
injury has not been described for Nmnat or for pro-degenerative axon death proteins 
(Gerdts et al., 2013; Milde et al., 2013). This is another case where large amounts of 
injured axonal material could be collected from a mammalian culture system at different 
time points, organellar compartments segregated and assessed for enrichment of Axedm. 
It is also possible that Axed clustering is a byproduct of axons breaking down into 
condensed fragments. If Axed does relocate after injury, it will be necessary to determine 
if this is required for Axed pro-degenerative function in axons or an artifact of 
degeneration. 
 
Discussion 5-5: The axon death pathway converges on Axed 
We next sought to address how Axed genetically interacts with known axon death 
regulators, such as dSarm, Nmnat, hiw, and MAPKs. To do this we took several 
approaches to assess epistatic relationships among axon death components using null 
alleles, knock-down via RNAi, and overexpression of full length and gain of function 
proteins. Through the application of these techniques we demonstrated that Axed is 
absolutely required for spontaneous axon disintegration downstream of activated dSarm 
and loss of Nmnat (Figure 3.3/4/5/6/7). Either event causes rapid degeneration within 
days in wild type and dsarm null neurons, while axed null clones persist morphologically 
intact for well past the mean lifetime of the fly, 30 to 50 days. Amazingly, both events 
can be induced together in combination with injury and the vast majority of axed null 
axons persist for at least 7 days. Consistent with previous evidence Hiw play roles 
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upstream of both events and thus upstream of Axed function, likely regulating Nmnat 
turnover. Additionally, we find no essential role for MAPKs either after axotomy or after 
prodegenerative dSarm signaling, at least in Drosophila wing sensory neurons (Table 
3.2). These findings clash with a number of proposed pathways of axon degeneration and 
also highlight possible conflicts when proposed conclusions cross between different 
models of axotomy and neuronal subtypes among Drosophila and mammal, both in vitro 
and in vivo. 
Numerous labs have found a role for kinases, specifically MAPKs, in regulating 
axon death before and after injury. Studies have described pro-degenerative roles for Dlk, 
Mkk4, Mkk7, Jnk3 and a number of other weaker kinases as well as scaffolding 
molecules required for their function and pro-survival roles for Akt (Klinedinst et al., 
2013; Rallis et al., 2010, 2013; Shin et al., 2012b; Wakatsuki et al., 2011; Walker et al., 
2017; Yang et al., 2015).  Outside of axon death, MAPK signaling cascades are required 
downstream of dSarm/Sarm1 in development and linker cell death and an obvious 
hypothesis would be to assume a similar signaling cascade occurs post injury (Chuang 
and Bargmann, 2005; Kinet et al., 2016). Drosophila have a single Jnk, bsk, and null 
alleles displayed no suppression of axon death after axotomy or dsarmΔARM expression in 
sensory neurons. We saw similarly no protection in Mkk4 and hep/Mkk7 null alleles, 
however they may be functionally redundant and we were unable to test double nulls. 
This data conflicts with a proposed requirement for MAPK downstream of Sarm1 (Yang 
et al., 2015), although agrees with recent findings that MAPK aid in the regulation of 
basal levels of Nmnat/Nmnat2 (Walker et al., 2017). Walker et al. demonstrated altering 
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bsk by RNAi or expression of dominant negative directly leads to higher levels of Nmnat, 
but only when overexpressing HA tagged Nmnat (Walker et al., 2017). Absolute change 
in level of endogenous Nmnat may be not be sufficient for protection after injury or 
dsarmΔARM. Interestingly, constitutively active hep causes spontaneous 
neurodegeneration, which may result from increased Nmnat turnover (data not in thesis). 
They also showed MAPK alteration fails to affect progression of degeneration and energy 
deficit after gain of function Sarm1(Walker et al., 2017). Since we find no protective 
phenotype we are unable to describe a relationship to Axed and our data suggest MAPK 
signaling cascades likely play a non-essential role in axon death.  
Degenerative dSarm signaling and loss of Nmnat remain central to the axon death 
pathway. The prevailing model in the field is that Nmnat2, by an unknown mechanism, 
keeps Sarm1 in an auto-inhibited state until injury eliminates Nmnat2 resupply from the 
cell soma to the distal axon (Gilley and Coleman, 2010; Gilley et al., 2015; Sasaki et al., 
2016). Lack of new Nmnat2, combined with rapid Nmnat2 degradation, results in 
dSarm/Sarm1 activation in which dimerized TIR domains actively consume NAD+ 
(Gerdts et al., 2015; Sasaki et al., 2016; Summers et al., 2016; Yamagishi and Tessier-
Lavigne, 2016). Accelerated NAD+ consumption cause local energy deficits likely from 
the breakdown of ATP production cycles that require NAD+/NADH redox reactions 
(Sasaki et al., 2016). 
If we first consider that dsarm mutants delay degeneration induced by gradual 
Nmnat knock down by NmnatRNAi, but completely fail to attenuate rapid cell death when 
Nmnat is completely removed, it would seem like Nmnat is playing dual roles, both 
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upstream and downstream of dSarm. However, these data may still fit with the above 
model. For example, in the case of RNAi, it is possible that in wild type, Nmnat levels 
fall to a concentration that releases dSarm inhibition and then rapidly destroys axons, 
while in dsarm nulls, degeneration only takes place if local NAD+ concentrations cannot 
be replenished, since NAD+ is not actively consumed by dSarm. Degeneration is likely 
delayed in this case, especially since RNAi incompletely eliminates Nmnat. Conversely, 
complete loss of Nmnat causes degeneration in the absence of dSarm in contrast to 
mammals where Nmnat2-/- animals survive only in a Sarm1-/- background (Gilley et al., 
2015).  This may be due to the fact that Drosophila only have a single Nmnat to generate 
NAD+, while mammals have a nuclear, axonal or cytoplasmic, and mitochondrial Nmnat. 
Thus, mammalian Nmnat2 functions to inhibit Sarm1 and Nmnat2-/-animals survive only 
when Sarm1 activity is eliminated, but Nmnat1/3 are enough to provide the cell with 
NAD+, especially within the mitochondria. Meanwhile, Drosophila neurons with no 
functional Nmnat enzymes simply perish due to the lack of NAD+ production, although 
we cannot definitely assess NAD+ levels. We attempted to generate a sensor for flies to 
assess steady state NAD+ levels, however it lacked the resolution to provide accurate 
measurement. 
 How then do axed null clones that survive with both supposed NAD+ consuming 
dSarm∆ARM activity and no intracellular Nmnat to provide NAD+? Since it is likely 
impossible for a cell to persist lacking NAD+, what scenarios preserve at least a modest 
amount NAD+ or conversely prevent rapid NAD+ consumption?  
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The most likely scenario might be that active dSarm requires Axed to deplete 
NAD+ or Axed itself depletes NAD+ downstream of dSarm. In this situation both ‘loss 
of Nmnat activated’ endogenous dSarm as well as constitutively active dSarm∆ARM do not 
consume NAD+ in absence of Axed. We could test this hypothesis with a construct, 
currently being injected into flies, to consume NAD+ on using an inducibly dimerizable 
Tankyrase1 (Tnk1) PARP domain to readily consume NAD+ on demand (Gerdts et al., 
2015). If NAD+ loss drives degeneration, activating Tnk1-PARP domain should 
overcome protection afforded in axed mutants and phenocopy effects of dSarmΔARM in 
wild type. If neurons still survive, NAD+ consumption is not driving degeneration or 
isn’t sufficient for degeneration and Axed may be required for some other pro-
degenerative downstream function, although this seems unlikely. Alternatively, we might 
also test whether dimerizable TIR domain from either mammals or C. elegans 
Sarm1/TIR-1 induce TIR specific NAD+ degradation in Drosophila Axed null 
background. If vastly different species TIR domains induce degeneration without Axed, it 
would support a model in which the TIR domain is responsible for NAD+ consumption. 
If they fail to elicit degeneration without Axed, we might attempt to define a physical 
interaction between Axed and TIR domains, or Axed acts itself as the NADase. Perhaps, 
Axed can consume NAD+ without dSarm and this explains why Nmnat, dsarm double 
null neurons degenerate, but Nmnat, axed double null neurons do not.  How the structure 
of either Axed or dSarm or a combination of the two might consume NAD+ is still an 
open question and is further discussed. 
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It might also be possible that Axed is responsible for releasing NAD+ from 
axonal compartments not accessible to cytoplasmic dSarm consumption. A candidate 
compartment for this could be mitochondria with approximately 50% of the cellular 
NAD+ pool. Partial mitochondrial localization of Wlds seems to grant it exceptional axon 
protective power and mPTP blockers offer modest delays in axon degeneration(Avery et 
al., 2012; Barrientos et al., 2011). A previous study in HEK293T cells also demonstrated 
that maintaining mitochondrial levels of NAD+ could delay overall cellular death even 
when both cytoplasmic and nuclear pools were depleted (Yang et al., 2007). Although 
unlikely, Axed might form a pore itself similar to the BTB tetramerisation domain in the 
potassium channel (Doyle et al., 1998; Stogios et al., 2005). Maybe the increase in 
AxedEGFP::FLAG signal after injury is due to a clustering at mitochondria or some other 
membrane and future experiment could test this hypothesis. We also might test this by 
targeting our NAD+ consumption construct to different cellular compartments. Curiously 
dSarm/Sarm1 has a mitochondrial localization sequence that is completely dispensable 
for axon death.  
 In these scenarios, it still remains to be determined how neurons are surviving 
with no internal NAD+ production since Hiw should still be actively destroying Nmnat in 
severed axons and no Nmnat is present in nulls. It is possible NAD+ could be imported 
either from the extracellular space or from glia via through P2X7-gated channels. These 
channels are present and active in both neurons and glia, specifically astrocytes, and 
facilitate the transport of NAD+ and NADH across plasma membranes (Alano et al., 
2010)(Lu et al., 2007). Even if P2X7 channels are not responsible, others have 
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demonstrated that NAD+ can enter axons in culture so there is some structure to facilitate 
transfer (Araki et al., 2004; Wang et al., 2005). There are no homologs of P2X7-gated 
channels in Drosophila, however channels within the degenerin/epithelial Na+ channel 
superfamily may be functional equivalents (Fountain and Burnstock, 2009; Schwiebert et 
al., 2005).  In the second situation, required NAD+ is sequestered in mitochondria away 
from dSarm consumption and neurons can be supplied with pyruvate abrogating the need 
for large pools of cytoplasmic NAD+, at least for glycolysis. Methyl pyruvate already has 
been shown to delay axon degeneration and pyruvate or lactate can be transferred from 
axons to glia via MCT2/1 channels (Bros et al., 2014; Fünfschilling et al., 2012; Yang et 
al., 2015). 
One may also argue that Axed is required for Nmnat turnover before and after 
injury such as Hiw, but to a stronger degree, and axed nulls have exceedingly high levels 
of Nmnat. While we were unable to assess Nmnat levels in an Axed null background, this 
hypothesis seems unlikely since UPS disruptions cannot phenocopy Axed nulls, 
discussed in detail below, cannot suppress from active dSarm or loss of Nmnat.  This 
matches proposed Hiw function in which nulls seem to only protect due the combination 
of higher baseline levels of Nmnat pre-injury and the eliminated turnover post injury, and 
provide no suppression of dSarmΔARM or Nmnat loss induced degeneration. 
 
Discussion 5-6: How does Axed precipitate axon death? 
In addition to genetically positioning Axed within an axon death cascade, we also 
sought to address which Axed domains were absolutely required and if Axed required 
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other protein partners to execute pro-degenerative function.  First, we assessed whether a 
series of axed deletion constructs could rescue wild type degeneration in severed null 
axed axons (Figure 4.1-A). We targeted the conserved BTB and BACK domains of axed, 
as well as the C-terminal region. Structural studies of other BTB proteins suggested that 
the BTB domain would be required for dimerization with another BTB domain, the 
BACK domain would be required to interact with a cullin E3 ligase via a ‘3 box’, and the 
C-terminal region would impart substrate specificity (Canning et al., 2013; Zhuang et al., 
2009).  Consistent with structural evidence suggesting BTB dimer unites two CRL 
complexes to increase efficiency, we observed severed axons with Axed lacking the BTB 
domain could still undergo axon degeneration, but only half as well as full length Axed 
(Figure 4.1-D). Since we were unable to definitively define a ‘3-box’ required for Cul3 
binding, possibly located within the linker region between the BTB and BACK domains, 
the BTB and BACK deletion constructs may retain their interactions with a CRL 
complex and partially function. Axed lacking the BACK domain had very little function 
with only a 1 of 5 severed axon degenerating (Figure 4.1-E). Since it retains some 
function, AxedΔBACK may incorporate into the complex but fail to efficiently orient a 
substrate for ubiquitylation. Consistent with this hypothesis, we found that the proposed 
substrate binding region somewhere in the C-terminus is absolutely required for function 
(Figure 4.1-F). None of the constructs tested had any dominant axon protective 
phenotype and failed to alter the course of degeneration induced by dSarmΔARM or loss of 
Nmnat (Figure 4.1-G/H). 
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Going forward with structural analysis it would be informative to determine if the 
linker region, possibly containing the cullin binding region, is required for all function. 
Also, if the C-terminus is actually binding a substrate required for axon survival, could 
overexpression of this region sequester a substrate away from ubiquitination and 
dominantly protect axons similar to the phenotype observed with mutations in the RING 
domain of hiw (Neukomm et al., 2014; Xiong et al., 2012).   If so, we might be able to 
identify the substrate by crosslinking followed by affinity purification and mass 
spectrometry techniques (Jüschke and Knoblich, 2008). Determining protein interactions 
in Drosophila in vivo in cell types of interest, namely adult neurons, is challenging 
because of the required starting material. I therefore tried to find binding partners with an 
unbiased yeast two hybrid assay. I identified Cul3 in a yeast two hybrid screen for 
protein-protein interactions with mouse BTBD2, however failed to detect any interaction 
in using Drosophila counterparts (data not presented in this thesis). In the future we could 
attempt to confirm these interactions in mammalian tissue using immunoprecipitation or 
antibody-bound column purification. 
Based on the this data and several previous studies describing functional 
interactions between BTB domain containing proteins and Cul3, along with the linker 
cell death pathway in C. elegans which requires axed homolog BTBD2 downstream of 
dsarm homolog TIR-1, we hypothesized axed would interact with Cullin 3 in a CRL 
complex to ubiquitinate a target, possibly for degradation by the proteasome (Kinet et al., 
2016; Pintard et al., 2004). We therefore tested loss of function mutants or deletions of 
the CRL complex components, anticipating that those utilized by Axed would phenocopy 
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axed mutant alleles and preserve axons after axotomy and dsarmΔARM expression. 
Unfortunately, cul3 mutant alleles were wild type for axon death and could not suppress 
dsarmΔARM induced death. We did not test for suppression of death induced by Nmnat loss 
due to constraints governing the genetic tools available. We also tested other cullins 
(cul1, cul4, cul5, cul6, CG11261) and CRL components such as the RING box regulators 
of cullins (Roc1a, Roc1b), the E1 uba1, the ubiquitin conjugating E2 eff, a deficiency 
uncovering E3 ligase sina/siah, and the CRL activator Nedd8 (Table 4.1) (Kinet et al., 
2016; Zhuang et al., 2009). None suppressed death in our two assays. It is possible that 
we did not uncover any genes required for E3 CRL complex in our original screen or 
candidate screening in axotomy or after Sarm pro-degenerative signaling due to genetic 
redundancy in the fly. While this hypothesis is likely in the case of E1 and E2 proteins, 
this seems unlikely for the cullins and ring box proteins, as their evolved variations 
persisted primarily to enhance specificity.  Going forward, additional candidates to be 
tested may be the TRIM family of ubiquitin E3 ligases based on their relationship to 
BTBD2 in mammals and protein interaction candidates from the yeast two hybrid screen. 
Before continuing to test more candidate ubiquitin ligases, we wanted to 
determine if Axed actually worked with the ubiquitin-proteasome system. We reasoned 
that disruptions to the UPS should phenocopy Axed null mutations and protect axons 
after axotomy as well as from death induced by Nmnat loss or knockdown and 
dSarmΔARM expression.  To date, UPS inhibitors have, with few exceptions, only been 
tested models of axotomy with mixed, cell-type specific results (Yang et al., 2013; Zhai 
et al., 2003). In Drosophila, incorporation of dominant negative proteasomal subunits can 
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significantly increase Nmnat levels, but by only small amounts relative to the increase 
observed in hiw nulls, while countering global ubiquitination by overexpression of the 
yeast de-ubiquitinating enzyme UBP2 can strongly suppress axon death, but not death 
from loss of Nmnat (Xiong et al., 2012).  
Therefore, I first tested whether severed axons with UBP2 remained intact after 
injury. Consistent with previous evidence in larval nerves at 24h, axon death was 
suppressed and intact axons persisted until at least 7 dpa (Figure 4.2-B/C) (Xiong et al., 
2012). Despite strongly suppressing axon death after injury, UBP2 failed to suppress 
death in Nmnat null clones after 5 days, but significantly delayed progression of 
degeneration (Figure 4.2D/E), matching observations that UBP2 could not suppress death 
induced by Nmnat-RNAi (Xiong et al., 2012). The delay in death might be attributed to 
significantly higher basal levels of Nmnat in neurons with UBP2 (Xiong et al., 2012), 
probably due to decreased turnover, and consistent with slight delay in death observed in 
hiw null clones expressing Nmnat-RNAi (Figure 3.4-D).  While UBP2 delayed 
progression of death after loss of Nmnat, it showed no significant suppression or delay of 
degeneration induced by activated dSarm (Figure 4.2-F/G). It is possible that UBP2 
cannot block degeneration downstream of dSarm or Nmnat because it is overwhelmed by 
massive up-regulation of ubiquitination processes during degenerative events, although to 
date, there is little direct evidence implicating a massive upregulation of UPS activity 
after axon injury or after pro-degenerative dSarm/Sarm1 signaling. To test this, it would 
be reasonable to simply transect axons in vitro or activate Sarm1 signaling, block the 
proteasome with a selective inhibitor such lactacystin, and assess the amount of ubiquitin 
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conjugated proteins. It might be possible to excise certain bands of interest and use mass 
spectrometry to identify these proteins. It is also possible that K48 ubiquitin chains, used 
primarily for recognition by the 26S proteasome, play outsized roles after injury signaling 
compared to K63 chains and no blockade is achieved because UBP2 preferentially targets 
K63 versus K48 ubiquitin chains (Kee et al., 2005). While this is possible, at high enough 
concentrations, UBP2 also deconstructs K48 chains, though UBP2 concentration present 
in neuronal clones in vivo is unknown (Kee et al., 2005). These experiments suggest that 
ubiquitination is not required beyond regulating baseline levels of Nmnat, as previously 
described (Brace et al., 2014; Xiong et al., 2012). 
Since the ubiquitination process can affect other processes outside of protein 
turnover, we attempted to disrupt the proteasome core to determine if proteolysis is 
specifically required in axon degeneration. To do this we expressed proteasome inhibitor 
31 kDa (PI31) (Bader et al., 2011) as well as temperature sensitive dominant negative β2 
and β6 subunits of the of the 20S core particle of the protein. When shifted to 29°C the 
mutated subunits severely hamper the function of the proteasome as evidenced in the 
Drosophila eye and wing (Schweisguth, 1999; Velentzas et al., 2013).  We would have 
expected to find at least some slight axon protection with double β2ts and β6ts, due to 
previously demonstrated increased Nmnat levels (Xiong et al., 2012), however neither 
β2ts, β6ts, or PI31 could suppress axon death after axotomy, Nmnat loss, or and 
dSarmΔARM expression. Interestingly this data aligns well with previous work showing 
Nmnat levels are only slightly higher after proteasome inhibition, but not as high as in 
UBP2 expression or loss of hiw, suggesting that Hiw may alter Nmnat with ubiquitin in 
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ways other than directing it to the proteasome (Xiong et al., 2012). It might be possible 
that ubiquitination alters cellular localization of Nmnat in a similar fashion to recently 
described palmitoylation events (Lau et al., 2010; Mayer et al., 2010; Milde et al., 2013). 
It is also possible that the proteasome wasn’t fully incapacitated using these constructs, 
especially since expressing neither β2ts together with β6ts leads to more severe 
dysfunction in eye development compared to either alone (Velentzas et al., 2013), and 
axon death only requires little functional proteasome to proceed. To disrupt the 
proteasome more completely, we might try null clones or RNAi knockdown of the α5, β2 
or β6 subunits of 20S core or the Rpn1, Rpn2, Rpn6 of the 19S cap. It remains to be seen 
if neuronal clones would be produced or how dysfunctional they might be without an 
active proteasome. Global dysfunction could mask any axon death phenotype and more 
specific targeting might be required.  
Of note, co-expression of apoptotic inhibitor P35 with UBP2 was required to 
attenuate progressive spontaneous death in neurons (Figure 4.2-A), possibly similar to a 
degenerative phenotypes observed with UPS inhibition during wing and eye development 
(Hay et al., 1994; Velentzas et al., 2013), and suggesting that ubiquitin homeostasis in a 
mature neuron is required to avoid the activation of an apoptotic death program.  
However, other apoptotic inhibitors such as BclXL or Z-VAD-FMK, P35 had no effect 
on axon degeneration induced by axotomy, dsarmΔARM expression, or Nmnat loss (Gerdts 
et al., 2013).  
Taken together, these data argue that the UPS system is not required for axon 
degeneration to proceed downstream of activated dSarm or Nmnat-loss and any axon 
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protective phenotypes result from increased basal levels of Nmnat. The failure of 
proteasome perturbation to prevent death downstream of pro-degenerative dSarm 
signaling is not particularly surprising since proteasome assembly, activation, and 
enzymatic coupling requires ATP, levels of which drop precipitously after dSarm 
induction (Liu et al., 2006; Peth et al., 2013). We might actually expect proteasome 
function to decrease after dSarm induction as the 26S proteasome dissociates when bound 
ATP is removed (Liu et al., 2006). From an evolutionary standpoint it seems puzzling to 
utilize the proteasome to recycle protein components in a doomed axon rather than 
simply cleaving structural proteins as in the case of calpains in late stage axon 
fragmentation for later recycling by glia or caspases in programmed cell death (George et 
al., 1995; Yang et al., 2013). However, utilizing components other than caspases to other 
forms of non-apoptotic programmed cell death has been hypothesized to be an 
evolutionarily conserved back-up to apoptotic processes (Kutscher and Shaham, 2017). 
For example, possible compensation by non-apoptotic death programs enables some 
bak/bax double knockout mice to develop and survive to adulthood lacking all apoptotic 
activity (Kutscher and Shaham, 2017; Lindsten et al., 2000). One example of non-
apoptotic death is linker cell death which requires proteasome activation and BTBD2 
downstream of TIR-1, although we cannot find a role for the proteasome in downstream 
axon death process, in addition to finding no roles for genes in this pathway (Table 4.1) 
(Kinet et al., 2016). While it seems almost too coincidental to have two axon death genes 
participate in another pathway, Sarm1/dSarm/TIR-1 has demonstrated signaling in 
multiple contexts depending on the cellular environment and its possible Axed/BTBD2 
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may have other roles as well (Chuang and Bargmann, 2005; Murata et al., 2013; 
Panneerselvam et al., 2013; Shivers et al., 2009).  
Since none of these experimental alterations to the UPS could phenocopy loss of 
Axed, we must then ask if Axed actually functions as an adaptor to ubiquitinate proteins 
in a CRL complex or with some other E3 ligase for degradation by the proteasome. While 
this hypothesis seems increasingly unlikely, we could attempt to assess ubiquitinated 
proteins species after overexpressing Axed while also blocking the proteasome. If Axed 
is required for the addition of ubiquitin to many different proteins we would expect to see 
a smear in a Western block stained for ubiquitin in Axed overexpressing cells. Ideally 
this experiment would be run in neurons and specifically axons. Although biochemical 
analyses like this are more amendable to a mammalian cell culture system than 
Drosophila. Also, Axed seems require some impetus for pro-degenerative function and 
carrying out the above experiment in axons challenged by injury or cellular stressors, 
such as activated Sarm1, could provide more valuable protein targets.  
In light of the data above, we might abandon completely our hypothesis that Axed 
requires the UPS or CRL complexes and speculate as to the structural requirements for 
Axed to actively degrade NAD+, possibly in complex with dSarm. Recent work has 
proposed that Sarm1 directly consumes NAD+ through NADase activity of a Sarm-
specific loop in the TIR domain, similar to the function of PARP1 in other forms of cell 
death, however definitive evidence such as activated Sarm1 directly interacting and 
destroying NAD+ in a minimal environment has yet to be demonstrated (Summers et al., 
2016). Axed may have its own intrinsic NADase activity, possibly in the C-terminal 
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region, or works in tandem with dSarm, however no structural elements seem to suggest 
this and we have been unable to produce a gain of function Axed. 
 
Discussion 5-7: Therapeutically Targeting Axon Death Components  
 Axons are primary therapeutic targets in peripheral neuropathies and traumatic 
brain injury, and possibly secondary targets in neurodegenerative diseases with axon 
dysfunction occurring before the onset of whole cell neuronal death such as Parkinson’s 
disease (Geisler et al., 2016; Henninger et al., 2016; Meyer zu Horste et al., 2011). The 
ultimate goal of fully elucidating the entire axon death pathway is to logically target 
specific components in certain traumatic and neurodegenerative disease. In the 
manuscript describing Axed function, Lukas Neukomm, with Stefanie Hampel and 
Andrew Seeds, also demonstrated that severed axons are not only morphologically 
preserved in axed, dsarm, or hiw null backgrounds, but remain highly functional and 
integrated into complex circuits, confirming previous data showing severed  Wlds 
preserved axons can sustain evoked axon potentials weeks after injury (Lunn et al., 
1989). This was achieved by expressing csChrimson in neurons controlling Drosophila 
grooming, performing axotomy by removing cell bodies in the antenna, and stimulating 
severed axons with red light to evoke a grooming response days and even weeks later 
(Hampel et al., 2015). These data suggest that therapies targeting the axon death pathway 
would retain not just cytoskeletal corpse, but a functional axon with preserved synaptic 
structure and integration. 
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Two obvious strategies emerge, either enhancing pro-survival Nmnat function or 
dampening the degenerative responses from molecules like Axed, Sarm1, Phr1, and a 
number of weaker players such as MAPKs, calpains, calcium channels, ROS formation 
and mPTP opening.  It is worth noting that particular strategies to inhibit axon death may 
be successful in one condition, yet fail in another simply due to the environment in which 
degeneration is occurring and the side effects or delivery mechanisms of the treatment. 
Axed may be a particularly good target, as it is required at a potential bottleneck 
in the pathway downstream of both pro-degenerative dSarm activity and Nmnat loss. We 
still do not know exactly how Axed elicits degeneration, so targeting specific structures is 
limited to targeting the C-terminal region, which is essential for function, or broadly 
knocking down expression of Axed’s mammalian homolog. The interface between BTB 
domain homo- or hetero-dimerization could also provide an attractive druggable target, 
since the BTB/BACK domains play some role in function. Unfortunately, Axed may 
have multiple functionally redundant mammalian counterparts, BTBD2/1/3/6/etc. which 
may complicate targeting and also explain why it may have been missed mammalian 
screens for axon death components. It also remains to be determined what other roles 
BTBD2/1 may play in neurons when uninjured, especially in complex with TRIM5δ or 
TOPI (Xu et al., 2002, 2003).  
Sarm1 is also an especially attractive to target for broad knock down of 
expression or domain specific inhibition.  Sarm1 is auto-inhibited by its N-terminus by a 
physical interaction with its TIR domain, so therapeutics might be developed that mimic 
N-terminal inhibition or that target the unknown mechanism by which inhibition is 
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released (Summers et al., 2016). Also, since TIR domains must dimerize for destructive 
Sarm1 function, whether by pro-degenerative signaling or NADase activity, small 
molecules interfering with SAM or TIR domain dimerization should strongly inhibit axon 
death. While Sarm1 null mice survive into adulthood, they do have subtle alterations in 
neuronal morphology and immune response, so therapeutically targeting Sarm1 may have 
similar side effects (Chen et al., 2011; Lin and Hsueh, 2014; Lin et al., 2014a, 2014b). 
However, acute Sarm1 inhibitors could target degenerative TIR activity, which may be 
separable from TIR MAPK signaling and avoid off target side effects (Chen et al., 2011; 
Summers et al., 2016).  
In contrast to inhibiting degenerative molecules, axon protection may be achieved 
through multiple strategies that enhance Nmnat production of NAD+.  One method could 
be to increase overall levels of Nmnat2 by inhibiting the Phr1/Skp1a/Fbxo45 complex 
formation or its ability to position Nmnat2 for ubiquitination and subsequent degradation 
by the proteasome (Babetto et al., 2013; Yamagishi and Tessier-Lavigne, 2016). Broad 
application UPS inhibitors are probably not useful as they cause extensive dysregulation 
of protein homeostasis leading to neuronal dysfunction and death (McNaught et al., 2004; 
Velentzas et al., 2013; Vernon et al., 2010); also see UBP2 data. Another strategy to 
decrease Nmnat2 turnover may be to eliminate membrane attachment by increasing de-
palmitoylated cytoplasmic form, possibly by increasing the activity of APT1/2 
thioesterases, decreasing the activity of zDHHC family of palmitoyltransferases, or 
blocking Nmnat2 palmitoylation sites (Milde and Coleman, 2014; Milde et al., 2013). 
However, palmitoylation is also required for vesicular transport, so strategies would 
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somehow still allow Nmnat2 transport to occur while increasing cytosolic forms in the 
axonal compartment. It may be possible to introduce strongly protective forms of Nmnat 
by gene therapy or introducing protein directly using a nanoparticles or cell penetrating 
peptide delivery systems (Asteriti et al., 2015; Bolhassani et al., 2017). Since the ultimate 
goal is to increase NAD+, we can also attempt to provide Nmnat2 with excess NMN to 
convert NAD+.  This can be achieved by supplementation with NR plus increased 
NRK1/2 activity or with increased activity of NAMPT. These manipulations protect 
axons in vitro and the small molecule P7C3 has demonstrated neuroprotective ability in a 
variety of contexts by activating NAMPT (Sasaki et al., 2016; Wang et al., 2014). The 
multiple strategies presented above provide hope that therapeutically preventing axon 
death should be feasible in the near future. 
 
Discussion 5-8: Concluding Remarks: 
This thesis has described the discovery of Drosophila BTB domain protein, Axed, 
as novel and essential component of injury induced axon death. Severed axed null axons 
remain intact for weeks in vivo and an equivalent suppression of axon degeneration axon 
is only observed dSarm and hiw null axons or after overexpression of Nmnat or Wlds. 
Furthermore, we demonstrate a requirement for Axed downstream of pro-degenerative 
dSarm function as well as death induced by loss of Nmnat. This poses a potential conflict 
with a proposed mechanism in the field positing that an uninhibited dSarm/Sarm1 TIR 
domain actively depletes NAD+. Since Axed is required downstream of dSarm, either 
NAD+ depletion is not a driving force in degeneration or Axed is required, with or 
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without dSarm, to deplete NAD+. While additional study is required to elucidate the 
exact mechanism of Axed function, we have demonstrated the C-terminal region plays an 
essential, yet unknown role and the canonical BTB protein interaction with UPS is likely 
not involved in axon death downstream of dSarm or Nmnat loss. Future experiments will 
to clarify interactions governed by the C-terminal region and also definitively identify a 
mammalian homolog Axed, likely BTBD2. Once functionally defined in mammals, 
Axed, as well as other components such as Sarm1, will be an attractive therapeutic targets 
in diseases with axon degeneration and dysfunction.  
  
139 
 
 
References 
Abel, H.J., and Duncavage, E.J. (2013). Detection of structural DNA variation from next 
generation sequencing data: a review of informatic approaches. Cancer Genet 206, 432–
440. 
Alano, C.C., Garnier, P., Ying, W., Higashi, Y., Kauppinen, T.M., and Swanson, R.A. 
(2010). NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-
mediated neuronal death. J Neurosci 30, 2967–2978. 
Alobuia, W.M., Xia, W., and Vohra, B.P.S. (2013). Axon degeneration is key component 
of neuronal death in amyloid-β toxicity. Neurochem Int 63, 782–789. 
Anderson, K.V., and Nüsslein-Volhard, C. (1984). Information for the dorsal--ventral 
pattern of the Drosophila embryo is stored as maternal mRNA. Nature 311, 223–227. 
Araki, T., Sasaki, Y., and Milbrandt, J. (2004). Increased nuclear NAD biosynthesis and 
SIRT1 activation prevent axonal degeneration. Science 305, 1010–1013. 
Asteriti, S., Dal Cortivo, G., Pontelli, V., Cangiano, L., Buffelli, M., and Dell’Orco, D. 
(2015). Effective delivery of recombinant proteins to rod photoreceptors via lipid 
nanovesicles. Biochem Biophys Res Commun 461, 665–670. 
Avery, M.A., Sheehan, A.E., Kerr, K.S., Wang, J., and Freeman, M.R. (2009). Wld S 
requires Nmnat1 enzymatic activity and N16-VCP interactions to suppress Wallerian 
degeneration. J Cell Biol 184, 501–513. 
Avery, M.A., Rooney, T.M., Pandya, J.D., Wishart, T.M., Gillingwater, T.H., Geddes, 
J.W., Sullivan, P.G., and Freeman, M.R. (2012). WldS prevents axon degeneration 
through increased mitochondrial flux and enhanced mitochondrial Ca2+ buffering. Curr 
Biol 22, 596–600. 
Babetto, E., Beirowski, B., Janeckova, L., Brown, R., Gilley, J., Thomson, D., 
Ribchester, R.R., and Coleman, M.P. (2010). Targeting NMNAT1 to axons and synapses 
transforms its neuroprotective potency in vivo. J Neurosci 30, 13291–13304. 
Babetto, E., Beirowski, B., Russler, E.V., Milbrandt, J., and DiAntonio, A. (2013). The 
Phr1 ubiquitin ligase promotes injury-induced axon self-destruction. Cell Rep 3, 1422–
1429. 
Bader, M., Benjamin, S., Wapinski, O.L., Smith, D.M., Goldberg, A.L., and Steller, H. 
(2011). A conserved F box regulatory complex controls proteasome activity in 
Drosophila. Cell 145, 371–382. 
Baker, R.T., Tobias, J.W., and Varshavsky, A. (1992). Ubiquitin-specific proteases of 
Saccharomyces cerevisiae. Cloning of UBP2 and UBP3, and functional analysis of the 
UBP gene family. J Biol Chem 267, 23364–23375. 
Baker, S.T., Opperman, K.J., Tulgren, E.D., Turgeon, S.M., Bienvenut, W., and Grill, B. 
(2014). RPM-1 uses both ubiquitin ligase and phosphatase-based mechanisms to regulate 
DLK-1 during neuronal development. PLoS Genet 10, e1004297. 
Ballinger, M.L., and Bittner, G.D. (1980). Ultrastructural studies of severed medial giant 
and other CNS axons in crayfish. Cell Tissue Res 208, 123–133. 
140 
 
 
Banerjee, A., and Gerondakis, S. (2007). Coordinating TLR-activated signaling pathways 
in cells of the immune system. Immunol Cell Biol 85, 420–424. 
Barrientos, S.A., Martinez, N.W., Yoo, S., Jara, J.S., Zamorano, S., Hetz, C., Twiss, J.L., 
Alvarez, J., and Court, F.A. (2011). Axonal degeneration is mediated by the 
mitochondrial permeability transition pore. J Neurosci 31, 966–978. 
Bellen, H.J., Levis, R.W., Liao, G., He, Y., Carlson, J.W., Tsang, G., Evans-Holm, M., 
Hiesinger, P.R., Schulze, K.L., Rubin, G.M., et al. (2004). The BDGP gene disruption 
project: single transposon insertions associated with 40% of Drosophila genes. Genetics 
167, 761–781. 
Belote, J.M., and Fortier, E. (2002). Targeted expression of dominant negative 
proteasome mutants in Drosophila melanogaster. Genesis 34, 80–82. 
Bennett, E.J., Rush, J., Gygi, S.P., and Harper, J.W. (2010). Dynamics of cullin-RING 
ubiquitin ligase network revealed by systematic quantitative proteomics. Cell 143, 951–
965. 
Berbusse, G.W., Woods, L.C., Vohra, B.P.S., and Naylor, K. (2016). Mitochondrial 
Dynamics Decrease Prior to Axon Degeneration Induced by Vincristine and are Partially 
Rescued by Overexpressed cytNmnat1. Front Cell Neurosci 10, 179. 
Bergmann, A., Agapite, J., McCall, K., and Steller, H. (1998). The Drosophila gene hid is 
a direct molecular target of Ras-dependent survival signaling. Cell 95, 331–341. 
Bischof, J., Maeda, R.K., Hediger, M., Karch, F., and Basler, K. (2007). An optimized 
transgenesis system for Drosophila using germ-line-specific phiC31 integrases. Proc Natl 
Acad Sci U S A 104, 3312–3317. 
Bolhassani, A., Jafarzade, B.S., and Mardani, G. (2017). In vitro and in vivo delivery of 
therapeutic proteins using cell penetrating peptides. Peptides 87, 50–63. 
Bommel, H., Xie, G., Rossoll, W., Wiese, S., Jablonka, S., Boehm, T., and Sendtner, M. 
(2002). Missense mutation in the tubulin-specific chaperone E (Tbce) gene in the mouse 
mutant progressive motor neuronopathy, a model of human motoneuron disease. J Cell 
Biol 159, 563–569. 
Bomont, P., Cavalier, L., Blondeau, F., Ben Hamida, C., Belal, S., Tazir, M., Demir, E., 
Topaloglu, H., Korinthenberg, R., Tüysüz, B., et al. (2000). The gene encoding 
gigaxonin, a new member of the cytoskeletal BTB/kelch repeat family, is mutated in 
giant axonal neuropathy. Nat Genet 26, 370–374. 
Brace, E.J., Wu, C., Valakh, V., and DiAntonio, A. (2014). SkpA restrains synaptic 
terminal growth during development and promotes axonal degeneration following injury. 
J Neurosci 34, 8398–8410. 
Brand, A.H., and Perrimon, N. (1993). Targeted gene expression as a means of altering 
cell fates and generating dominant phenotypes. Development 118, 401–415. 
Broderick, N.A., Buchon, N., and Lemaitre, B. (2014). Microbiota-induced changes in 
drosophila melanogaster host gene expression and gut morphology. MBio 5, e01117–14. 
141 
 
 
Bros, H., Millward, J.M., Paul, F., Niesner, R., and Infante-Duarte, C. (2014). Oxidative 
damage to mitochondria at the nodes of Ranvier precedes axon degeneration in ex vivo 
transected axons. Exp Neurol 261, 127–135. 
Buckmaster, E.A., Perry, V.H., and Brown, M.C. (1995). The rate of Wallerian 
degeneration in cultured neurons from wild type and C57BL/WldS mice depends on time 
in culture and may be extended in the presence of elevated K+ levels. Eur J Neurosci 7, 
1596–1602. 
Campenot, R.B. (1977). Local control of neurite development by nerve growth factor. 
Proc Natl Acad Sci U S A 74, 4516–4519. 
Cancalon, P. (1982). Slow flow in axons detached from their perikarya. J Cell Biol 95, 
989–992. 
Canning, P., Cooper, C.D.O., Krojer, T., Murray, J.W., Pike, A.C.W., Chaikuad, A., 
Keates, T., Thangaratnarajah, C., Hojzan, V., Ayinampudi, V., et al. (2013). Structural 
basis for Cul3 protein assembly with the BTB-Kelch family of E3 ubiquitin ligases. J 
Biol Chem 288, 7803–7814. 
Carlsson, E., Ding, J.L., and Byrne, B. (2016). SARM modulates MyD88-mediated TLR 
activation through BB-loop dependent TIR-TIR interactions. Biochim Biophys Acta 
1863, 244–253. 
Carthew, R.W., and Rubin, G.M. (1990). seven in absentia, a gene required for 
specification of R7 cell fate in the Drosophila eye. Cell 63, 561–577. 
Chang, C., Hsieh, Y.-W., Lesch, B.J., Bargmann, C.I., and Chuang, C.-F. (2011). 
Microtubule-based localization of a synaptic calcium-signaling complex is required for 
left-right neuronal asymmetry in C. elegans. Development 138, 3509–3518. 
Chen, C.-Y., Lin, C.-W., Chang, C.-Y., Jiang, S.-T., and Hsueh, Y.-P. (2011). Sarm1, a 
negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal 
morphology. J Cell Biol 193, 769–784. 
Chintapalli, V.R., Wang, J., and Dow, J.A.T. (2007). Using FlyAtlas to identify better 
Drosophila melanogaster models of human disease. Nat Genet 39, 715–720. 
Cho-Park, P.F., and Steller, H. (2013). Proteasome regulation by ADP-ribosylation. Cell 
153, 614–627. 
Chou, T.B., and Perrimon, N. (1996). The autosomal FLP-DFS technique for generating 
germline mosaics in Drosophila melanogaster. Genetics 144, 1673–1679. 
Chuang, C.-F., and Bargmann, C.I. (2005). A Toll-interleukin 1 repeat protein at the 
synapse specifies asymmetric odorant receptor expression via ASK1 MAPKKK 
signaling. Genes Dev 19, 270–281. 
Chung, T., Park, J.S., Kim, S., Montes, N., Walston, J., and Höke, A. (2016). Evidence 
for dying-back axonal degeneration in age-associated skeletal muscle decline. Muscle 
Nerve. 
Cole, S.H., Carney, G.E., McClung, C.A., Willard, S.S., Taylor, B.J., and Hirsh, J. 
(2005). Two functional but noncomplementing Drosophila tyrosine decarboxylase genes: 
142 
 
 
distinct roles for neural tyramine and octopamine in female fertility. J Biol Chem 280, 
14948–14955. 
Coleman, M.P., and Perry, V.H. (2002). Axon pathology in neurological disease: a 
neglected therapeutic target. Trends Neurosci 25, 532–537. 
Collins, C.A., Wairkar, Y.P., Johnson, S.L., and DiAntonio, A. (2006). Highwire 
restrains synaptic growth by attenuating a MAP kinase signal. Neuron 51, 57–69. 
Conforti, L., Wilbrey, A., Morreale, G., Janeckova, L., Beirowski, B., Adalbert, R., 
Mazzola, F., Di Stefano, M., Hartley, R., Babetto, E., et al. (2009). Wld S protein 
requires Nmnat activity and a short N-terminal sequence to protect axons in mice. J Cell 
Biol 184, 491–500. 
Conforti, L., Gilley, J., and Coleman, M.P. (2014). Wallerian degeneration: an emerging 
axon death pathway linking injury and disease. Nat Rev Neurosci 15, 394–409. 
Cook, R.K., Deal, M.E., Deal, J.A., Garton, R.D., Brown, C.A., Ward, M.E., Andrade, 
R.S., Spana, E.P., Kaufman, T.C., and Cook, K.R. (2010). A new resource for 
characterizing X-linked genes in Drosophila melanogaster: systematic coverage and 
subdivision of the X chromosome with nested, Y-linked duplications. Genetics 186, 
1095–1109. 
Cook, R.K., Christensen, S.J., Deal, J.A., Coburn, R.A., Deal, M.E., Gresens, J.M., 
Kaufman, T.C., and Cook, K.R. (2012). The generation of chromosomal deletions to 
provide extensive coverage and subdivision of the Drosophila melanogaster genome. 
Genome Biol 13, R21. 
Coutinho-Budd, J., and Freeman, M.R. (2013). Probing the enigma: unraveling glial cell 
biology in invertebrates. Curr Opin Neurobiol 23, 1073–1079. 
Cusack, C.L., Swahari, V., Hampton Henley, W., Michael Ramsey, J., and Deshmukh, 
M. (2013). Distinct pathways mediate axon degeneration during apoptosis and axon-
specific pruning. Nat Commun 4, 1876. 
Davis, C.O., Kim, K.-Y., Bushong, E.A., Mills, E.A., Boassa, D., Shih, T., Kinebuchi, 
M., Phan, S., Zhou, Y., Bihlmeyer, N.A., et al. (2014). Transcellular degradation of 
axonal mitochondria. Proc Natl Acad Sci U S A 111, 9633–9638. 
Dietzl, G., Chen, D., Schnorrer, F., Su, K.-C., Barinova, Y., Fellner, M., Gasser, B., 
Kinsey, K., Oppel, S., Scheiblauer, S., et al. (2007). A genome-wide transgenic RNAi 
library for conditional gene inactivation in Drosophila. Nature 448, 151–156. 
Dikranian, K., Cohen, R., Mac Donald, C., Pan, Y., Brakefield, D., Bayly, P., and 
Parsadanian, A. (2008). Mild traumatic brain injury to the infant mouse causes robust 
white matter axonal degeneration which precedes apoptotic death of cortical and thalamic 
neurons. Exp Neurol 211, 551–560. 
Dobritsa, A.A., van der Goes van Naters, W., Warr, C.G., Steinbrecht, R.A., and Carlson, 
J.R. (2003). Integrating the molecular and cellular basis of odor coding in the Drosophila 
antenna. Neuron 37, 827–841. 
143 
 
 
Donaldson, T.D., Noureddine, M.A., Reynolds, P.J., Bradford, W., and Duronio, R.J. 
(2004). Targeted disruption of Drosophila Roc1b reveals functional differences in the 
Roc subunit of Cullin-dependent E3 ubiquitin ligases. Mol Biol Cell 15, 4892–4903. 
Doyle, D.A., Morais Cabral, J., Pfuetzner, R.A., Kuo, A., Gulbis, J.M., Cohen, S.L., 
Chait, B.T., and MacKinnon, R. (1998). The structure of the potassium channel: 
molecular basis of K+ conduction and selectivity. Science 280, 69–77. 
Errington, W.J., Khan, M.Q., Bueler, S.A., Rubinstein, J.L., Chakrabartty, A., and Privé, 
G.G. (2012). Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin 
ligase. Structure 20, 1141–1153. 
Fang, Y., Soares, L., Teng, X., Geary, M., and Bonini, N.M. (2012). A novel Drosophila 
model of nerve injury reveals an essential role of Nmnat in maintaining axonal integrity. 
Curr Biol 22, 590–595. 
Fauvarque, M.-O., Laurenti, P., Boivin, A., Bloyer, S., Griffin-Shea, R., Bourbon, H.-M., 
and Dura, J.-M. (2001). Dominant modifiers of the polyhomeotic extra-sex-combs 
phenotype induced by marked P element insertional mutagenesis in Drosophila. Genet 
Res (Camb) 78. 
Finn, J.T., Weil, M., Archer, F., Siman, R., Srinivasan, A., and Raff, M.C. (2000). 
Evidence that Wallerian degeneration and localized axon degeneration induced by local 
neurotrophin deprivation do not involve caspases. J Neurosci 20, 1333–1341. 
Fountain, S.J., and Burnstock, G. (2009). An evolutionary history of P2X receptors. 
Purinergic Signal 5, 269–272. 
Frühbeis, C., Fröhlich, D., Kuo, W.P., and Krämer-Albers, E.-M. (2013). Extracellular 
vesicles as mediators of neuron-glia communication. Front Cell Neurosci 7, 182. 
Fünfschilling, U., Supplie, L.M., Mahad, D., Boretius, S., Saab, A.S., Edgar, J., 
Brinkmann, B.G., Kassmann, C.M., Tzvetanova, I.D., Möbius, W., et al. (2012). 
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485, 
517–521. 
Geisler, S., Doan, R.A., Strickland, A., Huang, X., Milbrandt, J., and DiAntonio, A. 
(2016). Prevention of vincristine-induced peripheral neuropathy by genetic deletion of 
SARM1 in mice. Brain 139, 3092–3108. 
George, E.B., Glass, J.D., and Griffin, J.W. (1995). Axotomy-induced axonal 
degeneration is mediated by calcium influx through ion-specific channels. J Neurosci 15, 
6445–6452. 
Gerdts, J., Summers, D.W., Sasaki, Y., DiAntonio, A., and Milbrandt, J. (2013). Sarm1-
mediated axon degeneration requires both SAM and TIR interactions. J Neurosci 33, 
13569–13580. 
Gerdts, J., Brace, E.J., Sasaki, Y., DiAntonio, A., and Milbrandt, J. (2015). SARM1 
activation triggers axon degeneration locally via NAD+ destruction. Science 348, 453–
457. 
Gilley, J., and Coleman, M.P. (2010). Endogenous Nmnat2 is an essential survival factor 
for maintenance of healthy axons. PLoS Biol 8, e1000300. 
144 
 
 
Gilley, J., Orsomando, G., Nascimento-Ferreira, I., and Coleman, M.P. (2015). Absence 
of SARM1 rescues development and survival of NMNAT2-deficient axons. Cell Rep 10, 
1974–1981. 
Gillingwater, T.H., Ingham, C.A., Parry, K.E., Wright, A.K., Haley, J.E., Wishart, T.M., 
Arbuthnott, G.W., and Ribchester, R.R. (2006). Delayed synaptic degeneration in the 
CNS of Wlds mice after cortical lesion. Brain 129, 1546–1556. 
Glass, J.D., Culver, D.G., Levey, A.I., and Nash, N.R. (2002). Very early activation of m-
calpain in peripheral nerve during Wallerian degeneration. J Neurol Sci 196, 9–20. 
Glise, B., Bourbon, H., and Noselli, S. (1995). hemipterous encodes a novel Drosophila 
MAP kinase kinase, required for epithelial cell sheet movement. Cell 83, 451–461. 
Gonzalez, M.A., Van Booven, D., Hulme, W., Ulloa, R.H., Lebrigio, R.F.A., Osterloh, J., 
Logan, M., Freeman, M., and Zuchner, S. (2012). Whole Genome Sequencing and a New 
Bioinformatics Platform Allow for Rapid Gene Identification in D. melanogaster EMS 
Screens. Biology 1, 766–777. 
Grill, B., Murphey, R.K., and Borgen, M.A. (2016). The PHR proteins: intracellular 
signaling hubs in neuronal development and axon degeneration. Neural Dev 11, 8. 
Gyoneva, S., and Ransohoff, R.M. (2015). Inflammatory reaction after traumatic brain 
injury: therapeutic potential of targeting cell-cell communication by chemokines. Trends 
Pharmacol Sci 36, 471–480. 
Hampel, S., Franconville, R., Simpson, J.H., and Seeds, A.M. (2015). A neural command 
circuit for grooming movement control. Elife 4, e08758. 
Hay, B.A., Wolff, T., and Rubin, G.M. (1994). Expression of baculovirus P35 prevents 
cell death in Drosophila. Development 120, 2121–2129. 
Henninger, N., Bouley, J., Sikoglu, E.M., An, J., Moore, C.M., King, J.A., Bowser, R., 
Freeman, M.R., and Brown, R.H. (2016). Attenuated traumatic axonal injury and 
improved functional outcome after traumatic brain injury in mice lacking Sarm1. Brain 
139, 1094–1105. 
Hicks, A.N., Lorenzetti, D., Gilley, J., Lu, B., Andersson, K.-E., Miligan, C., Overbeek, 
P.A., Oppenheim, R., and Bishop, C.E. (2012). Nicotinamide mononucleotide 
adenylyltransferase 2 (Nmnat2) regulates axon integrity in the mouse embryo. PLoS 
ONE 7, e47869. 
Le Hir, H., Nott, A., and Moore, M.J. (2003). How introns influence and enhance 
eukaryotic gene expression. Trends Biochem Sci 28, 215–220. 
Hoopfer, E.D., McLaughlin, T., Watts, R.J., Schuldiner, O., O’Leary, D.D.M., and Luo, 
L. (2006). Wlds protection distinguishes axon degeneration following injury from 
naturally occurring developmental pruning. Neuron 50, 883–895. 
Hou, Y.-J., Banerjee, R., Thomas, B., Nathan, C., García-Sastre, A., Ding, A., and 
Uccellini, M.B. (2013). SARM is required for neuronal injury and cytokine production in 
response to central nervous system viral infection. J Immunol 191, 875–883. 
145 
 
 
Hu, J., Zacharek, S., He, Y.J., Lee, H., Shumway, S., Duronio, R.J., and Xiong, Y. 
(2008). WD40 protein FBW5 promotes ubiquitination of tumor suppressor TSC2 by 
DDB1-CUL4-ROC1 ligase. Genes Dev 22, 866–871. 
Hu, Y., Comjean, A., Perrimon, N., and Mohr, S.E. (2017). The Drosophila Gene 
Expression Tool (DGET) for expression analyses. BMC Bioinformatics 18, 98. 
Joseph, B.S. (1973). Somatofugal events in Wallerian degeneration: a conceptual 
overview. Brain Res 59, 1–18. 
Jüschke, C., and Knoblich, J.A. (2008). Purification of Drosophila protein complexes for 
mass spectrometry. Methods Mol Biol 420, 347–358. 
Kee, Y., Lyon, N., and Huibregtse, J.M. (2005). The Rsp5 ubiquitin ligase is coupled to 
and antagonized by the Ubp2 deubiquitinating enzyme. EMBO J 24, 2414–2424. 
Kerckhove, N., Collin, A., Condé, S., Chaleteix, C., Pezet, D., and Balayssac, D. (2017). 
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-
Induced Peripheral Neuropathies: A Comprehensive Literature Review. Frontiers in 
Pharmacology 8, 86. 
Khurana, B., Zhuang, L., Moitra, P.K., Stantchev, T.S., Broder, C.C., Cutler, M.L., and 
D’Arpa, P. (2010). Human TOP1 residues implicated in species specificity of HIV-1 
infection are required for interaction with BTBD2, and RNAi of BTBD2 in old world 
monkey and human cells increases permissiveness to HIV-1 infection. Virol J 7, 332. 
Kinet, M.J., Malin, J.A., Abraham, M.C., Blum, E.S., Silverman, M.R., Lu, Y., and 
Shaham, S. (2016). HSF-1 activates the ubiquitin proteasome system to promote non-
apoptotic developmental cell death in C. elegans. Elife 5. 
Klinedinst, S., Wang, X., Xiong, X., Haenfler, J.M., and Collins, C.A. (2013). 
Independent pathways downstream of the Wnd/DLK MAPKKK regulate synaptic 
structure, axonal transport, and injury signaling. J Neurosci 33, 12764–12778. 
Knöferle, J., Koch, J.C., Ostendorf, T., Michel, U., Planchamp, V., Vutova, P., Tönges, 
L., Stadelmann, C., Brück, W., Bähr, M., et al. (2010). Mechanisms of acute axonal 
degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A 107, 6064–6069. 
Kreusch, A., Pfaffinger, P.J., Stevens, C.F., and Choe, S. (1998). Crystal structure of the 
tetramerization domain of the Shaker potassium channel. Nature 392, 945–948. 
Kutscher, L.M., and Shaham, S. (2017). Non-apoptotic cell death in animal development. 
Cell Death Differ. 
Laser, H., Conforti, L., Morreale, G., Mack, T.G.M., Heyer, M., Haley, J.E., Wishart, 
T.M., Beirowski, B., Walker, S.A., Haase, G., et al. (2006). The slow Wallerian 
degeneration protein, WldS, binds directly to VCP/p97 and partially redistributes it 
within the nucleus. Mol Biol Cell 17, 1075–1084. 
Lau, C., Dölle, C., Gossmann, T.I., Agledal, L., Niere, M., and Ziegler, M. (2010). 
Isoform-specific targeting and interaction domains in human nicotinamide 
mononucleotide adenylyltransferases. J Biol Chem 285, 18868–18876. 
Lauwers, E., and Verstreken, P. (2013). Chaperoning the synapse--NMNAT protects 
Bruchpilot from crashing. EMBO Rep 14, 5–6. 
146 
 
 
Lázár, O. (1980). Long-term persistence, after eye-removal, of unmyelinated fibres in the 
frog visual pathway. Brain Res 199, 219–224. 
Lee, T., and Luo, L. (2001). Mosaic analysis with a repressible cell marker (MARCM) 
for Drosophila neural development. Trends Neurosci 24, 251–254. 
Lee, T., Winter, C., Marticke, S.S., Lee, A., and Luo, L. (2000). Essential roles of 
Drosophila RhoA in the regulation of neuroblast proliferation and dendritic but not 
axonal morphogenesis. Neuron 25, 307–316. 
LeMosy, E.K., and Hashimoto, C. (2000). The nudel protease of Drosophila is required 
for eggshell biogenesis in addition to embryonic patterning. Dev Biol 217, 352–361. 
Lin, C.-W., and Hsueh, Y.-P. (2014). Sarm1, a neuronal inflammatory regulator, controls 
social interaction, associative memory and cognitive flexibility in mice. Brain Behav 
Immun 37, 142–151. 
Lin, D.M., and Goodman, C.S. (1994). Ectopic and increased expression of Fasciclin II 
alters motoneuron growth cone guidance. Neuron 13, 507–523. 
Lin, Y., and Wen, L. (2013). Inflammatory response following diffuse axonal injury. Int J 
Med Sci 10, 515–521. 
Lin, C.-W., Liu, H.-Y., Chen, C.-Y., and Hsueh, Y.-P. (2014a). Neuronally-expressed 
Sarm1 regulates expression of inflammatory and antiviral cytokines in brains. Innate 
Immun 20, 161–172. 
Lin, C.-W., Chen, C.-Y., Cheng, S.-J., Hu, H.-T., and Hsueh, Y.-P. (2014b). Sarm1 
deficiency impairs synaptic function and leads to behavioral deficits, which can be 
ameliorated by an mGluR allosteric modulator. Front Cell Neurosci 8, 87. 
Lin, H.-C., Wu, J.-T., Tan, B.C.-M., and Chien, C.-T. (2009). Cul4 and DDB1 regulate 
Orc2 localization, BrdU incorporation and Dup stability during gene amplification in 
Drosophila follicle cells. J Cell Sci 122, 2393–2401. 
Lindsten, T., Ross, A.J., King, A., Zong, W.X., Rathmell, J.C., Shiels, H.A., Ulrich, E., 
Waymire, K.G., Mahar, P., Frauwirth, K., et al. (2000). The combined functions of 
proapoptotic Bcl-2 family members bak and bax are essential for normal development of 
multiple tissues. Mol Cell 6, 1389–1399. 
Liu, C.-W., Li, X., Thompson, D., Wooding, K., Chang, T., Tang, Z., Yu, H., Thomas, 
P.J., and DeMartino, G.N. (2006). ATP binding and ATP hydrolysis play distinct roles in 
the function of 26S proteasome. Mol Cell 24, 39–50. 
Liu, H.-Y., Chen, C.-Y., and Hsueh, Y.-P. (2014). Innate immune responses regulate 
morphogenesis and degeneration: roles of Toll-like receptors and Sarm1 in neurons. 
Neurosci Bull 30, 645–654. 
Loreto, A., Di Stefano, M., Gering, M., and Conforti, L. (2015). Wallerian Degeneration 
Is Executed by an NMN-SARM1-Dependent Late Ca(2+) Influx but Only Modestly 
Influenced by Mitochondria. Cell Rep 13, 2539–2552. 
Lu, H., Burns, D., Garnier, P., Wei, G., Zhu, K., and Ying, W. (2007). P2X7 receptors 
mediate NADH transport across the plasma membranes of astrocytes. Biochem Biophys 
Res Commun 362, 946–950. 
147 
 
 
Lunn, E.R., Perry, V.H., Brown, M.C., Rosen, H., and Gordon, S. (1989). Absence of 
Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve. Eur J 
Neurosci 1, 27–33. 
Ma, M., Ferguson, T.A., Schoch, K.M., Li, J., Qian, Y., Shofer, F.S., Saatman, K.E., and 
Neumar, R.W. (2013). Calpains mediate axonal cytoskeleton disintegration during 
Wallerian degeneration. Neurobiol Dis 56, 34–46. 
MacDonald, J.M., Beach, M.G., Porpiglia, E., Sheehan, A.E., Watts, R.J., and Freeman, 
M.R. (2006). The Drosophila cell corpse engulfment receptor Draper mediates glial 
clearance of severed axons. Neuron 50, 869–881. 
Mack, T.G., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, 
D., Gillingwater, T., Court, F., Conforti, L., et al. (2001). Wallerian degeneration of 
injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 4, 
1199–1206. 
Mahr, A., and Aberle, H. (2006). The expression pattern of the Drosophila vesicular 
glutamate transporter: a marker protein for motoneurons and glutamatergic centers in the 
brain. Gene Expr Patterns 6, 299–309. 
Massoll, C., Mando, W., and Chintala, S.K. (2013). Excitotoxicity upregulates SARM1 
protein expression and promotes Wallerian-like degeneration of retinal ganglion cells and 
their axons. Invest Ophthalmol Vis Sci 54, 2771–2780. 
Matsui, A., Tran, M., Yoshida, A.C., Kikuchi, S.S., U, M., Ogawa, M., and Shimogori, T. 
(2013). BTBD3 controls dendrite orientation toward active axons in mammalian 
neocortex. Science 342, 1114–1118. 
Matsumoto, D.E., and Scalia, F. (1981). Long-term survival of centrally projecting axons 
in the optic nerve of the frog following destruction of the retina. J Comp Neurol 202, 
135–155. 
Mayer, P.R., Huang, N., Dewey, C.M., Dries, D.R., Zhang, H., and Yu, G. (2010). 
Expression, localization, and biochemical characterization of nicotinamide 
mononucleotide adenylyltransferase 2. J Biol Chem 285, 40387–40396. 
McNaught, K.S.P., Perl, D.P., Brownell, A.-L., and Olanow, C.W. (2004). Systemic 
exposure to proteasome inhibitors causes a progressive model of Parkinson’s disease. 
Ann Neurol 56, 149–162. 
Melnick, A., Ahmad, K.F., Arai, S., Polinger, A., Ball, H., Borden, K.L., Carlile, G.W., 
Prive, G.G., and Licht, J.D. (2000). In-depth mutational analysis of the promyelocytic 
leukemia zinc finger BTB/POZ domain reveals motifs and residues required for 
biological and transcriptional functions. Mol Cell Biol 20, 6550–6567. 
Melom, J.E., and Littleton, J.T. (2013). Mutation of a NCKX eliminates glial 
microdomain calcium oscillations and enhances seizure susceptibility. J Neurosci 33, 
1169–1178. 
Meng, L., Mohan, R., Kwok, B.H., Elofsson, M., Sin, N., and Crews, C.M. (1999). 
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo 
antiinflammatory activity. Proc Natl Acad Sci U S A 96, 10403–10408. 
148 
 
 
Metaxakis, A., Oehler, S., Klinakis, A., and Savakis, C. (2005). Minos as a genetic and 
genomic tool in Drosophila melanogaster. Genetics 171, 571–581. 
Meyer zu Horste, G., Miesbach, T.A., Muller, J.I., Fledrich, R., Stassart, R.M., Kieseier, 
B.C., Coleman, M.P., and Sereda, M.W. (2011). The Wlds transgene reduces axon loss in 
a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic 
axonal degeneration. Neurobiol Dis 42, 1–8. 
Milde, S., and Coleman, M.P. (2014). Identification of palmitoyltransferase and 
thioesterase enzymes that control the subcellular localization of axon survival factor 
nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2). J Biol Chem 289, 
32858–32870. 
Milde, S., Gilley, J., and Coleman, M.P. (2013). Subcellular localization determines the 
stability and axon protective capacity of axon survival factor Nmnat2. PLoS Biol 11, 
e1001539. 
Miller, B.R., Press, C., Daniels, R.W., Sasaki, Y., Milbrandt, J., and DiAntonio, A. 
(2009). A dual leucine kinase-dependent axon self-destruction program promotes 
Wallerian degeneration. Nat Neurosci 12, 387–389. 
Mistry, H., Wilson, B.A., Roberts, I.J.H., O’Kane, C.J., and Skeath, J.B. (2004). Cullin-3 
regulates pattern formation, external sensory organ development and cell survival during 
Drosophila development. Mech Dev 121, 1495–1507. 
Morii, H., Shiraishi-Yamaguchi, Y., and Mori, N. (2006). SCG10, a microtubule 
destabilizing factor, stimulates the neurite outgrowth by modulating microtubule 
dynamics in rat hippocampal primary cultured neurons. J Neurobiol 66, 1101–1114. 
Mukherjee, P., Woods, T.A., Moore, R.A., and Peterson, K.E. (2013). Activation of the 
innate signaling molecule MAVS by bunyavirus infection upregulates the adaptor protein 
SARM1, leading to neuronal death. Immunity 38, 705–716. 
Murata, H., Sakaguchi, M., Kataoka, K., and Huh, N.-H. (2013). SARM1 and TRAF6 
bind to and stabilize PINK1 on depolarized mitochondria. Mol Biol Cell 24, 2772–2784. 
Murray, M., and Edwards, M.A. (1982). A quantitative study of the reinnervation of the 
goldfish optic tectum following optic nerve crush. J Comp Neurol 209, 363–373. 
Muthukumar, A.K., Stork, T., and Freeman, M.R. (2014). Activity-dependent regulation 
of astrocyte GAT levels during synaptogenesis. Nat Neurosci 17, 1340–1350. 
Nern, A., Pfeiffer, B.D., and Rubin, G.M. (2015). Optimized tools for multicolor 
stochastic labeling reveal diverse stereotyped cell arrangements in the fly visual system. 
Proc Natl Acad Sci U S A 112, E2967–76. 
Neukomm, L.J., Burdett, T.C., Gonzalez, M.A., Züchner, S., and Freeman, M.R. (2014). 
Rapid in vivo forward genetic approach for identifying axon death genes in Drosophila. 
Proc Natl Acad Sci U S A 111, 9965–9970. 
Newsome, T.P., Asling, B., and Dickson, B.J. (2000). Analysis of Drosophila 
photoreceptor axon guidance in eye-specific mosaics. Development 127, 851–860. 
149 
 
 
Noureddine, M.A., Donaldson, T.D., Thacker, S.A., and Duronio, R.J. (2002). Drosophila 
Roc1a encodes a RING-H2 protein with a unique function in processing the Hh signal 
transducer Ci by the SCF E3 ubiquitin ligase. Dev Cell 2, 757–770. 
O’Donnell, K.C., Vargas, M.E., and Sagasti, A. (2013). WldS and PGC-1α regulate 
mitochondrial transport and oxidation state after axonal injury. J Neurosci 33, 14778–
14790. 
O’Neill, L.A.J., and Bowie, A.G. (2007). The family of five: TIR-domain-containing 
adaptors in Toll-like receptor signalling. Nat Rev Immunol 7, 353–364. 
Osterloh, J.M., Yang, J., Rooney, T.M., Fox, A.N., Adalbert, R., Powell, E.H., Sheehan, 
A.E., Avery, M.A., Hackett, R., Logan, M.A., et al. (2012). dSarm/Sarm1 is required for 
activation of an injury-induced axon death pathway. Science 337, 481–484. 
Ou, C.-Y., Lin, Y.-F., Chen, Y.-J., and Chien, C.-T. (2002). Distinct protein degradation 
mechanisms mediated by Cul1 and Cul3 controlling Ci stability in Drosophila eye 
development. Genes Dev 16, 2403–2414. 
Panneerselvam, P., Singh, L.P., Selvarajan, V., Chng, W.J., Ng, S.B., Tan, N.S., Ho, B., 
Chen, J., and Ding, J.L. (2013). T-cell death following immune activation is mediated by 
mitochondria-localized SARM. Cell Death Differ 20, 478–489. 
Parks, A.L., Cook, K.R., Belvin, M., Dompe, N.A., Fawcett, R., Huppert, K., Tan, L.R., 
Winter, C.G., Bogart, K.P., Deal, J.E., et al. (2004). Systematic generation of high-
resolution deletion coverage of the Drosophila melanogaster genome. Nat Genet 36, 288–
292. 
Perge, J.A., Niven, J.E., Mugnaini, E., Balasubramanian, V., and Sterling, P. (2012). 
Why do axons differ in caliber? J Neurosci 32, 626–638. 
Peth, A., Nathan, J.A., and Goldberg, A.L. (2013). The ATP costs and time required to 
degrade ubiquitinated proteins by the 26 S proteasome. J Biol Chem 288, 29215–29222. 
Pintard, L., Willems, A., and Peter, M. (2004). Cullin-based ubiquitin ligases: Cul3-BTB 
complexes join the family. EMBO J 23, 1681–1687. 
Polilov, A.A. (2012). The smallest insects evolve anucleate neurons. Arthropod Struct 
Dev 41, 29–34. 
Powell, J.R., and Dion, K. (2015). Effects of codon usage on gene expression: empirical 
studies on Drosophila. J Mol Evol 80, 219–226. 
Prelich, G. (2012). Gene overexpression: uses, mechanisms, and interpretation. Genetics 
190, 841–854. 
Rallis, A., Moore, C., and Ng, J. (2010). Signal strength and signal duration define two 
distinct aspects of JNK-regulated axon stability. Dev Biol 339, 65–77. 
Rallis, A., Lu, B., and Ng, J. (2013). Molecular chaperones protect against JNK- and 
Nmnat-regulated axon degeneration in Drosophila. J Cell Sci 126, 838–849. 
Ratajczak, J., Joffraud, M., Trammell, S.A.J., Ras, R., Canela, N., Boutant, M., Kulkarni, 
S.S., Rodrigues, M., Redpath, P., Migaud, M.E., et al. (2016). NRK1 controls 
nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. 
Nat Commun 7, 13103. 
150 
 
 
Ren, J., Wen, L., Gao, X., Jin, C., Xue, Y., and Yao, X. (2008). CSS-Palm 2.0: an 
updated software for palmitoylation sites prediction. Protein Eng Des Sel 21, 639–644. 
Rongvaux, A., Andris, F., Van Gool, F., and Leo, O. (2003). Reconstructing eukaryotic 
NAD metabolism. Bioessays 25, 683–690. 
Rooney, T.M., and Freeman, M.R. (2014). Drosophila models of neuronal injury. ILAR J 
54, 291–295. 
Roy, S., Hsiung, F., and Kornberg, T.B. (2011). Specificity of Drosophila cytonemes for 
distinct signaling pathways. Science 332, 354–358. 
Sasaki, Y., and Milbrandt, J. (2010). Axonal degeneration is blocked by nicotinamide 
mononucleotide adenylyltransferase (Nmnat) protein transduction into transected axons. J 
Biol Chem 285, 41211–41215. 
Sasaki, Y., Araki, T., and Milbrandt, J. (2006). Stimulation of nicotinamide adenine 
dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 
26, 8484–8491. 
Sasaki, Y., Nakagawa, T., Mao, X., DiAntonio, A., and Milbrandt, J. (2016). NMNAT1 
inhibits axon degeneration via blockade of SARM1-mediated NAD(+) depletion. Elife 5. 
Schlaepfer, W.W. (1974). Calcium-induced degeneration of axoplasm in isolated 
segments of rat peripheral nerve. Brain Res 69, 203–215. 
Schlaepfer, W.W. (1977). Structural alterations of peripheral nerve induced by the 
calcium ionophore A23187. Brain Res 136, 1–9. 
Schlaepfer, W.W., and Bunge, R.P. (1973). Effects of calcium ion concentration on the 
degeneration of amputated axons in tissue culture. J Cell Biol 59, 456–470. 
Schlaepfer, W.W., and Hasler, M.B. (1979). Characterization of the calcium-induced 
disruption of neurofilaments in rat peripheral nerve. Brain Res 168, 299–309. 
Schonrock, N., Humphreys, D.T., Preiss, T., and Götz, J. (2012). Target gene repression 
mediated by miRNAs miR-181c and miR-9 both of which are down-regulated by 
amyloid-β. J Mol Neurosci 46, 324–335. 
Schuldiner, O., Berdnik, D., Levy, J.M., Wu, J.S., Luginbuhl, D., Gontang, A.C., and 
Luo, L. (2008). piggyBac-based mosaic screen identifies a postmitotic function for 
cohesin in regulating developmental axon pruning. Dev Cell 14, 227–238. 
Schweiger, M., Hennig, K., Lerner, F., Niere, M., Hirsch-Kauffmann, M., Specht, T., 
Weise, C., Oei, S.L., and Ziegler, M. (2001). Characterization of recombinant human 
nicotinamide mononucleotide adenylyl transferase (NMNAT), a nuclear enzyme essential 
for NAD synthesis. FEBS Lett 492, 95–100. 
Schweisguth, F. (1999). Dominant-negative mutation in the beta2 and beta6 proteasome 
subunit genes affect alternative cell fate decisions in the Drosophila sense organ lineage. 
Proc Natl Acad Sci U S A 96, 11382–11386. 
Schwiebert, E.M., Liang, L., Cheng, N.-L., Williams, C.R., Olteanu, D., Welty, E.A., and 
Zsembery, A. (2005). Extracellular zinc and ATP-gated P2X receptor calcium entry 
channels: New zinc receptors as physiological sensors and therapeutic targets. Purinergic 
Signal 1, 299–310. 
151 
 
 
Sebo, Z.L., Lee, H.B., Peng, Y., and Guo, Y. (2014). A simplified and efficient germline-
specific CRISPR/Cas9 system for Drosophila genomic engineering. Fly (Austin) 8, 52–
57. 
Shapira, S., Bakhrat, A., Bitan, A., and Abdu, U. (2011). The Drosophila javelin gene 
encodes a novel actin-associated protein required for actin assembly in the bristle. Mol 
Cell Biol 31, 4582–4592. 
Shin, J.E., and DiAntonio, A. (2011). Highwire regulates guidance of sister axons in the 
Drosophila mushroom body. J Neurosci 31, 17689–17700. 
Shin, J.E., Miller, B.R., Babetto, E., Cho, Y., Sasaki, Y., Qayum, S., Russler, E.V., 
Cavalli, V., Milbrandt, J., and DiAntonio, A. (2012a). SCG10 is a JNK target in the 
axonal degeneration pathway. Proc Natl Acad Sci U S A 109, E3696–705. 
Shin, J.E., Cho, Y., Beirowski, B., Milbrandt, J., Cavalli, V., and DiAntonio, A. (2012b). 
Dual leucine zipper kinase is required for retrograde injury signaling and axonal 
regeneration. Neuron 74, 1015–1022. 
Shivers, R., Kooistra, T., Chu, S., Pagano, D., and Kim, D. (2009). Tissue-Specific 
Activities of SARM-ASK1-MKK3 Signaling Coordinate Immunity and Behavior to 
Pathogenic and Nutritional Bacteria in C. elegans. Cell Host Microbe. 
Sieburth, D., Ch’ng, Q., Dybbs, M., Tavazoie, M., Kennedy, S., Wang, D., Dupuy, D., 
Rual, J.-F., Hill, D.E., Vidal, M., et al. (2005). Systematic analysis of genes required for 
synapse structure and function. Nature 436, 510–517. 
Simon, D.J., Weimer, R.M., McLaughlin, T., Kallop, D., Stanger, K., Yang, J., O’Leary, 
D.D.M., Hannoush, R.N., and Tessier-Lavigne, M. (2012). A caspase cascade regulating 
developmental axon degeneration. J Neurosci 32, 17540–17553. 
Sluss, H.K., Han, Z., Barrett, T., Goberdhan, D.C., Wilson, C., Davis, R.J., and Ip, Y.T. 
(1996). A JNK signal transduction pathway that mediates morphogenesis and an immune 
response in Drosophila. Genes Dev 10, 2745–2758. 
Smith, D.H. (2009). Stretch growth of integrated axon tracts: extremes and exploitations. 
Prog Neurobiol 89, 231–239. 
Soltysik-Espanola, M., Rogers, R.A., Jiang, S., Kim, T.A., Gaedigk, R., White, R.A., 
Avraham, H., and Avraham, S. (1999). Characterization of Mayven, a novel actin-
binding protein predominantly expressed in brain. Mol Biol Cell 10, 2361–2375. 
Spradling, A.C., Stern, D., Beaton, A., Rhem, E.J., Laverty, T., Mozden, N., Misra, S., 
and Rubin, G.M. (1999). The Berkeley Drosophila Genome Project gene disruption 
project: Single P-element insertions mutating 25% of vital Drosophila genes. Genetics 
153, 135–177. 
Srivastava, S. (2016). Emerging therapeutic roles for NAD(+) metabolism in 
mitochondrial and age-related disorders. Clinical and Translational Medicine 5, 25. 
St Johnston, D. (2002). The art and design of genetic screens: Drosophila melanogaster. 
Nat Rev Genet 3, 176–188. 
Di Stefano, M., Nascimento-Ferreira, I., Orsomando, G., Mori, V., Gilley, J., Brown, R., 
Janeckova, L., Vargas, M.E., Worrell, L.A., Loreto, A., et al. (2015). A rise in NAD 
152 
 
 
precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration. 
Cell Death Differ 22, 731–742. 
Stein, L.R., and Imai, S. (2012). The dynamic regulation of NAD metabolism in 
mitochondria. Trends Endocrinol Metab 23, 420–428. 
Stino, A.M., and Smith, A.G. (2017). Peripheral neuropathy in prediabetes and the 
metabolic syndrome. Journal of Diabetes Investigation. 
Stogios, P.J., and Privé, G.G. (2004). The BACK domain in BTB-kelch proteins. Trends 
Biochem Sci 29, 634–637. 
Stogios, P.J., Downs, G.S., Jauhal, J.J.S., Nandra, S.K., and Privé, G.G. (2005). Sequence 
and structural analysis of BTB domain proteins. Genome Biol 6, R82. 
Stork, T., Sheehan, A., Tasdemir-Yilmaz, O.E., and Freeman, M.R. (2014). Neuron-glia 
interactions through the Heartless FGF receptor signaling pathway mediate 
morphogenesis of Drosophila astrocytes. Neuron 83, 388–403. 
Summers, D.W., DiAntonio, A., and Milbrandt, J. (2014). Mitochondrial dysfunction 
induces Sarm1-dependent cell death in sensory neurons. J Neurosci 34, 9338–9350. 
Summers, D.W., Gibson, D.A., DiAntonio, A., and Milbrandt, J. (2016). SARM1-
specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced 
SARM1 activation. Proc Natl Acad Sci U S A 113, E6271–E6280. 
T’Jampens, D., Devriendt, L., De Corte, V., Vandekerckhove, J., and Gettemans, J. 
(2002). Selected BTB/POZ-kelch proteins bind ATP. FEBS Lett 516, 20–26. 
Tasdemir-Yilmaz, O.E., and Freeman, M.R. (2014). Astrocytes engage unique molecular 
programs to engulf pruned neuronal debris from distinct subsets of neurons. Genes Dev 
28, 20–33. 
Tazuke, S.I., Schulz, C., Gilboa, L., Fogarty, M., Mahowald, A.P., Guichet, A., Ephrussi, 
A., Wood, C.G., Lehmann, R., and Fuller, M.T. (2002). A germline-specific gap junction 
protein required for survival of differentiating early germ cells. Development 129, 2529–
2539. 
Thibault, S.T., Singer, M.A., Miyazaki, W.Y., Milash, B., Dompe, N.A., Singh, C.M., 
Buchholz, R., Demsky, M., Fawcett, R., Francis-Lang, H.L., et al. (2004). A 
complementary transposon tool kit for Drosophila melanogaster using P and piggyBac. 
Nat Genet 36, 283–287. 
Vargas, M.E., Yamagishi, Y., Tessier-Lavigne, M., and Sagasti, A. (2015). Live Imaging 
of Calcium Dynamics during Axon Degeneration Reveals Two Functionally Distinct 
Phases of Calcium Influx. J Neurosci 35, 15026–15038. 
Velentzas, P.D., Velentzas, A.D., Pantazi, A.D., Mpakou, V.E., Zervas, C.G., 
Papassideri, I.S., and Stravopodis, D.J. (2013). Proteasome, but not autophagy, disruption 
results in severe eye and wing dysmorphia: a subunit- and regulator-dependent process in 
Drosophila. PLoS ONE 8, e80530. 
Vernon, A.C., Johansson, S.M., and Modo, M.M. (2010). Non-invasive evaluation of 
nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson’s 
disease. BMC Neurosci 11, 1. 
153 
 
 
Vial, J.D. (1958). The Early Changes in the Axoplasm during Wallerian Degeneration. J 
Cell Biol 4, 551–556. 
Wakatsuki, S., Saitoh, F., and Araki, T. (2011). ZNRF1 promotes Wallerian degeneration 
by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat Cell Biol 
13, 1415–1423. 
Walker, L.J., Summers, D.W., Sasaki, Y., Brace, E.J., Milbrandt, J., and DiAntonio, A. 
(2017). MAPK signaling promotes axonal degeneration by speeding the turnover of the 
axonal maintenance factor NMNAT2. Elife 6. 
Waller, A. (1850). Experiments on the section of the glossopharyngeal and hypoglossal 
nerves of the frog, and observations of the alterations produced thereby in the structure of 
their primitive fibres. Philosophical Transactions of the Royal Society of London 140, 
423–429. 
Wan, H.I., DiAntonio, A., Fetter, R.D., Bergstrom, K., Strauss, R., and Goodman, C.S. 
(2000). Highwire regulates synaptic growth in Drosophila. Neuron 26, 313–329. 
Wang, G., Han, T., Nijhawan, D., Theodoropoulos, P., Naidoo, J., Yadavalli, S., Mirzaei, 
H., Pieper, A.A., Ready, J.M., and McKnight, S.L. (2014). P7C3 neuroprotective 
chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158, 
1324–1334. 
Wang, J., Zhai, Q., Chen, Y., Lin, E., Gu, W., McBurney, M.W., and He, Z. (2005). A 
local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 
170, 349–355. 
Wang, M.S., Davis, A.A., Culver, D.G., and Glass, J.D. (2002). WldS mice are resistant 
to paclitaxel (taxol) neuropathy. Ann Neurol 52, 442–447. 
Wang, X., Kim, J.H., Bazzi, M., Robinson, S., Collins, C.A., and Ye, B. (2013). Bimodal 
control of dendritic and axonal growth by the dual leucine zipper kinase pathway. PLoS 
Biol 11, e1001572. 
Wilbrey, A.L., Haley, J.E., Wishart, T.M., Conforti, L., Morreale, G., Beirowski, B., 
Babetto, E., Adalbert, R., Gillingwater, T.H., Smith, T., et al. (2008). VCP binding 
influences intracellular distribution of the slow Wallerian degeneration protein, Wld(S). 
Mol Cell Neurosci 38, 325–340. 
Wishart, T.M., Rooney, T.M., Lamont, D.J., Wright, A.K., Morton, A.J., Jackson, M., 
Freeman, M.R., and Gillingwater, T.H. (2012). Combining comparative proteomics and 
molecular genetics uncovers regulators of synaptic and axonal stability and degeneration 
in vivo. PLoS Genet 8, e1002936. 
Wong, J.J.L., Li, S., Lim, E.K.H., Wang, Y., Wang, C., Zhang, H., Kirilly, D., Wu, C., 
Liou, Y.-C., Wang, H., et al. (2013). A Cullin1-based SCF E3 ubiquitin ligase targets the 
InR/PI3K/TOR pathway to regulate neuronal pruning. PLoS Biol 11, e1001657. 
Wu, J.S., and Luo, L. (2006). A protocol for dissecting Drosophila melanogaster brains 
for live imaging or immunostaining. Nat Protoc 1, 2110–2115. 
154 
 
 
Wu, C., Wairkar, Y.P., Collins, C.A., and DiAntonio, A. (2005). Highwire function at the 
Drosophila neuromuscular junction: spatial, structural, and temporal requirements. J 
Neurosci 25, 9557–9566. 
Wu, C., Daniels, R.W., and DiAntonio, A. (2007). DFsn collaborates with Highwire to 
down-regulate the Wallenda/DLK kinase and restrain synaptic terminal growth. Neural 
Dev 2, 16. 
Xiong, X., and Collins, C.A. (2012). A conditioning lesion protects axons from 
degeneration via the Wallenda/DLK MAP kinase signaling cascade. J Neurosci 32, 610–
615. 
Xiong, X., Wang, X., Ewanek, R., Bhat, P., Diantonio, A., and Collins, C.A. (2010). 
Protein turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal 
injury. J Cell Biol 191, 211–223. 
Xiong, X., Hao, Y., Sun, K., Li, J., Li, X., Mishra, B., Soppina, P., Wu, C., Hume, R.I., 
and Collins, C.A. (2012). The Highwire ubiquitin ligase promotes axonal degeneration by 
tuning levels of Nmnat protein. PLoS Biol 10, e1001440. 
Xu, T., and Rubin, G.M. (1993). Analysis of genetic mosaics in developing and adult 
Drosophila tissues. Development 117, 1223–1237. 
Xu, D., Li, Y., Arcaro, M., Lackey, M., and Bergmann, A. (2005). The CARD-carrying 
caspase Dronc is essential for most, but not all, developmental cell death in Drosophila. 
Development 132, 2125–2134. 
Xu, L., Yang, L., Hashimoto, K., Anderson, M., Kohlhagen, G., Pommier, Y., and 
D’Arpa, P. (2002). Characterization of BTBD1 and BTBD2, two similar BTB-domain-
containing Kelch-like proteins that interact with Topoisomerase I. BMC Genomics 3, 1. 
Xu, L., Yang, L., Moitra, P.K., Hashimoto, K., Rallabhandi, P., Kaul, S., Meroni, G., 
Jensen, J.P., Weissman, A.M., and D’Arpa, P. (2003). BTBD1 and BTBD2 colocalize to 
cytoplasmic bodies with the RBCC/tripartite motif protein, TRIM5δ. Exp Cell Res 288, 
84–93. 
Yamagishi, Y., and Tessier-Lavigne, M. (2016). An Atypical SCF-like Ubiquitin Ligase 
Complex Promotes Wallerian Degeneration through Regulation of Axonal Nmnat2. Cell 
Rep 17, 774–782. 
Yamamoto, S., Jaiswal, M., Charng, W.-L., Gambin, T., Karaca, E., Mirzaa, G., 
Wiszniewski, W., Sandoval, H., Haelterman, N.A., Xiong, B., et al. (2014). A drosophila 
genetic resource of mutants to study mechanisms underlying human genetic diseases. 
Cell 159, 200–214. 
Yan, D., Wu, Z., Chisholm, A.D., and Jin, Y. (2009). The DLK-1 kinase promotes 
mRNA stability and local translation in C. elegans synapses and axon regeneration. Cell 
138, 1005–1018. 
Yang, H., Yang, T., Baur, J.A., Perez, E., Matsui, T., Carmona, J.J., Lamming, D.W., 
Souza-Pinto, N.C., Bohr, V.A., Rosenzweig, A., et al. (2007). Nutrient-sensitive 
mitochondrial NAD+ levels dictate cell survival. Cell 130, 1095–1107. 
155 
 
 
Yang, J., Weimer, R.M., Kallop, D., Olsen, O., Wu, Z., Renier, N., Uryu, K., and Tessier-
Lavigne, M. (2013). Regulation of axon degeneration after injury and in development by 
the endogenous calpain inhibitor calpastatin. Neuron 80, 1175–1189. 
Yang, J., Wu, Z., Renier, N., Simon, D.J., Uryu, K., Park, D.S., Greer, P.A., Tournier, C., 
Davis, R.J., and Tessier-Lavigne, M. (2015). Pathological axonal death through a MAPK 
cascade that triggers a local energy deficit. Cell 160, 161–176. 
Yin, T.C., Voorhees, J.R., Genova, R.M., Davis, K.C., Madison, A.M., Britt, J.K., 
Cintrón-Pérez, C.J., McDaniel, L., Harper, M.M., and Pieper, A.A. (2016). Acute Axonal 
Degeneration Drives Development of Cognitive, Motor, and Visual Deficits after Blast-
Mediated Traumatic Brain Injury in Mice. eNeuro 3. 
Ylikallio, E., Pöyhönen, R., Zimon, M., De Vriendt, E., Hilander, T., Paetau, A., 
Jordanova, A., Lönnqvist, T., and Tyynismaa, H. (2013). Deficiency of the E3 ubiquitin 
ligase TRIM2 in early-onset axonal neuropathy. Hum Mol Genet 22, 2975–2983. 
Zang, S., Ali, Y.O., Ruan, K., and Zhai, R.G. (2013). Nicotinamide mononucleotide 
adenylyltransferase maintains active zone structure by stabilizing Bruchpilot. EMBO Rep 
14, 87–94. 
Zhai, Q., Wang, J., Kim, A., Liu, Q., Watts, R., Hoopfer, E., Mitchison, T., Luo, L., and 
He, Z. (2003). Involvement of the ubiquitin-proteasome system in the early stages of 
wallerian degeneration. Neuron 39, 217–225. 
Zhai, R.G., Cao, Y., Hiesinger, P.R., Zhou, Y., Mehta, S.Q., Schulze, K.L., Verstreken, 
P., and Bellen, H.J. (2006). Drosophila NMNAT maintains neural integrity independent 
of its NAD synthesis activity. PLoS Biol 4, e416. 
Zhang, Y., Chen, K., Sloan, S.A., Bennett, M.L., Scholze, A.R., O’Keeffe, S., Phatnani, 
H.P., Guarnieri, P., Caneda, C., Ruderisch, N., et al. (2014). An RNA-sequencing 
transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral 
cortex. J Neurosci 34, 11929–11947. 
Zhang, Z., Fujiki, M., Guth, L., and Steward, O. (1996). Genetic influences on cellular 
reactions to spinal cord injury: a wound-healing response present in normal mice is 
impaired in mice carrying a mutation (WldS) that causes delayed Wallerian degeneration. 
J Comp Neurol 371, 485–495. 
Zhu, W., and Oxford, G.S. (2011). Differential gene expression of neonatal and adult 
DRG neurons correlates with the differential sensitization of TRPV1 responses to nerve 
growth factor. Neurosci Lett 500, 192–196. 
Zhu, S., Perez, R., Pan, M., and Lee, T. (2005). Requirement of Cul3 for axonal 
arborization and dendritic elaboration in Drosophila mushroom body neurons. J Neurosci 
25, 4189–4197. 
Zhuang, M., Calabrese, M.F., Liu, J., Waddell, M.B., Nourse, A., Hammel, M., Miller, 
D.J., Walden, H., Duda, D.M., Seyedin, S.N., et al. (2009). Structures of SPOP-substrate 
complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell 
36, 39–50. 
156 
 
 
 
